yo
femal
refer
clinic
histori
multilineag
cytopeniasevan
syndrom
histori
idiopath
thrombocytopen
purpura
hemolyt
anemia
chronic
neutropenia
lymphopenia
hypogammaglobulinemia
treat
ivig
patient
healthi
year
old
time
develop
joint
pain
rash
bruis
found
evan
syndrom
idiopath
thrombocytopen
purpura
itp
neutropenia
lymphopenia
initi
diagnos
lupu
given
steroid
bone
marrow
biopsi
conclud
myelokathesi
year
old
remain
thrombopen
start
high
dose
immunoglobulin
replac
therapi
year
old
develop
polyarthr
upper
lower
extrem
year
old
sever
noseble
admit
treat
amicar
twice
platelet
found
kul
receiv
rituximab
weekli
week
result
increas
platelet
count
recent
march
splenectomi
remov
larg
spleen
sinc
platelet
rebound
place
longterm
immunoglobulin
replac
therapi
hospit
bilater
pneumonia
night
requir
iv
antibiot
treatment
develop
treat
anoth
pneumonia
famili
histori
character
multipl
member
autoimmun
multilineag
cytopenia
well
autoimmun
diseas
multipl
sclerosi
mother
thyroid
enteropathi
physic
examin
present
wart
remaind
physic
examin
unremark
except
scar
splenectomi
cervic
lymphadenopathi
immunolog
evalu
show
igg
mgdl
iga
mgdl
igm
mgdl
cbc
differenti
lymphocyt
screen
follow
wbc
hemoglobin
gdl
platelet
x
neutrophil
anc
lymphocyt
monocyt
eosinophil
absolut
total
tcell
number
cellsmcl
tcell
tcell
natur
killer
cell
cell
mcl
absolut
number
b
cell
cell
mcl
came
clinic
sister
also
multilineag
cytopenia
hypogammaglobulinemia
treat
monthli
ivig
nephew
neutropenia
base
famili
present
three
underw
whole
exom
sequenc
we
patient
patient
sister
patient
nephew
found
variant
frameshift
mutat
chromosom
refnt
tca
altnt
import
note
patient
bone
marrow
biopsi
conclud
myelokathesi
summari
patient
trilineag
cytopenia
hypogammaglobulinemia
without
wart
myelokathexi
whim
syndrom
wart
hypogammaglobulinemia
immunodefici
myelokathexi
discov
studi
we
identif
specif
diagnosi
allow
us
discuss
potenti
futur
indic
plerifaxor
antagonist
alpha
chemokin
receptor
equal
import
discuss
famili
plan
futur
pregnanc
given
mutat
autosomaldomin
submiss
id
taha
alshaikhli
mbchb
kathleen
mohan
arnp
matthew
basiaga
msce
introduct
complement
share
classic
lectin
altern
complement
activ
pathway
major
opsonin
facilit
phagocytosi
encapsul
microorgan
inherit
defici
rare
associ
increas
risk
bacteri
infect
subject
connect
tissu
diseas
ctd
nephrit
factor
low
occasion
undetect
level
yet
underappreci
infecti
risk
hypothes
excess
consumpt
secondari
complement
defici
disord
scd
associ
higher
risk
bacteri
infect
similar
primari
complement
defici
disord
pcd
object
compar
rate
bacteri
infect
pcd
scd
patient
evalu
associ
level
bacteri
infect
risk
method
perform
retrospect
cohort
studi
subject
undetect
complement
activ
complement
compon
measur
seattl
children
hospit
includ
studi
record
number
infect
observ
period
diagnosi
pcd
scd
underli
etiolog
lowest
complement
compon
level
immunosuppress
agent
use
date
birth
date
lowest
level
consid
start
point
calcul
observ
period
pcd
scd
subject
respect
infect
requir
hospit
parenter
antibiot
categor
seriou
bacteri
infect
sbi
descript
analys
perform
determin
median
rang
continu
variabl
differ
rate
bacteri
infect
assess
use
chisquar
kruskalw
test
appropri
among
subject
ctd
treat
everi
measur
singl
observ
studi
associ
concentr
odd
sbi
multivari
logist
regress
perform
determin
infect
risk
base
level
control
contribut
factor
result
identifi
subject
pcd
subject
scd
scd
consist
three
subgroup
ctdrelat
nephrit
factorrel
infectionrel
collect
ctd
subject
lower
median
rate
sbi
compar
pcd
subject
p
subject
ctd
level
higher
rate
bacteri
infect
sever
p
sbi
p
compar
ctd
subject
begin
observ
period
figur
control
immunosuppress
level
pediatr
resid
baystat
medic
center
faculti
advisor
baystat
medic
center
introduct
code
acid
enzym
member
sykprotein
tyrosin
kinas
famili
play
import
role
cell
develop
activ
phosphoryl
tyrosin
kinas
residu
upon
cell
receptor
tcr
stimul
result
tcrmediat
signal
transduct
src
famili
kinas
defici
result
rare
tb
nk
sever
combin
immunodefici
scid
report
novel
compound
heterozyg
mutat
lead
presum
absent
function
infant
normal
trec
newborn
screen
scid
case
descript
patient
term
fulli
immun
femal
born
nonconsanguin
parent
hospit
rsv
bronchiol
mo
mo
develop
erythemat
papular
rash
face
extrem
nonrespons
topic
antifung
therapi
mo
rehospit
rsv
bronchiol
subsequ
treat
multipl
cours
antibiot
presum
bacteri
pneumonia
follow
albuterol
oral
steroid
possibl
reactiv
airway
diseas
cours
treatment
rash
resolv
mo
present
failur
thrive
wt
age
multifoc
pneumonia
respiratori
failur
requir
intub
bronchial
alveolar
lavag
confirm
pneumocysti
jiroveci
pneumonia
prompt
immun
evalu
total
immunoglobulin
normal
age
howev
antibodi
titer
tetanu
diphtheria
streptococcu
pneumonia
absent
lymphocyt
enumer
reveal
elev
cell
markedli
diminish
cell
normal
b
nk
cell
cell
prolifer
mitogen
pha
pwm
antigen
candida
tetanu
absent
howev
cell
prolifer
normal
stimul
pma
ionomycin
trec
number
normal
newborn
screen
std
deviat
mean
would
result
posit
screen
upon
repeat
invita
gene
scid
panel
reveal
two
variant
unknown
signific
g
lead
substitut
arg
gli
result
prematur
translat
stop
signal
expect
disrupt
last
amino
acid
protein
parent
sequenc
reveal
variant
opposit
chromosom
patient
success
treat
pjp
pneumonia
sinc
success
engraft
match
unrel
donor
stem
cell
transplant
discuss
report
novel
compound
heterozyg
mutat
presum
led
b
nk
scid
patient
clinic
present
failur
thrive
recurr
lower
respiratori
tract
infect
dermatolog
find
pjp
pneumonia
consist
previous
report
case
scid
pauciti
cell
abund
cell
absent
prolifer
mitogen
also
consist
previous
describ
case
normal
prolifer
cell
bypass
tcr
stimul
cell
ionomycin
pma
confirm
defect
tcr
believ
second
document
case
miss
scid
newborn
screen
sinc
implement
trec
screen
pediatr
resid
pgi
iii
goryeb
children
hospit
attend
physician
pediatr
adult
asthma
allergi
immunolog
llc
introduct
acut
otiti
media
aom
one
common
reason
antibiot
use
earli
childhood
explor
challeng
aom
fail
tradit
therapi
immunolog
evalu
identifi
commonli
describ
immunodefici
case
descript
eighteenmonthold
male
present
episod
aom
recurr
purul
otorrhea
requir
intraven
antibiot
laboratori
evalu
reveal
normal
cbc
normal
immunoglobulin
igg
iga
igm
ige
igg
subclass
lymphocyt
subset
panel
normal
initi
respons
dtap
prevnar
booster
normal
howev
rapid
declin
tetanu
pneumococc
antibodi
titer
sub
optim
respons
haemophilu
influenza
type
b
vaccin
note
although
vaccin
twice
mmr
never
mount
mump
specif
igg
mitogen
respons
pha
normal
decreas
respons
cona
pokewe
detect
tetanu
candida
respons
investig
reveal
decreas
nonclass
class
switch
memori
bcell
patient
recent
vaccin
present
time
protect
titer
discuss
previous
suggest
decreas
memori
b
cell
may
contribut
decreas
antibodi
respons
select
vaccin
antigen
result
recurr
aom
children
case
support
need
investig
beyond
typic
immunolog
screen
immunodefici
introduct
dna
mismatch
repair
mmr
system
correct
replic
error
newli
synthes
dna
prevent
recombin
dna
sequenc
ident
part
mmr
gene
case
tenyearold
girl
present
fever
brown
spot
skin
hair
loss
recurr
pulmonari
infect
arthriti
left
hand
right
ankl
also
follow
nf
figur
firstdegre
cousin
marriag
parent
physic
examin
reveal
find
pneumonia
nf
antinuclear
antibodi
antindna
antidsdna
antihiston
anti
antinucleosom
antibodi
posit
immunolog
assess
show
low
igg
iga
level
associ
high
igm
level
tabl
coexist
nf
hyper
igm
syndrom
sle
consid
patient
intraven
ig
mgkg
everi
week
treatment
start
due
hypogammaglobinemia
frame
shift
mutat
exon
gene
detect
boztug
laboratori
follow
period
admit
year
old
back
pain
mass
left
paravertebr
area
relat
spinal
canal
neural
foramina
detect
level
spinal
mri
lymphadenopathi
around
liver
hilum
left
pariet
bone
lesion
develop
within
two
month
despit
surgic
excis
primari
mass
figur
result
pet
examin
suvmax
found
around
mass
lesion
paravertebr
region
suvmax
valu
exceed
lymphadenopathi
mass
atyp
cellular
infiltr
suggest
neoplast
event
includ
smallmedium
size
atyp
pleomorph
mononuclear
cell
cell
sinc
format
indic
definit
cancer
chemotherapi
start
interestingli
although
chemotherapi
given
progress
stop
partial
spontan
regress
observ
discuss
effect
mutat
patient
may
significantli
vari
inherit
pattern
leukemia
lymphoma
common
heterozygot
mmr
gene
defect
howev
homozygot
mutat
mmr
gene
show
differ
pattern
wimmer
etzler
propos
new
term
constitut
mismatch
repairdefici
syndrom
cmmrd
patient
homozyg
mutat
mmr
cmmrd
character
develop
childhood
cancer
mainli
hematolog
malign
andor
brain
tumor
well
earlyonset
colorect
cancer
neurofibromatosi
type
biallel
germlin
mutat
mmr
gene
involv
increas
hematolog
malign
mutat
associ
mani
cancer
sinc
identif
leukemia
lymphoma
colorect
cancer
endometri
cancer
brain
tumor
cancer
type
defici
import
diseas
affect
differ
system
time
high
risk
malign
case
therefor
must
close
monitor
case
also
shown
atyp
lymphoprolifer
may
occur
homozyg
mutant
case
normal
rage
background
advanc
inborn
error
human
immun
support
discoveri
new
syndrom
mark
strike
featur
autoimmun
immun
dysregul
often
associ
cytopenia
lymphoprolifer
predisposit
reticuloendotheli
malign
lead
evalu
hematologistsoncologist
moreov
hematologistsoncologist
also
seen
increas
use
effector
cellbas
therapi
checkpoint
inhibitor
immunomodulatori
target
therapi
result
autoimmun
hyperinflammatori
complic
work
knowledg
clinic
immunolog
could
help
practic
hematologistsoncologist
identif
manag
condit
object
support
advanc
aspho
member
field
facilit
educ
regard
best
practic
diagnosi
manag
immunolog
disord
creat
platform
develop
collabor
clinic
research
patient
hematologicaloncolog
manifest
immunolog
disord
requir
hematopoiet
stem
cell
transplant
underli
immunolog
disord
designmethod
aspho
clinic
immunolog
sig
initi
base
collabor
clinic
immunolog
societi
ci
aspho
member
pediatr
hematolog
oncolog
clinician
clinic
research
traine
elig
particip
establish
steer
committe
repres
across
unit
state
canada
divers
clinic
research
expertis
regular
teleconfer
annual
inperson
meet
develop
platform
provid
member
network
immunolog
resourc
ensur
strong
foundat
knowledg
tool
conduct
clinic
care
research
pertain
diagnosi
evalu
treatment
patient
immunolog
disord
result
current
support
member
within
onlin
commun
sever
educ
initi
success
launch
submit
invit
review
pediatr
blood
cancer
provid
casebas
review
primari
immun
regulatori
disord
host
first
immunolog
hematolog
oncolog
practic
ihop
casedbas
webinar
seri
seri
featur
casebas
discuss
patient
primari
immunodefici
disord
present
fellow
traine
mentor
senior
clinician
also
host
aspho
webinar
focus
laboratori
evalu
primari
immunodefici
immun
dysregul
syndrom
also
begun
process
lay
groundwork
clinic
research
initi
conclus
aspho
clinic
immunolog
sig
seek
serv
collabor
resourc
pediatr
hematologyoncolog
clinician
research
develop
educ
research
initi
envis
improv
care
patient
immunolog
disord
often
manag
pediatr
hematologistsoncologist
moreov
hope
broaden
understand
applic
clinic
immunolog
within
pediatr
hematologyoncolog
hope
success
initi
serv
blueprint
develop
futur
collabor
specialti
societi
patient
group
autoimmun
polyendocrinopathycandidiasisectoderm
dystrophi
apec
rare
autosom
recess
diseas
caus
air
gene
mutat
clinic
diagnosi
establish
presenc
least
two
compon
classic
triad
chronic
mucocutan
candidiasi
hypoparathyroid
addison
diseas
europ
classic
present
wide
recogn
nonendocrin
autoimmun
manifest
rare
report
recent
studi
american
apec
patient
demonstr
heterolog
present
mani
nonendocrin
manifest
includ
urticari
erupt
hepat
gastriti
intestin
dysfunct
pneumon
sjogrenslik
syndrom
uncommon
european
report
within
american
cohort
patient
develop
mean
three
nontriad
manifest
reach
classic
triad
find
air
mutat
hightit
antiifnautoantibodi
seen
european
american
cohort
present
case
two
sibl
demonstr
apecedlik
phenotyp
classic
atyp
featur
share
heterozyg
air
mutat
older
eightyearold
boy
histori
prematur
bronchopulmonari
dysplasia
onychomadesi
infanc
came
medic
attent
month
age
due
failur
thrive
ftt
addit
fever
urticari
rash
last
month
mmr
vaccin
fever
resolv
anakinra
discontinu
two
year
later
due
pneumonia
age
develop
alp
neg
lymphadenopathi
selfresolv
lung
issu
includ
chronic
cough
initi
treat
asthma
poor
bronchodil
respons
frequent
lung
infect
includ
pneumonia
per
year
age
five
evalu
ftt
reveal
growth
hormon
defici
two
year
later
diagnos
primari
addison
diseas
chronic
abdomin
discomfort
bloat
cyclic
constipationdiarrhea
recurr
rash
dystroph
nail
sicca
symptom
also
present
sister
age
five
show
ftt
growth
hormon
defici
age
one
develop
fever
rash
syndrom
last
month
sever
gerd
constip
start
infanc
ongo
age
three
develop
transamin
initi
diagnos
ebv
later
thought
autoimmun
hepat
frequent
viral
respiratori
infect
pneumonia
age
two
chronic
cough
poor
bronchodil
respons
life
evalu
seizur
age
three
show
normal
brain
activ
brain
mri
reveal
partial
agenesi
corpu
callosum
microgyria
brother
similar
mri
find
children
development
motor
delay
poor
tone
brain
dysgenesi
neurodevelopment
delay
previous
describ
apec
although
typic
atyp
symptom
histori
combin
genet
find
led
investig
apecedlik
syndrom
autoantibodi
test
confirm
hightit
antiifnautoantibodi
typic
apec
children
hightit
autoantibodi
found
almost
exclus
apec
pneumon
brother
whole
exom
sequenc
copi
number
variat
analys
underway
evalu
patient
condit
case
demonstr
import
clinic
present
evalu
genet
result
guidanc
therapeut
manag
submiss
id
rational
infant
low
cell
receptor
excis
circl
trec
born
queen
nassau
suffolk
counti
refer
center
evalu
studi
elucid
demograph
laboratori
characterist
refer
infant
transient
persist
idiopath
cell
lymphopenia
tcl
without
clearli
identifi
genet
acquir
etiolog
method
retrospect
analysi
perform
septemb
trec
screen
start
end
decemb
descript
statist
calcul
demograph
laboratori
characterist
ttest
mannwhitney
test
use
compar
laboratori
variabl
pearson
spearman
test
use
determin
correl
initi
trec
level
cell
count
definit
popul
transient
tcl
patient
normal
age
year
result
eighteen
infant
transient
persist
tcl
identifi
male
compris
transient
persist
tcl
cohort
white
compris
transient
persist
tcl
cohort
mean
initi
trec
level
differ
transient
persist
cohort
vs
trecsl
blood
p
mean
initi
absolut
count
vs
cellsl
p
vs
cellsl
p
median
initi
absolut
count
vs
cellsl
p
higher
transient
vs
persist
cohort
initi
trec
level
correl
initi
absolut
count
median
age
resolut
transient
cohort
day
rang
absolut
count
rare
exceed
report
median
valu
age
remain
closer
percentil
age
day
life
major
transient
persist
tcl
patient
demonstr
unremark
lymphocyt
prolifer
mitogen
conclus
center
transient
tcl
cohort
appear
predominantli
male
nonwhit
wherea
persist
tcl
cohort
evenli
distribut
sex
still
predominantli
nonwhit
transient
cohort
lower
initi
trec
level
higher
initi
cell
count
cohort
appear
rel
intact
vitro
function
introduct
primari
immun
defici
diseas
pidd
typic
consid
pediatr
ill
although
advanc
treatment
diagnosi
chang
paradigm
current
data
pidd
older
patient
limit
object
character
preval
pidd
among
older
individu
use
patient
databas
maintain
consortium
independ
immunolog
clinic
ciic
compris
specialti
immunolog
outpati
practic
us
method
patient
pidd
identifi
ciic
databas
use
code
total
record
geographicallydivers
clinic
identifi
character
age
gender
pidd
diagnosi
result
pidd
patient
ciic
registri
year
age
see
figur
within
age
group
patient
femal
common
diagnos
among
patient
year
age
includ
common
variabl
immunodefici
predomin
abnorm
bcell
number
function
antibodi
defici
near
normal
immunoglobulin
comparison
registri
includ
patient
age
year
age
group
predominantli
male
common
code
within
younger
cohort
rel
evenli
distribut
hereditari
hypogammaglobulinemia
antibodi
defici
near
normal
immunoglobulin
common
variabl
immunodefici
predomin
abnorm
bcell
number
function
conclus
data
suggest
pidd
patient
age
may
preval
previous
report
addit
research
need
corrobor
find
character
natur
pidd
popul
determin
whether
uniqu
diagnost
treatment
consider
within
demograph
introductionbackground
increas
suscept
invas
infect
neisseria
well
document
patient
defici
termin
complement
protein
molecular
attack
complex
construct
complement
compon
defici
complement
describ
previous
african
american
south
african
popul
complement
defici
inherit
codomin
pattern
multipl
known
mutat
present
case
previous
healthi
male
present
invas
n
meningitid
infect
found
novel
mutat
note
genet
sequenc
complement
gene
object
present
case
previous
healthi
male
present
invas
n
meningitid
infect
genet
sequenc
found
three
mutat
complement
gene
two
describ
previous
third
novel
mutat
method
male
known
histori
present
us
histori
emesi
found
febril
quickli
decompens
develop
septic
shock
blood
cultur
drawn
within
hour
grew
n
meningitid
treat
broad
spectrum
antibiot
upon
arriv
subsequ
narrow
ceftriaxon
hospit
cours
complic
dissemin
intravascular
coagul
well
acut
tubular
necrosi
lead
endstag
renal
diseas
list
kidney
transplant
result
immunodefici
evalu
note
undetect
refer
rang
complement
level
return
refer
rang
refer
rang
complement
function
screen
return
refer
rang
complement
level
within
normal
limit
genet
sequenc
show
patient
compound
heterozyg
two
known
four
variant
report
recur
african
patient
complement
defici
includ
predict
result
frameshift
prematur
protein
termin
also
found
heterozyg
sequenc
result
amino
acid
substitut
variant
rare
one
larg
databas
report
allel
homozyg
state
report
case
complement
defici
previous
conclus
present
case
previous
healthi
male
invas
meningococc
diseas
compound
heterozyg
two
mutat
associ
total
complement
defici
howev
found
subtot
defici
furthermor
third
novel
mutat
complement
gene
investig
warrant
signific
find
impact
relev
possibl
kidney
transplant
background
measur
function
classic
pathway
complement
activ
use
sever
diseas
state
includ
complement
defici
autoimmun
condit
system
lupu
erythematosu
certain
form
nephriti
origin
method
assess
classic
pathway
activ
haemolyt
method
assay
time
consum
reagent
stabil
issu
due
use
sheep
red
blood
cell
also
high
labtolab
variabl
due
differ
protocol
use
report
assay
characterist
autom
commerci
liposomebas
assay
measur
activ
also
compar
result
obtain
use
tradit
haemolyt
method
autom
liposomebas
method
use
spaplu
turbidimetr
analys
method
linear
studi
perform
base
clsi
guidelin
linear
rang
spaplu
liposom
assay
establish
analysi
seri
sampl
dilut
evalu
result
predefin
goal
recoveri
cv
precis
assess
base
clsi
guidelin
day
sampl
differ
activ
uml
run
duplic
two
run
per
day
use
reagent
lot
differ
analys
interfer
analysi
perform
spike
haemoglobin
bilirubin
chyle
ascorb
acid
salin
control
sampl
measur
activ
assay
comparison
studi
sera
routin
patient
sampl
use
sampl
collect
chulalongkorn
hospit
faculti
medicin
chulalongkorn
univers
thailand
classic
pathway
activ
assess
use
haemolyt
method
also
use
liposom
base
assay
use
spaplu
turbidimetr
analys
bind
site
ltd
birmingham
uk
protein
concentr
also
avail
sampl
result
liposom
assay
give
linear
respons
rang
uml
cover
measur
rang
assay
uml
standard
analys
dilut
neat
within
run
run
day
cv
total
cv
sampl
minim
interfer
observ
four
common
interfer
test
signific
correl
observ
two
method
p
agreement
method
determin
whether
patient
lower
limit
assay
normal
rang
individu
disagr
normal
result
use
haemolyt
method
low
valu
liposom
assay
valu
avail
concentr
lower
limit
assay
normal
rang
conclus
liposom
assay
use
spaplu
analys
pass
assay
develop
guidelin
base
set
clsi
linear
precis
interfer
strong
correl
autom
assay
haemolyt
method
use
five
addit
patient
low
concentr
defin
low
use
spaplu
liposom
method
compar
haemolyt
method
submiss
id
backgroundaim
rotaviru
vaccin
live
viral
vaccin
part
routin
us
childhood
immun
schedul
live
viral
vaccin
administ
infant
mother
receiv
biolog
medic
pregnanc
potenti
caus
vaccineassoci
diseas
infant
death
dissemin
mycobacteri
infect
vaccin
bacil
calmetteguerin
bcg
infant
whose
mother
receiv
infliximab
pregnanc
report
current
recommend
infant
born
women
receiv
biolog
therapi
pregnanc
receiv
live
viral
vaccin
howev
pauciti
inform
regard
advers
event
live
viral
vaccin
report
two
infant
born
mother
receiv
infliximab
pregnanc
toler
complet
seri
rotaviru
vaccin
method
two
infant
receiv
rotaviru
vaccin
whose
mother
receiv
infliximab
monoclon
antibodi
tumor
necrosi
factor
alpha
block
inflammatori
respons
pregnanc
identifi
chart
review
mother
chart
assess
time
biolog
dose
pregnanc
concurr
immunosuppress
therapi
result
mother
first
infant
crohn
diseas
receiv
infliximab
everi
week
throughout
pregnanc
final
infus
approxim
week
estim
gestat
age
ega
take
addit
immunosuppress
drug
throughout
pregnanc
infant
born
week
ega
infant
receiv
rotaviru
vaccin
month
age
infant
coexist
medic
condit
record
hospit
first
year
life
side
effect
rotaviru
vaccin
document
well
child
examin
child
growth
normal
first
year
life
mother
second
infant
also
crohn
diseas
receiv
infliximab
infus
everi
six
week
pregnanc
week
ega
addit
took
mesalamin
antiinflammatori
daili
infant
born
week
ega
babi
brief
uncompl
neonat
intens
care
unit
stay
medic
condit
diagnos
time
birth
first
year
life
child
receiv
rotaviru
vaccin
month
chronolog
age
infant
experi
document
advers
reaction
child
present
emerg
depart
twice
first
year
life
thrush
month
age
viral
gastroenter
month
age
child
growth
curv
unremark
conclus
report
two
infant
whose
mother
receiv
infliximab
pregnanc
safe
toler
seri
rotaviru
vaccin
neither
infant
case
seri
suffer
minor
sever
advers
event
direct
consequ
receiv
rotaviru
vaccin
suggest
administr
rotaviru
vaccin
may
safe
infant
whose
mother
receiv
biolog
therapi
introduct
combin
immunodefici
cid
aris
partial
loss
function
variant
recogn
scid
gene
lead
rel
lymphopenia
poorli
function
oligoclon
cell
cid
commonli
associ
variant
rag
gene
gene
also
implic
clinic
symptom
may
less
sever
onset
gener
delay
compar
typic
scid
present
case
report
femal
present
histori
recurr
progress
worsen
infect
involv
multipl
microorgan
organ
start
infanc
requir
frequent
hospit
bacteri
viral
infect
includ
rhinosinus
otiti
media
herpet
stomat
dental
abscess
pneumonia
pulmonari
mycobacteri
abscess
cmv
hepat
urinari
tract
infect
dermal
abscess
groin
hidraden
fungal
yeast
infect
includ
cryptococc
mening
oral
thrush
dermatophytosi
face
osteomyel
finger
onychomycosi
laboratori
test
show
mildli
low
cell
count
revers
ratio
cell
almost
absent
b
cell
low
nk
cell
count
cell
mostli
memori
phenotyp
cell
develop
show
low
count
cell
tcell
stimul
test
demonstr
poor
prolifer
respons
concanavalin
tetanu
toxoid
candida
albican
nearnorm
respons
pokewe
pha
low
ig
level
iga
igm
ige
except
igg
ml
due
replac
sinc
earli
childhood
limit
genet
evalu
age
show
heterozyg
variant
gene
c
c
discuss
loss
function
variant
gene
known
caus
tbnk
type
scid
missens
variant
report
diseaseassoci
variant
predominantli
zinc
bind
region
missens
variant
patient
also
lie
within
zinc
bind
region
amino
acid
variant
rare
mean
allel
frequenc
gnomad
identifi
least
one
individu
scid
b
cell
nk
although
classifi
variant
unknown
signific
occurr
least
two
individu
defici
b
cellswithin
function
import
domainsupport
interpret
variant
may
pathogen
patient
cid
rag
variant
either
homozyg
poorli
function
allel
one
nonunfuciton
second
poorli
function
allel
detect
singl
potenti
pathogen
allel
patient
decreas
nk
cell
addit
b
cell
defect
genet
studi
includ
whole
exom
sequenc
plan
identifi
variant
relev
gene
rational
infant
low
cell
receptor
excis
circl
trec
born
queen
nassau
suffolk
counti
new
york
refer
northwel
health
evalu
abnorm
newborn
screen
demograph
immun
paramet
infant
transient
cell
lymphopenia
ttcl
without
clearli
identifi
genet
acquir
etiolog
describ
tcl
consid
transient
lymphopenia
resolv
month
age
similar
data
follow
infant
low
lymphocyt
fill
program
unit
state
immunodefici
network
usidnet
present
method
retrospect
analysi
two
separ
patient
cohort
ttcl
describ
cohort
includ
patient
refer
singl
center
northwel
health
ny
septemb
decemb
usidnet
use
data
track
fill
june
juli
result
referr
northwel
infant
ttcl
identifi
infant
predominantli
male
noncaucasian
fill
particip
infant
ttcl
identifi
infant
predominantli
male
noncaucasian
initi
laboratori
paramet
northwel
versu
fill
cohort
summar
median
trec
level
vs
trecl
blood
b
median
absolut
count
vs
cellsl
c
median
count
vs
cellsl
median
absolut
count
vs
cellsl
initi
cell
inform
avail
northwel
fill
infant
median
mitogen
prolifer
studi
perform
northwel
fill
infant
northwel
fill
infant
demonstr
normal
prolifer
genet
test
target
genet
panel
chromosom
microarray
cma
perform
northwel
fill
infant
genet
chromosom
aberr
identifi
whole
exom
sequenc
we
perform
either
cohort
northwel
fill
infant
receiv
initi
rotaviru
vaccin
fill
infant
vaccin
advers
effect
report
northwel
infant
receiv
first
rotaviru
dose
normal
mitogen
prolifer
decreas
prolifer
phytohemagglutinin
conclus
identifi
biomark
ttcl
develop
evidencebas
guidelin
diagnosi
manag
ttcl
import
knowledg
gap
descript
studi
limit
small
sampl
size
constraint
registrybas
research
although
appear
differ
cohort
find
suggest
ttcl
may
disproportion
affect
differ
segment
popul
ttcl
infant
normal
mitogen
prolifer
may
abl
toler
rotaviru
vaccin
thu
routin
check
prolifer
studi
ttcl
infant
may
help
risk
stratifi
patient
minim
vaccinerel
advers
event
current
insuffici
evid
recommend
extens
genet
test
genet
panel
cma
we
systemat
collect
inform
patient
characterist
outcom
well
encourag
increas
particip
registri
fill
may
help
address
shortcom
background
system
lupu
erythematosu
sle
chronic
inflammatori
diseas
affect
multipl
organ
measur
antidsdna
antibodi
ab
gold
standard
serolog
test
use
diagnosi
monitor
sle
higher
serum
level
associ
wors
prognosi
howev
antidsdna
ab
pathogen
patient
consist
high
level
low
diseas
activ
one
mechan
suggest
pathogen
antibodi
complement
activ
describ
assay
measur
bind
activ
antidsdna
ab
sle
patient
materi
method
concentr
antidsdna
ab
determin
use
quantalit
dsdna
elisa
kit
inova
per
manufactur
instruct
order
determin
bind
capac
bound
ab
sampl
ad
precoat
plate
incub
bound
antidsdna
complex
detect
use
biotinyl
antibodi
ngml
streptavidin
peroxidas
mgml
normal
refer
rang
develop
serum
sampl
healthi
control
upper
limit
normal
rang
use
cutoff
dsdna
ab
bind
capac
bound
ab
assess
sle
patient
compar
marker
sle
diseas
activ
index
sledai
score
result
display
absorb
au
result
conclus
percentil
rang
antidsdna
ab
au
bind
activ
au
develop
measur
gener
healthi
serum
sampl
sle
patient
increas
anti
dsdna
ab
concentr
au
separ
low
au
high
au
bind
activ
patient
whose
dsdna
ab
high
bind
activ
found
significantli
higher
sledai
score
mean
vs
serum
concentr
serum
dsdna
ab
measur
anoth
method
serum
concentr
significantli
differ
two
group
assay
suggest
dsdna
ab
sle
patient
differ
abil
bind
complement
high
complement
bind
activ
antibodi
may
link
activ
form
diseas
xlink
lymphoprolif
xlp
primari
immunodefici
caus
signal
lymphocyt
activ
molecul
slam
associ
protein
sap
defici
patient
xlp
sever
immun
dysregul
usual
trigger
ebv
infect
lead
fulmin
infecti
mononucleosi
dysgammaglobulinemia
lymphoprolifer
without
hematopoiet
stem
cell
transplant
hsct
fatal
reportedli
age
report
natur
histori
xlp
patient
describ
lesson
learn
patient
healthi
develop
normal
age
develop
progress
respiratori
symptom
lung
biopsi
reveal
matur
lymphoplasmacyt
infiltr
alveolar
septa
consist
lymphoid
interstiti
pneumonia
lip
receiv
corticosteroid
cyclophosphamid
signific
improv
age
develop
sever
infecti
mononucleosi
fever
hepatosplenomegali
lymphadenopathi
lymphocytosi
protract
clinic
cours
eventu
recov
seroconvert
typic
convalesc
pattern
subsequ
develop
hypogammaglobulinemia
start
intraven
immunoglobulin
ivig
year
brother
develop
lip
subsequ
hemophagocyt
lymphohistocytosi
hlh
die
within
month
overwhelm
candidiasi
unfortun
youngest
brother
age
develop
lip
die
month
later
massiv
gastrointestin
bleed
sibl
treat
corticosteroid
cyclophosphamid
detect
ebv
infect
age
year
patient
experienc
recurr
stroke
found
biopsyproven
cn
vascul
treat
interferonand
recov
residu
left
side
weak
lost
followup
continu
ivig
immunomodulatori
agent
sever
decad
progress
lung
diseas
recurr
seizur
control
antiepilept
age
develop
sudden
vision
chang
headach
rightsid
weak
follow
seizur
mri
brain
reveal
small
bilater
area
acut
infarct
suggest
central
embol
event
howev
primari
thrombu
identifi
receiv
immunosuppress
anticoagul
eventu
discharg
home
resolut
weak
baselin
patient
refer
clinic
discharg
reevalu
year
immun
profil
time
show
therapeut
igg
trough
lowundetect
igma
normal
tbnkcell
count
normal
spontan
decreas
antibodydepend
nk
cytotox
sap
protein
express
cell
delet
x
chromosom
encompass
gene
encod
sap
mother
carrier
delet
function
statu
exclud
option
hsct
year
later
rapid
deterior
recurr
lung
infect
liver
failur
thrombocytopenia
bone
marrow
biopsi
reveal
hodgkin
lymphoma
declin
chemotherapi
die
day
diagnosi
case
repres
rare
patient
xlp
surviv
fifth
decad
without
hsct
particularli
experienc
mononucleosi
nonebv
relat
cn
vascul
patient
surviv
decad
longer
brother
like
share
genet
defect
without
evid
somat
revers
sap
express
explain
milder
clinic
phenotyp
case
may
help
understand
natur
histori
xlp
confirm
prognosi
remain
poor
without
hsct
haematolog
oncolog
chu
de
major
neg
regul
immun
respons
haploinsuffici
identifi
monogen
caus
primari
immunodefici
patient
present
common
variabl
immunodefici
cvid
phenotyp
autoimmun
present
case
pb
man
follow
immunolog
servic
center
year
diagnosi
cvid
first
made
patient
present
atyp
transvers
myeliti
low
immunoglobulin
level
lymphopenia
year
clinic
pictur
domin
variou
form
autoimmun
name
inflammatori
demyelin
disord
central
nervou
system
autoimmun
haemolyt
anemia
immun
thrombocytopenia
cryptogen
organ
pneumonia
rheumatoidlik
polyarthr
chronic
liver
transamin
biopsyproven
moder
fibrosi
lymphocyt
coliti
malabsorpt
immunoglobulin
replac
therapi
start
diagnosi
autoimmun
sequenti
treat
methotrex
interferon
beta
cyclophosphamid
mycophenol
mofetil
rituximab
final
combin
lowdos
prednison
sirolimu
stabil
neurolog
condit
debilit
complic
immun
dysregul
syndrom
bone
marrow
transplant
offer
declin
patient
due
perceiv
good
qualiti
life
compar
transplantassoci
risk
patient
later
refer
hematolog
ward
juli
septic
shock
complic
febril
neutropenia
part
twomonth
gradualonset
pancytopenia
diagnosi
immunemedi
aplast
anemia
soon
becam
appar
demonstr
bone
marrow
biopsi
perform
peripher
center
two
day
prior
admiss
underli
pneumonia
thereaft
biopsyinduc
staphylococcu
aureu
iliac
osteomyel
softtissu
abscess
treat
broadspectrum
antibiot
well
multipl
surgic
intervent
patient
start
eltrombopag
highdos
corticosteroid
cyclosporin
latter
promptli
switch
tacrolimu
due
liver
enzym
disturb
result
signific
hematolog
respons
despit
seven
week
treatment
concurr
treatment
complic
infect
upper
gastrointestin
bleed
intensivecareunit
myopathi
time
genet
confirm
haploinsuffici
receiv
patient
thereaft
start
abatacept
day
current
hospit
administr
equin
antithymocyt
initi
foregon
perceiv
infecti
risk
set
poor
iliac
wound
heal
superimpos
adenoviru
viremia
howev
given
lack
respons
given
day
hospit
haematolog
respons
began
day
hospit
steadi
rise
alllineag
myelopoiesi
complet
neutrophil
respons
platelet
nearcomplet
respons
well
resolut
transfus
need
day
wait
wellmatch
bone
marrow
donor
isol
platelet
decreas
observ
attribut
multipl
factor
includ
lowgrad
thrombot
microangiopathi
inflammatori
consumpt
drugrel
thrombocytopenia
patient
remain
well
knowledg
patient
present
one
sever
manifest
haploinsuffici
respond
target
therapi
abatacept
bridg
hematopoiet
stem
cell
transplant
resolut
immun
infecti
complic
show
genet
diagnosi
help
optim
manag
presum
cvid
patient
hospit
de
octubr
health
research
institut
madrid
spain
dept
immunolog
univers
hospit
octubr
madrid
spain
background
xlfcernnuno
defici
rare
primari
immunodefici
classifi
within
dna
repair
defect
patient
present
sever
growth
retard
microcephali
lymphopenia
increas
cellular
sensit
ioniz
radiat
describ
two
unrel
case
nonsens
mutat
gene
show
signific
differ
clinic
present
immunolog
profil
similar
dna
repair
defect
method
missens
mutat
identifi
target
nextgener
sequenc
inhous
design
panel
gene
foci
experi
primari
skin
fibroblast
irradi
ioniz
irradi
treat
etoposid
hour
irradi
cell
seed
densiti
cellsml
flask
triplic
evalu
cell
sensit
gammair
gy
adher
cell
trypsin
count
day
later
pbmc
patient
healthi
control
irradi
fix
stain
phosphohiston
mean
fluoresc
intens
mfi
evalu
gate
lymphocyt
result
report
two
patient
harbor
homozyg
mutat
gene
strikingli
clinic
phenotyp
rang
sever
combin
immunodefici
isol
thrombocytopenia
follow
escolar
age
tabl
harbour
mutat
gene
differ
immunolog
featur
tabl
present
mild
lymphopenia
hypersensit
nhej
repair
defect
typic
patient
defect
hand
present
sever
phenotyp
tb
howev
hypersensit
nhej
repair
defect
similar
note
surviv
first
decad
live
patient
aliv
well
hsct
discuss
usual
repair
defect
disord
assess
immunofluoresc
assay
irradiationinduc
foci
use
skin
fibroblast
high
throughput
sensit
reliabl
assay
quantifi
foci
pbmc
isol
blood
sampl
would
valuabl
tool
diagnos
patient
perform
hsct
earli
flow
cytometri
fc
appli
rapid
diagnost
tool
dna
repair
disord
patient
homozyg
mutat
gene
previous
report
two
patient
die
year
anoth
patient
alreadi
year
old
aliv
without
hsct
howev
none
patient
present
sever
lymphopenia
observ
first
patient
conclus
assign
time
accur
diagnosi
paramount
import
manag
patient
defect
dna
repair
era
nb
abnorm
trec
assay
follow
ng
approach
cernunno
defici
may
present
earli
life
scid
rsscid
defect
sinc
genet
diagnosi
take
time
function
radiosensit
assay
peripher
blood
may
lead
correct
diagnosi
avoid
exposur
alkyl
agent
condit
regimen
prior
genet
diagnosi
would
also
help
cancer
patient
individu
guid
dose
ioniz
radiat
ir
andor
genotox
agent
avoid
accumul
cell
genom
instabl
could
acceler
cancer
develop
figur
skin
lesion
also
significantli
improv
start
medic
figur
hospit
complic
fluid
overload
hypertens
fluid
overload
hypertens
resolv
prior
discharg
remain
prednison
daili
cetirizin
ranitidin
cromolyn
benadryl
hydroxyzin
prn
knowledg
youngest
patient
success
treat
midostaurin
well
therapi
appar
side
effect
resolut
mani
system
mastocytosi
symptom
includ
skin
lesion
axillari
mass
improv
diarrhea
growth
well
object
improv
tryptas
level
case
report
twoyearold
male
present
hospit
pain
nonprurit
facial
groin
rash
rash
start
one
week
prior
present
associ
fever
histori
remark
failur
thrive
ftt
chronic
bilater
leg
pain
antalg
gait
preced
month
diagnos
handfootmouth
diseas
varicella
also
recurr
cervic
lymphadenopathi
lad
greater
one
year
requir
incis
drainag
gram
stain
gomori
methenaminesilv
nitrat
stain
gm
neg
patholog
show
acut
chronic
inflamm
area
necrosi
famili
histori
neg
autoimmun
diseas
immunodefici
infecti
exposur
histori
signific
incarcer
father
unknown
tuberculosi
statu
histori
live
shelter
physic
examin
patient
well
appear
multipl
erythemat
papul
superfici
eros
scab
face
figur
lower
abdomen
genit
area
buttock
proxim
lower
extrem
larg
firm
nontend
submandibular
lymph
node
also
small
palpabl
axillari
inguin
lymph
node
bilater
laboratori
workup
reveal
normal
white
blood
cell
platelet
count
microcyt
anemia
erythrocyt
sediment
rate
mmhr
creactiv
protein
mgdl
full
bodi
magnet
reson
imag
mri
reveal
bilater
cervic
supraclavicular
right
hilar
inguin
lymphadenopathi
patchi
right
upper
lobe
consolid
least
one
small
area
cavit
figur
adjac
smaller
area
ring
enhanc
also
reveal
three
small
nonspecif
hypodens
foci
within
right
lobe
liver
borderlin
splenomegali
given
find
concern
granulomat
diseas
patient
underw
liver
biopsi
figur
show
nonspecif
evid
necrot
granulomat
diseas
microbiolog
cultur
stain
bacteria
acidfast
bacilli
fungi
neg
infecti
workup
neg
hsv
tuberculosi
hiv
syphili
histoplasmosi
toxoplasmosi
superfici
bacteri
cultur
face
groin
grew
mix
gram
posit
neg
organ
includ
methicillinsuscept
staphylococcu
aureu
mssa
immunolog
workup
reveal
borderlin
elev
iga
igg
normal
igm
normal
b
nkcell
count
pneumococc
tetanu
titer
dihydrorhodamin
dhr
flow
cytometr
test
posit
consist
diagnosi
chronic
granulomat
diseas
cgd
genet
test
confirm
xlink
diseas
treat
acyclovir
ceftriaxon
resolut
rash
conclus
present
case
twoyearold
male
newli
diagnos
xlink
cgd
though
seen
multipl
healthcar
provid
recurr
lymphadenopathi
preced
year
histori
recurr
viral
bacteri
infect
signific
famili
histori
might
implic
primari
immunodefici
time
present
diffus
rash
could
caus
palpabl
lymphadenopathi
exam
high
index
suspicion
cgd
set
recurr
lad
ftt
prompt
send
dhr
led
diagnosi
chronic
granulomat
diseas
cgd
inherit
primari
immunodefici
pid
result
inflammatori
respons
dysregul
increas
suscept
certain
bacteri
fungal
infect
without
cur
treatment
bone
marrow
transplant
remain
chronic
diseas
daili
medic
manag
intermitt
treatment
lifelong
surveil
gener
chronic
diseas
involv
physic
psycholog
social
effect
affect
patient
qualiti
life
although
research
done
pid
affect
qualiti
life
littl
research
unit
state
cgd
affect
patient
qualiti
life
examin
effect
cgd
patient
qualiti
life
part
voluntari
research
protocol
examin
natur
histori
immun
defici
administ
qolbref
instrument
adult
cgd
patient
enrol
nih
irb
approv
protocol
seen
infecti
diseas
clinic
nation
institut
health
nih
fivemonth
period
qolbref
compris
item
measur
follow
broad
domain
physic
health
psycholog
health
social
relationship
environ
item
rate
likert
scale
valid
cross
cultur
wide
field
test
survey
interview
administ
patient
male
femal
genet
confirm
cgd
age
rang
year
old
mean
age
year
distribut
xlink
cgd
autosom
recess
cgd
result
obtain
present
rational
common
variabl
immunodefici
cvid
common
primari
immunodefici
estim
preval
aim
analyz
clinic
present
associ
comorbid
amongst
cvid
patient
usa
method
data
cvid
patient
report
unit
state
immunodefici
network
usidnet
analyz
base
clinic
immunolog
genet
factor
univari
analysi
spearman
rank
coeffici
done
analyz
correl
diseas
outcom
observ
surviv
estim
use
kaplanmei
method
result
among
patient
femal
male
median
age
diagnosi
year
mean
sd
rang
iqr
median
age
onset
year
mean
sd
rang
iqr
femal
show
longer
delay
diagnosi
vs
year
higher
bodi
mass
index
bmi
linearli
correl
age
diagnosi
r
surviv
analysi
delay
age
diagnosi
increas
risk
death
hr
ci
conclus
studi
suggest
longer
delay
diagnosi
femal
subject
strong
associ
diagnosi
cvid
patient
higher
bmi
femal
may
longer
period
without
symptom
lead
diagnost
delay
genderbas
disparitiesbas
inquiri
trend
may
need
addit
studi
physic
wellb
primari
immunodefici
pi
physic
maladi
pi
welldocu
sinc
advanc
identif
treatment
pi
mani
led
live
physic
infect
group
diseas
manag
howev
well
understood
emot
mental
health
aspect
live
pi
part
larger
survey
project
idf
nation
patient
survey
studi
aim
quantifi
potenti
mental
health
issu
challeng
face
adult
pi
hypothesisthos
pi
suffer
statist
higher
rate
depress
compar
us
gener
popul
idf
nation
patient
survey
nation
distribut
unincentiv
mailbas
survey
person
idf
patient
databas
identifi
either
adult
pi
parentcaretak
child
pi
questionnair
compris
approxim
main
question
pi
well
valid
brief
fatigu
inventori
patient
health
instrument
addit
question
ask
current
use
prescript
medic
anxieti
depress
stress
pain
purpos
studi
adult
respond
pi
includ
basi
analysi
twoitem
patient
health
questionnair
meet
criteria
gener
screen
depress
suggest
us
prevent
servic
task
forc
score
scale
score
three
higher
suggest
cutpoint
depress
screen
accord
ahrq
studi
util
mep
data
respond
score
three
greater
survey
adult
score
three
greater
overal
survey
score
lower
mc
scale
compar
us
popul
p
adult
pi
score
three
higher
averag
mc
met
phq
threshold
survey
also
like
report
moder
sever
limit
normal
activ
result
emot
problem
fell
threshold
versu
p
surprisingli
met
phq
threshold
report
much
higher
use
prescript
medic
anxieti
depress
stress
versu
threshold
p
well
higher
report
use
prescript
pain
medic
versu
threshold
p
though
moder
sever
fatigu
report
threshold
phq
score
threshold
report
experienc
moder
sever
fatigu
p
health
care
provid
consid
includ
overal
health
assess
patient
pi
score
three
higher
refer
appropri
profession
evalu
lek
et
al
semiconserv
amino
acid
substitut
may
impact
secondari
protein
structur
insilico
analys
support
deleteri
effect
locat
within
domain
critic
function
domain
chandesri
et
al
koskela
et
al
thu
determin
variant
like
pathogen
patient
prophylact
treatment
optim
tmpsmx
twice
daili
prevent
infect
also
start
hibiclen
chlorhexidin
bath
per
week
refer
pulmonolog
optim
pulmonari
health
set
bronchiectasi
mild
declin
dlco
advis
followup
yearli
basi
primari
immunodefici
clinic
assess
recurr
infect
chang
pulmonari
health
final
target
test
clinic
evalu
patient
parent
recommend
determin
inherit
aros
de
novo
pathogen
role
missens
chang
would
support
occur
de
novo
segreg
diseas
famili
upload
file
upload
pulmonari
function
test
resultspdf
j
clin
immunol
suppl
introduct
lipopolysacchariderespons
beigelik
anchor
protein
lrba
defici
rare
autosom
recess
diseas
immun
system
character
hypogammaglobulinemia
decreas
express
regulatori
cell
reg
due
defect
intracellular
traffick
previou
vitro
studi
shown
signific
increas
express
lrba
defici
cell
overnight
cultur
chloroquin
older
antimalari
agent
effect
like
due
increas
lysosom
ph
howev
evid
effect
human
subject
administr
weight
appropri
dose
antimalari
agent
present
set
sibl
lrba
defici
express
measur
four
week
start
hydroxychloroquin
case
report
case
eastindian
boy
autoimmun
thyroid
type
diabet
mellitu
dm
short
statur
autoimmun
cytopenia
lymphadenopathi
refer
immunolog
clinic
year
age
suspicion
autoimmun
lymphoprolif
disord
primari
immunodefici
genet
panel
sent
reveal
homozyg
mutat
lrba
gene
novel
variant
result
frameshift
creat
prematur
stop
codon
amino
acid
downstream
locat
may
lead
absent
abnorm
protein
lung
ct
scan
show
interstiti
lung
diseas
lung
biopsi
show
interstiti
nodular
diffus
lymphoid
prolifer
diagnosi
led
test
sister
case
given
histori
autoimmun
ill
famili
histori
consanguin
case
girl
type
dm
autoimmun
thyroid
lymphadenopathi
psoriat
arthriti
seizur
lung
imag
show
pulmonari
nodul
without
interstiti
lung
diseas
case
receiv
hydroxychloroquin
wait
insur
approv
abatacept
express
treg
measur
prior
four
week
start
hydroxychloroquin
treatment
baselin
case
cell
treg
express
contrast
treg
healthi
control
mean
fluoresc
intens
mfi
ratio
mfi
chang
week
hydroxychloroquin
treatment
mgkgday
solubl
receptor
level
measur
case
baselin
level
pgml
decreas
pgml
week
hydroxychloroquin
treatment
case
cell
found
treg
express
ratio
increas
one
month
hydroxychloroquin
increas
mfi
also
note
case
drop
solubl
receptor
level
pgml
treatment
conclus
contrast
previou
vitro
assay
find
signific
increas
express
regulatori
cell
vivo
week
hydroxychloroquin
interestingli
solubl
receptor
level
improv
dramat
hydroxychloroquin
submiss
id
human
defect
result
defect
intrins
bcell
differenti
function
class
switch
introductionbackground
autosom
domin
heterozyg
mutat
encod
protein
identifi
etiolog
form
primari
immunodefici
disord
present
hypogammaglobulinemia
defect
bcell
matur
endocrinopathi
autoimmun
manifest
human
effect
alter
mechan
immun
system
impair
fulli
delin
object
understand
mechan
antibodi
defici
patient
hypomorph
mutat
evalu
blymphocyt
prolifer
differenti
function
gene
express
method
immunophenotyp
primari
bcell
subject
mutant
complet
flow
cytometri
prolifer
bcell
assess
cfse
stimul
primari
bcell
healthi
mutant
subject
differenti
healthi
affect
bcell
plasmablast
follow
stimul
assess
flow
cytometri
supernat
cell
assay
iga
igg
igm
product
elisa
studi
defect
classswitch
recombin
bcell
ebvtransform
bcell
affect
healthi
individu
stimul
express
aicda
gene
quantifi
qpcr
parallel
experi
ebv
bcell
wildtyp
mutant
individu
stimul
aid
activationinduc
cytidin
deaminas
protein
level
determin
western
blot
result
patient
hypomorph
mutat
low
memori
bcell
igdigm
classswitch
memori
bcell
igdigm
number
vitro
primari
bcell
patient
demonstr
reduct
prolifer
cell
divis
respons
p
compar
healthi
bcell
mutant
bcell
signific
reduct
plasmablast
differenti
p
secret
significantli
lower
level
immunoglobulin
respons
stimul
mutant
bcell
mutant
ebv
bcell
fail
increas
aicda
express
aid
protein
level
respons
stimul
conclus
studi
demonstr
hypomorph
mutat
human
affect
intrins
bcell
prolifer
differenti
mutat
impair
transcript
aicda
gene
encod
aid
key
protein
involv
bcell
classswitch
recombin
gene
defect
also
impair
immunoglobulin
product
seen
common
variabl
immunodeficiencylik
case
studi
provid
uniqu
translat
insight
physiolog
activ
downstream
immunolog
output
human
expand
suggest
experiment
observ
mice
background
studi
evalu
qualiti
life
qol
patient
report
outcom
primari
immunodefici
diseas
pidd
patient
studi
assess
medic
provid
percept
pidd
patient
qol
neurocognit
physic
wellb
psychosoci
health
understand
provid
belief
regard
patient
report
outcom
essenti
improv
clinic
manag
pidd
report
pidd
medic
provid
survey
result
method
provid
contact
via
email
assist
clinic
immunolog
societi
particip
complet
adult
andor
pediatricbas
likert
scale
survey
question
via
secur
onlin
survey
servic
addit
demograph
inform
survey
question
assess
provid
percept
patient
overal
qol
impress
impact
diseas
associ
treatment
mental
health
physic
wellb
neurocognit
social
relationship
schoolwork
perform
clinician
expect
make
assess
base
pidd
patient
cohort
whole
rather
specif
diagnos
patient
given
small
sampl
size
pvalu
consid
statist
signific
repeat
measur
anova
pair
ttest
analys
use
result
studi
particip
primarili
unit
state
born
train
allergi
immunolog
survey
taker
practic
within
academ
center
femal
care
children
provid
concurr
care
adult
statist
signific
differ
perceiv
overal
qol
pediatr
versu
adult
pidd
patient
provid
feel
though
pediatr
patient
good
qol
believ
adult
patient
good
qol
clinician
believ
adult
pidd
individu
difficulti
relat
associ
comorbid
rather
actual
pidd
compar
pediatr
pidd
patient
provid
felt
neurocognit
school
perform
children
often
neg
affect
pidd
neurocognit
work
perform
immunodefici
adult
clinician
believ
children
pidd
frequent
difficulti
relat
concentr
memori
p
care
pidd
adult
believ
patient
work
perform
daili
mental
function
time
neg
impact
anxieti
symptom
social
relationship
view
neg
impact
pidd
diagnosi
treatment
anger
depress
symptom
children
adult
p
pediatr
clinician
feel
pidd
patient
experi
anxieti
symptom
often
almost
alway
physic
health
paramet
energi
rather
mobil
pain
deem
deleteri
influenc
immunodefici
adult
pediatr
patient
p
conclus
result
show
medic
provid
perceiv
overal
qol
pediatr
pidd
patient
superior
adult
pidd
clinician
feel
diagnosi
associ
treatment
regimen
pidd
neg
impact
physic
wellb
psychosoci
health
schoolwork
perform
neurocognit
children
adult
cbm
complex
critic
signal
adaptor
regul
lymphocyt
activ
prolifer
surviv
metabol
primari
immunodefici
affect
compon
term
cbmopathi
result
broad
clinic
manifest
rang
sever
combin
immunodefici
scid
lymphoprolifer
present
laboratori
clinic
find
two
canadian
first
nation
patient
found
homozyg
novel
mutat
result
identifi
boy
present
sever
case
enterorhinoviru
bronchiol
interstiti
lung
diseas
boy
histori
sever
pulmonari
infect
includ
pjp
chronic
sinus
candidiasi
invas
bacteremia
sever
ileocol
oral
ulcer
requir
total
colectomi
patient
possess
absent
treg
absent
memori
b
cell
hypogammaglobulinemia
howev
poor
cell
prolifer
pha
cona
patient
found
homozyg
novel
variant
mutat
render
protein
express
unstabl
undetect
immunoblot
confirm
defici
stimul
patient
b
cell
phorbol
acet
pma
ionomycin
across
timecours
immunoblot
variou
signal
protein
nfb
ikk
ib
mapk
pathway
well
variou
cleavag
substrat
paracaspas
relb
cyld
nfb
jnk
activ
complet
absent
malt
paracapas
activ
lost
surprisingli
act
upstream
jnk
intact
furthermor
coimmunoprecipit
experi
reveal
requir
optim
associ
respons
stimul
conclus
two
case
highlight
crucial
role
regul
lymphocyt
develop
function
humor
respons
addit
identifi
oldest
known
live
individu
defici
present
uniqu
inflammatori
gastrointestin
diseas
addit
scid
ad
spectrum
phenotyp
associ
primari
immunodefici
abstract
usidnet
registri
began
niaid
contract
immun
defici
foundat
continu
today
aim
provid
resourc
clinic
lab
research
enrol
known
immunodefici
patient
nation
registri
usidnet
nih
major
nation
intern
referr
center
clinic
trial
inborn
error
immun
primari
immunodefici
diseas
mechan
deposit
nih
data
usidnet
registri
patient
inform
may
help
us
understand
mani
peopl
diseas
inform
may
improv
diagnos
treat
condit
patient
registri
design
obtain
longitudin
data
larg
number
patient
primari
immunodefici
diseas
come
nih
particip
research
data
collect
nih
electron
medic
record
system
cri
deposit
secur
registri
restrict
monitor
access
medic
inform
anonym
patient
privaci
depart
biochemistri
emori
univers
atlanta
ga
intracellular
sensor
dsrna
gener
second
messeng
activ
rnasel
mean
antivir
defens
describ
four
patient
complex
earlyonset
autoinflammatori
immunodefici
diseas
caus
heterozyg
de
novo
mutat
patient
present
earli
life
lung
inflamm
includ
pulmonari
alveolar
proteinosi
interstiti
lung
diseas
febril
flare
dermat
specif
macular
pustul
bullou
featur
often
progress
ulcer
infant
episod
bloodi
diarrhea
patient
assoc
villou
blunt
cryptiti
two
patient
oesophag
one
patient
immunoglobulin
igm
igg
iga
level
low
cell
b
cell
nk
cell
number
gener
normal
rang
exom
sequenc
identifi
de
novo
heterozyg
missens
mutat
patient
one
patient
heterozyg
de
novo
mutat
mutant
protein
express
ex
vivo
gener
cell
blast
sort
primari
patient
monocyt
b
cell
associ
spontan
rna
degrad
apoptosi
determin
rna
chip
technolog
flow
cytometri
respect
cell
affect
monocyt
display
disturb
termin
differenti
function
indic
reduc
gmcsfr
express
signal
bcell
display
reduc
classswitchrecombin
prolifer
allogen
tcell
reduc
respons
sort
mutat
monocyt
bcell
activ
interferon
respons
gene
pbmc
detect
two
unrel
patient
heterozyg
de
novo
mutat
appear
compromis
protein
stabil
transform
patient
fibroblast
transfect
cell
transfect
mutant
protein
reduc
oligoadenyl
synthesi
compar
wild
type
transfect
cell
immort
fibroblast
line
demonstr
higher
level
inflammatori
cytokin
spontan
cleavag
rna
patient
clinic
phenotyp
heterozyg
de
novo
variant
yet
formal
valid
variant
three
patient
underw
hematopoiet
stem
cell
transplant
effort
control
diarrhea
skin
inflamm
one
patient
die
ongo
chronic
graft
versu
host
diseas
two
other
aliv
reason
well
followup
year
untranspl
patient
die
result
respiratori
failur
summari
patient
de
novo
heterozyg
mutat
chronic
ongo
inflamm
multipl
organ
least
part
due
spontan
rna
cleavag
apoptosi
product
inflammatori
cytokin
type
interferon
defin
new
categori
autoinflammatori
disord
introduct
increas
suscept
infect
common
complic
chronic
granulomat
diseas
cgd
hemophagocyt
lymphohistiocytosi
hlh
sever
disord
result
hyperinflamm
hypercytokinemia
lead
multiorgan
system
dysfunct
character
certain
criteria
fever
splenomegali
cytopenia
hypofibrinogenemia
hypertriglyceridemia
hyperferritinemia
increas
solubl
evid
hemophagocytosi
decreasedabs
nk
cell
cytotox
secondari
hlh
occur
infrequ
often
preced
smolder
infect
cgd
present
case
hlh
old
male
youngest
report
case
cgd
case
old
male
previous
diagnos
xlink
cgd
due
known
famili
histori
present
fever
initi
evalu
unrev
includ
chest
xray
urinalysi
blood
csf
cultur
admit
treat
empir
cefepim
ct
demonstr
multipl
multifoc
nodul
lung
spleen
lung
nodul
biopsi
perform
antimicrobi
therapi
broaden
iv
meropenem
voriconazol
micafungin
despit
continu
fever
develop
new
onset
tachycardia
respiratori
distress
lactic
acidosi
decompens
vasoact
refractori
shock
treat
vasopressor
stress
dose
hydrocortison
addit
laboratori
evalu
reveal
rise
liver
enzym
ast
alt
cytopenia
hemoglobin
gdl
anc
platelet
coagulopathi
fibrinogen
splenomegali
present
abdomin
ultrasound
diagnosi
evolv
hlh
consid
dexamethason
administ
within
hour
clinic
decompens
patient
die
multiorgan
failur
subsequ
blood
cultur
return
gramneg
rod
ultim
burkholderia
cepacia
autopsi
confirm
hemophagocytosi
within
bone
marrow
mutat
found
gene
associ
primari
hlh
discuss
patient
cgd
suscept
infecti
complic
autoinflamm
commonli
involv
lung
gi
gu
system
patient
cgd
increas
risk
hyperinflammatori
syndrom
secondari
infect
chronic
inflamm
shown
includ
case
hlh
present
infanc
deadli
earli
consider
direct
treatment
hlh
imper
even
set
sepsi
malign
prolifer
gammadelta
cell
includ
hepatosplen
tcell
lymphoma
hstl
primari
cutan
tcell
lymphoma
tcell
larg
granular
lymphocyt
leukemia
tlgl
former
two
often
associ
splenomegali
cytopenia
howev
reactiv
prolifer
gammadelta
cell
spleen
mimick
malign
report
signific
risk
misdiagnosi
femal
present
two
year
unintent
weight
loss
persist
leukopenia
thrombocytopenia
leucocyt
around
x
platelet
around
x
l
also
associ
macrocyt
anemia
laboratori
evid
dat
direct
antiglobin
test
neg
hemolysi
physic
examin
comput
tomographi
ct
imag
show
splenomegali
hepatomegali
lymphadenopathi
serum
liver
function
test
autoimmun
studi
hemolysi
hereditari
diseas
workup
viral
bacteri
serolog
normal
neg
except
mild
hyperbilirubinemia
ldh
elev
bone
marrow
examin
perform
four
month
prior
splenectomi
reveal
mildli
hypocellular
marrow
trilineag
hematopoiesi
flow
cytometr
analysi
cytogenet
bone
marrow
aspir
peripher
blood
normal
except
small
popul
larg
granular
lymphocyt
mild
low
absolut
b
cell
count
peripher
blood
laparoscop
splenectomi
perform
diagnost
therapeut
purpos
due
patient
worsen
luq
pain
treatment
given
prior
surgeri
hour
postsplenectomi
leucocyt
increas
platelet
threemonth
postsplenectomi
wbc
count
platelet
count
respect
hemoglobin
also
improv
patholog
show
red
pulp
expans
small
lymphocyt
fig
subsequ
ihc
immunohistochemistri
posit
fig
neg
difficult
interpret
eber
neg
flow
cytometri
fig
show
increas
gammadelta
tcell
popul
posit
cd
neg
cd
cd
molecular
studi
pcr
didnt
reveal
tcell
receptor
gamma
beta
gene
rearrang
cytogenet
neg
isochromosom
abnorm
symptom
free
month
splenectomi
morpholog
immunophenotyp
gammadelta
cell
show
signific
overlap
malign
cell
seen
hstl
tlgl
loss
downregul
awar
reactiv
condit
necessari
prevent
make
wrong
diagnosi
malign
diseas
potenti
benign
spontan
resolv
diseas
addit
studi
similar
case
need
order
establish
definit
criterion
separ
benign
malign
process
delin
role
gammadelta
cell
upload
file
upload
fig
flow
cytomterypptx
background
sex
steroid
human
thymic
environ
influenc
air
express
well
interact
partner
ie
gene
code
air
interactor
investig
effect
sex
steroid
interact
minipuberti
surg
sex
hormon
occur
along
first
six
month
life
month
life
employ
networkbas
approach
investig
aireinteractor
genegen
relationship
abundantli
coexpress
thymic
mirna
covari
gene
aireinteractor
network
allow
measur
genderrel
differ
genegen
express
correl
disclos
relev
differ
minipuberti
group
method
total
rna
extract
thymic
surgic
explant
obtain
male
femal
f
infant
age
month
group
mm
mf
minipuberti
month
group
nm
nf
nonpuberti
use
dna
microarray
assay
gene
coexpress
network
gcn
analys
perform
air
interactor
mirnagen
coexpress
analysi
set
gene
code
airetarget
protein
previous
identifi
tec
abramson
et
al
cell
aireinteractor
network
obtain
group
link
strength
cutoff
genegen
mirnagen
air
express
mtec
quantifi
immunohistochemistri
methodolog
describ
moreirafilho
et
al
sci
rep
result
mm
x
mf
network
comparison
show
abundantli
express
mirna
interact
differ
air
interactor
gene
network
interest
note
network
topolog
similar
nm
nf
group
although
air
interact
one
distinct
mirna
network
nm
group
nf
group
convers
nonpuberti
network
set
mirna
interact
gene
distinct
network
immunohistochemistri
analysi
reveal
higher
percentag
mtec
air
posit
cell
minipuberti
group
ie
signific
differ
mm
x
nm
p
mf
x
nf
p
conclus
minipuberti
genom
mechan
shape
thymic
sexual
dimorph
along
first
month
life
process
involv
chang
air
express
gender
differ
interact
air
partner
persist
throughout
nonpuberti
period
probabl
regul
mirna
also
genet
epigenet
factor
introduct
neutrophil
presum
defend
aspergillu
speci
releas
reactiv
oxygen
speci
ro
neutrophil
extracellular
trap
net
degrad
fungal
hypha
triazol
antifung
synergist
enhanc
neutrophil
mediat
hyphal
degrad
patient
cgd
particularli
suscept
aspergillu
speci
like
due
inabl
creat
ro
net
sever
case
may
amen
antifung
therapi
alon
object
present
case
sever
dissemin
aspergillosi
patient
cgd
gt
serv
import
adjunct
antifung
therapi
bridg
transplant
result
boy
known
cgd
lost
follow
nonadher
prophylaxi
present
acut
rightsid
hemiparesi
neuroimag
reveal
embol
left
middl
cerebr
arteri
infarct
cardiac
magnet
reson
imag
show
extens
veget
involv
right
left
ventricl
atria
eject
fraction
patient
admit
intens
care
start
liposom
amphotericin
b
meropenem
vancomycin
underw
debulk
intracardiac
mass
post
admiss
day
pad
oper
find
show
sever
constrict
pericard
multipl
abscess
intracardiac
veget
thorough
debrid
veget
undertaken
howev
deep
seat
abscess
myocardium
amen
oper
cultur
posit
aspergillu
fumigatu
clinic
statu
remain
precari
ongo
requir
inotrop
ventil
support
antimicrobi
therapi
refin
voriconazol
amphotericin
b
remain
board
therapeut
level
voriconazol
achiev
effect
neutrophil
integr
immun
respons
aspergillu
decis
made
start
granulocyt
transfus
aid
clinic
stabil
prior
hsct
interferon
gamma
infus
administ
risk
advers
effect
potenti
increas
transplant
reject
gt
start
pad
dose
approxim
granulocyt
three
time
week
patient
toler
infus
well
allerg
inflammatori
respons
neutrophil
oxid
burst
measur
one
hour
post
infus
show
mean
fluoresc
intens
compar
baselin
figur
clinic
improv
seen
inotrop
cessat
pad
extub
bipap
pad
human
leukocyt
antigen
hla
allosensitizaton
test
pad
day
first
gt
evid
hla
antibodi
total
gt
given
month
prior
proceed
hla
match
relat
donor
transplant
pad
two
transfus
given
neutrophil
engraft
anc
day
patient
stabl
month
post
transplant
evid
graft
reject
remain
chronic
suppress
antifung
therapi
continu
full
lymphoid
reconstitut
conclus
gt
may
use
adjunct
antifung
therapi
patient
impair
neutrophil
function
sever
invas
aspergillosi
potenti
provid
life
sustain
bridg
hsct
method
subject
enrol
irb
protocol
implant
quadricep
immunosuppress
result
subject
normal
hypocalcemia
asd
pda
abnorm
ear
subject
receiv
cord
blood
transplant
mismatch
hlab
hlac
allel
age
month
subsequ
mild
graftversushost
diseas
gvhd
develop
treat
antithymocyt
globulin
steroid
cyclosporin
donor
cell
develop
low
number
twelv
year
later
subject
develop
epstein
barr
viru
lymphoma
suffer
two
relaps
remiss
subject
receiv
unmatch
two
week
implant
subject
develop
adenoviru
infect
result
skin
gut
gvhd
presum
activ
cord
blood
cell
subject
treat
corticosteroid
cyclosporin
cidofovir
infliximab
four
year
post
subject
healthi
genet
recipi
cell
subject
normal
asd
pda
hypoparathyroid
cell
birth
genet
defect
unknown
subject
treat
ric
myeloabl
allogen
unrel
cord
blood
transplant
subsequ
myeloabl
unrel
cord
blood
transplant
hematopoiet
chimer
establish
without
cell
develop
express
one
allel
recipi
express
second
cord
donor
postthym
transplant
cours
includ
immun
thrombocytopenia
requir
rituximab
splenectomi
gener
adenopathi
year
gvhd
fail
wean
immunoglobulin
replac
three
year
post
activ
school
subject
absent
trec
newborn
screen
cell
singl
mutat
identifi
spars
scalp
hair
subject
receiv
match
unrel
umbil
cord
transplant
posttranspl
cours
complic
signific
morbid
cell
develop
express
one
allel
recipi
cord
blood
donor
subject
develop
gvhd
healthi
month
cell
resolut
longstand
noroviru
sapoviru
gastroenter
conclus
improv
cell
immun
poor
fail
correct
allogen
hematopoiet
transplant
subject
gvhd
post
relat
acut
viral
infect
cord
cell
attack
hla
mismatch
recipi
subject
given
match
recipi
allel
express
hematopoiet
donor
hypothes
thymocyt
develop
strongli
reactiv
recipientmismatch
allel
delet
bonemarrowdonor
dendrit
cell
acquir
recipi
mhc
recipientallelematch
thymic
epitheli
cell
therebi
prevent
gvhd
rational
haploinsuffici
autosom
domin
immun
dysregul
syndrom
character
variabl
phenotyp
present
young
woman
diagnos
evan
syndrom
lymphoprolifer
child
found
novel
variant
young
adult
develop
hypogammaglobulinemia
bacteri
endocard
stabil
replac
therapi
method
sequenc
gene
includ
primari
immunodefici
panel
result
patient
diagnos
evan
syndrom
age
manifest
anemia
thrombocytopenia
recalcitr
treatment
mani
year
steroid
cyclosporin
vincristin
bone
marrow
biopsi
reportedli
show
normal
trilineag
matur
symptom
respond
short
time
splenectomi
age
symptom
recur
age
also
found
pulmonari
reticular
opac
promin
lymph
node
elev
b
cell
repeat
bone
marrow
lymph
node
biopsi
time
unrev
minor
respons
treatment
ivig
rituximab
mycophenol
mofetil
gcsf
note
age
develop
varicellarel
enceph
shortli
vaccin
strong
suspicion
immun
dysregul
syndrom
immun
evalu
reveal
normal
immunoglobulin
good
vaccin
respons
elev
b
cell
number
normal
cell
number
normal
mitogen
prolifer
sequenc
reveal
mutat
exon
caus
prematur
translat
stop
signal
consist
previous
report
case
haploinsuffici
start
rapamycin
initi
cytopenia
transit
success
abatacept
almost
complet
resolut
anemia
neutropenia
pulmonari
opac
month
stabl
control
develop
precipit
drop
platelet
eventu
diagnos
streptococcu
viridan
endocard
nativ
mitral
valv
respond
antimicrobi
therapi
eventu
need
surgic
intervent
due
ongo
insuffici
around
time
also
found
newli
hypogammaglobulinem
necessit
ongo
igg
supplement
therapi
success
replac
mitral
valv
biosynthet
prosthesi
note
aortic
valv
also
evid
previou
diseas
implic
prior
endocard
part
clinic
syndrom
well
conclus
patient
present
recalcitr
cytopenia
lymphadenopathi
elev
b
cell
vaccineinduc
viral
infect
lung
find
precipit
concern
immun
dysregul
syndrom
allow
identif
novel
deleteri
mutat
addit
previous
report
clinic
find
patient
present
first
report
case
repeat
endocard
set
insuffici
diseas
given
find
patient
prior
unrecogn
diseas
regularli
screen
patient
insuffici
evid
cardiac
affect
may
prudent
clinic
research
nurs
john
hopkin
univers
background
relationship
elev
serum
alpha
fetoprotein
afp
concentr
age
mortal
genotyp
neurolog
outcom
ataxia
telangiectasia
patient
remain
inconclus
past
decad
leav
afp
use
marker
diseas
diagnosi
without
clinic
signific
object
examin
relationship
afp
level
age
mortal
genotyp
neurolog
outcom
use
data
set
larger
prior
studi
method
retrospect
collect
data
patient
john
hopkin
medic
center
year
age
classic
predict
protein
null
variant
includ
serum
afp
measur
serial
level
patient
max
observ
per
patient
mix
model
compound
symmetri
covari
use
statist
analysi
examin
effect
age
visit
afp
level
subgroup
analysi
mutat
type
mortal
feedingswallow
score
surrog
neurolog
function
xray
induc
vitro
chromosom
breakag
serum
transaminas
level
similarli
analyz
result
signific
associ
age
afp
level
found
everi
year
increas
age
afp
level
increas
ngml
p
subgroup
analysi
mutat
type
found
patient
missens
mutat
show
neg
linear
relationship
log
afp
level
age
r
found
greater
afp
level
patient
subsequ
die
control
age
least
squar
mean
afp
level
log
scale
greater
deceas
patient
versu
live
patient
found
signific
declin
feed
score
unit
score
rang
per
ngml
afp
increas
adjust
age
signific
relationship
afp
level
serum
transaminas
level
conclus
afp
increas
age
patient
though
may
appli
patient
missens
mutat
statist
signific
increas
mortal
worsen
swallow
score
increas
afp
level
remain
proven
clinic
signific
present
pediatr
hae
patient
recurr
abdomin
attack
constip
secondari
adhd
medic
dexmethylphenid
focalin
appear
trigger
import
first
pediatr
patient
hae
describ
safe
undergon
capsul
endoscopi
direct
visual
gastrointestin
tract
done
decreas
risk
associ
invas
procedur
tradit
endoscopi
colonoscopi
case
present
patient
male
hereditari
angioedema
present
day
histori
diffus
abdomin
pain
nausea
ed
patient
acut
distress
abdomin
ultrasound
show
sever
circumferenti
thicken
wall
multipl
bowel
loop
larg
amount
simpl
ascit
xray
reveal
stool
colon
admit
pain
control
hydrat
next
year
visit
ed
five
time
exacerb
angioedema
hand
peni
bowel
time
present
underli
abdomin
pain
constip
seen
gastroenterolog
workup
neg
helicobact
pylori
parasit
gastrointestin
infect
evalu
abdomin
pain
capsul
endoscopi
perform
well
toler
admiss
januari
receiv
full
inpati
bowel
cleanout
angioedema
final
improv
note
diagnos
adhd
start
dexmethylphenid
focalin
prior
period
recurr
angioedema
attack
attack
summer
month
medic
discuss
abdomin
pain
common
complaint
pediatr
hospit
workup
consist
endoscopi
colonoscopi
may
easili
accomplish
gener
popul
howev
patient
hae
procedur
carri
greater
risk
may
avoid
lead
delay
diagnosi
treatment
newer
less
commonli
use
altern
direct
visual
gastrointestin
tract
capsul
endoscopi
benefit
requir
sedat
less
invas
less
like
irrit
mucosa
addit
sinc
psycholog
stress
may
trigger
angioedema
attack
decreas
stress
associ
noninvas
procedur
capsul
endoscopi
make
safer
use
limit
capsul
endoscopi
includ
depend
batteri
life
inabl
biopsi
administ
therapi
need
hereditari
angioedema
treatment
consist
primarili
avoid
trigger
manag
acut
episod
first
case
hae
pediatr
patient
capsul
endoscopi
use
procedur
well
toler
without
complic
recogn
constip
trigger
capsul
endoscopi
safe
method
direct
visual
gastrointestin
tract
help
other
control
decreas
sever
hae
attack
well
year
old
male
past
medic
histori
common
variabl
immun
defici
cvid
relat
autoimmun
complic
includ
granulomatouslymphocyt
interstiti
lung
diseas
glild
hepatosplenomegali
leukopenia
thrombocytopenia
toler
monthli
subcutan
immunoglobulin
replac
outpati
sever
year
infrequ
infecti
complic
four
month
ago
found
elev
liver
enzym
routin
chemistri
liver
biopsi
two
month
later
show
patholog
consist
nodular
regen
hyperplasia
nrh
without
overt
cirrhosi
hepat
venou
pressur
gradient
hvpg
mmhg
found
consist
portal
hypertens
hepat
viral
marker
neg
drink
portal
venogram
neg
thrombosi
earli
octob
patient
admit
hospit
anasarca
tens
ascit
underw
diagnost
therapeut
larg
volum
paracentesi
also
found
spontan
bacteri
periton
sbp
bacteremia
group
b
streptococcu
patient
cours
complic
polymicrobi
periton
vre
bacteremia
fungemia
varic
hemorrhag
hepat
encephalopathi
hepatoren
syndrom
hepat
complic
portal
hypertens
proport
liver
parenchym
diseas
transjugular
intrahepat
portosystem
shunt
tip
consid
allevi
portal
hypertens
feasibl
due
degre
encephalopathi
immunosuppress
high
dose
steroid
given
hospit
plan
start
rituximab
treat
patient
glild
recov
acut
infect
unfortun
two
month
hospit
patient
succumb
sepsi
progress
liver
failur
case
emphas
import
systemat
screen
continu
vigil
hepat
complic
patient
cvid
studi
shown
nrh
liver
present
cvid
patient
undergo
liver
biopsi
pmid
crosssect
studi
patient
primari
hypogammaglobulinemia
hepat
dysfunct
found
histolog
find
nrh
present
cvid
patient
associ
portal
hypertens
case
pmid
anoth
studi
estim
minim
preval
nrh
cvid
patient
pmid
state
like
gross
underestim
nrh
may
also
present
patient
normal
liver
function
test
routin
biopsi
therefor
liver
enzym
level
may
anticip
sever
liver
involv
current
treatment
cvidrel
liver
diseas
caus
noncirrhot
portal
hypertens
includ
hepat
venoocclus
diseas
buddchiari
syndrom
rule
treat
cvid
patient
present
hepat
diseas
case
hepat
nrh
cvid
patient
earli
detect
could
lead
earlier
intervent
tip
prior
hepat
encephalopathi
mitig
complic
describ
applic
epigenet
quantif
regulatori
treg
cell
addit
cell
b
cell
nk
cell
monocyt
neutrophil
littl
fresh
frozen
dri
blood
method
yield
ident
result
flow
cytometri
fresh
blood
sampl
healthi
donor
cohort
advantag
sensit
precis
limit
amount
blood
minim
sampl
prepar
sci
transl
med
use
method
immunophenotyp
patient
earli
onset
immun
regulatori
disord
pird
primari
immun
defici
pid
evalu
cell
subset
reconstitut
earli
hematopoiet
stem
cell
transplant
hsct
patient
immun
dysregul
polyendocrinopathi
enteropathi
xlink
ipex
ipexlik
pird
evalu
analyz
tregspecif
demethyl
region
tsdr
locu
total
tcell
despit
dysfunct
mutat
protein
ipex
patient
exhibit
elev
cell
ratio
seem
correl
diseas
sever
contrast
patient
ipexlik
symptom
without
mutat
exhibit
decreas
cell
ratio
line
possibl
central
pathogen
role
treg
function
number
pird
use
epigenet
quantif
nk
cell
confirm
scid
xla
case
correctli
identifi
within
cohort
newborn
dri
blood
spot
db
sampl
sensit
specif
method
identifi
one
delay
onset
scid
well
xla
case
miss
combin
treckrec
test
epigenet
immun
cell
quantif
miss
one
scid
case
matern
engraft
identifi
combin
treckrec
test
abnorm
elev
ratio
also
detect
db
newborn
subsequ
confirm
affect
ipex
syndrom
appli
serial
blood
sampl
engraft
reconstitut
posthsct
epigenet
method
allow
identif
differ
blood
cell
subset
includ
treg
cell
earlier
time
point
flow
cytometri
accord
current
clinic
practic
open
way
better
understand
correl
earli
immun
reconstitut
event
graft
vs
host
diseas
viral
reactiv
earlier
current
method
differ
type
hsct
studi
underscor
suitabl
epigenet
immun
cell
quantif
accur
measur
multipl
immun
cell
type
limit
blood
sampl
sourc
propos
method
uniqu
suitabl
novel
molecular
diagnost
applic
set
limit
fresh
blood
sampl
limit
cell
number
point
care
well
newborn
screen
evalu
male
hyperpyrexia
hypertrichosi
conic
hypodontia
histori
ill
concern
nemodefici
syndrom
start
six
month
age
suffer
recurr
episod
acut
otiti
media
nontyp
hib
actinobact
iwolffli
pneumonia
rsv
bronchiol
whole
exom
sequenc
demonstr
de
novo
heterozyg
mutat
edareceptor
edar
gene
present
parent
dna
physic
exam
find
mutat
consist
hypohidrot
ectoderm
dysplasia
hed
rare
genet
condit
character
abnorm
develop
skin
teeth
hair
sweat
gland
hed
caus
defect
ectodysplasina
eda
nfkb
signal
pathway
typic
associ
immun
defici
consist
immunophenotyp
show
normal
subpopul
b
nkcell
immunoglobulin
complement
level
quantit
appropri
normal
mitogeninduc
lymphocyt
prolifer
normal
antibodi
respons
pneumococc
vaccin
nkcell
studi
demonstr
robust
cytotox
howev
nasal
mucosa
biopsi
show
diffus
squamou
metaplasia
absenc
ciliat
epitheli
cell
hypothes
recurr
infect
patient
aros
impair
mucociliari
clearanc
due
ciliari
defect
case
rais
possibl
associ
edar
variant
ciliari
dysfunct
also
underscor
import
evalu
immun
statu
hed
patient
recurr
infect
could
mimic
nemodefici
broad
implic
clinic
manag
rapid
pace
new
gene
discoveri
phenotyp
expans
primari
immunodefici
diseas
pidd
creat
challeng
genet
test
variant
interpret
wherea
welldescrib
clinic
case
report
publish
literatur
tradit
serv
sourc
phenotyp
data
use
variant
interpret
pidd
causal
variant
often
privat
patient
famili
thu
sole
sourc
phenotyp
inform
novel
genet
variant
frequent
histori
provid
clinician
test
requisit
form
take
account
heterogen
inform
variant
interpret
requir
establish
object
criteria
inclus
part
variant
interpret
process
end
adapt
laboratori
preexist
evidencebas
variant
classif
framework
call
sherloc
develop
pointbas
criteria
inclus
clinic
inform
patient
phenotyp
famili
segreg
pattern
whether
variant
inherit
de
novo
patient
part
process
defin
clinic
criteria
pidd
gene
illustr
applic
method
import
integr
clinic
inform
variant
interpret
april
octob
commerci
diagnost
laboratori
perform
immunolog
genet
test
inform
patient
clinic
histori
provid
order
restrict
analysi
gene
case
report
inform
current
use
variant
interpret
test
reveal
variant
classifi
pathogen
like
pathogen
plp
inform
case
report
descript
segreg
pattern
de
novo
statu
appli
plp
variant
respect
case
clinic
inform
provid
clinician
test
requisit
form
use
evid
classif
patient
variant
plp
ten
variant
initi
classifi
uncertain
signific
reclassifi
follow
receipt
clinic
inform
test
addit
rel
addit
suspici
variant
uncertain
signific
identifi
one
two
addit
patient
case
report
would
allow
reclassif
uncertain
signific
plp
data
illustr
import
provid
good
qualiti
clinic
inform
genet
test
laboratori
time
sampl
submiss
follow
receipt
genet
test
result
background
cartilagehair
hypoplasia
chh
skelet
dysplasia
combin
immunodefici
variabl
clinic
cours
increas
risk
malign
mostli
nonhodgkin
lymphoma
basal
cell
carcinoma
pauciti
longterm
followup
data
well
knowledg
prognost
factor
chh
object
conduct
prospect
cohort
studi
finnish
patient
chh
describ
clinic
cours
analyz
risk
factor
advers
outcom
method
recruit
finnish
patient
chh
perform
clinic
followup
obtain
health
inform
finnish
nation
medic
databas
cover
time
period
finnish
cancer
registri
causeofdeath
registri
statist
finland
analyz
patient
health
record
standard
mortal
ratio
smr
calcul
base
popul
data
primari
outcom
includ
immunodeficiencyrel
death
infect
respiratori
diseas
malign
develop
lymphoma
develop
skin
cancer
result
studi
cohort
includ
male
femal
median
age
recruit
yr
rang
week
yr
median
durat
followup
surviv
patient
yr
rang
yr
half
patient
symptom
immunodefici
patient
manifest
symptom
humor
combin
immunodefici
respect
includ
six
case
lateonset
immunodefici
signific
proport
patient
clinic
featur
immunodefici
progress
time
patient
nonskin
cancer
eight
preced
symptom
immunodefici
altogeth
patient
deceas
confid
interv
ci
includ
death
due
pneumonia
malign
lung
diseas
malign
diagnos
patient
mostli
lymphoma
skin
cancer
sever
short
statur
birth
compar
normal
smrsmr
symptom
combin
immunodefici
compar
asymptomat
vs
hirschsprung
diseas
odd
ratio
pneumonia
first
year
life
recurr
adulthood
autoimmun
adulthood
associ
earli
mortal
addit
recurr
pneumonia
childhood
associ
develop
lymphoma
wart
actin
keratosi
associ
develop
skin
cancer
birth
length
standard
deviat
score
correl
significantli
age
diagnosi
first
malign
lymphoma
skin
cancer
demonstr
patient
shorter
birth
length
develop
malign
earlier
age
conclus
patient
chh
high
mortal
due
infect
malign
also
lung
diseas
subject
present
lateonset
immunodefici
malign
without
preced
symptom
immun
defect
warrant
care
followup
screen
cancer
even
asymptomat
patient
provid
clinician
risk
factor
advers
outcom
assist
manag
decis
autoimmun
lymphoprolif
syndrom
alp
relat
disord
character
insuffici
apoptosi
due
defect
fa
apoptosi
pathway
fadd
defici
omim
autosom
recess
disord
result
mutat
fasassoci
protein
death
domain
fadd
adaptor
protein
involv
fa
signal
caspas
present
case
fadd
defici
identifi
whole
exom
sequenc
novel
genet
mutat
describ
two
brother
recurr
febril
episod
accompani
seizur
respiratori
compromis
older
sibl
initi
present
statu
epilepticu
follow
measl
mump
rubella
vaccin
later
experienc
similar
episod
demis
month
age
younger
sibl
unvaccin
present
month
fever
rash
vomit
diarrhea
develop
statu
epilepticu
respiratori
depress
requir
intub
also
enlarg
cervic
lymph
node
regress
antibiot
steroid
recov
episod
subsequ
seri
similar
ill
fever
alter
mental
statu
seizur
except
elev
igg
extens
infecti
workup
instanc
neg
previous
describ
fadd
defici
patient
demonstr
alp
like
phenotyp
increas
circul
doubl
neg
cell
lymphocyt
apoptosi
defect
elev
fa
ligand
encephalopathi
function
asplen
splenomegali
lymphadenopathi
patient
clinic
laboratori
find
similar
normal
igg
iga
decreas
igm
lack
isohemagglutinin
absolut
count
elev
elev
percent
tcr
normal
mitogen
antigen
lymphocyt
stimul
defect
pokewe
induc
b
cell
prolifer
fa
ligand
level
increas
see
tabl
hepatosplenomegali
howel
jolli
bodi
detect
peripher
blood
indic
function
hyposplen
wholeexom
sequenc
reveal
two
differ
genet
alter
fadd
gene
matern
inherit
nonsens
mutat
predict
sever
truncat
protein
patern
inherit
missens
mutat
codon
although
patern
mutat
describ
pathogen
differ
variant
nucleotid
fadd
associ
fadd
defici
case
literatur
fadd
defici
patient
overal
prognosi
poor
compar
classic
alp
patient
patient
signific
risk
deadli
sepsi
encapsul
organ
death
neurolog
complic
fadd
defici
patient
describ
literatur
sever
die
prior
year
old
pneumococc
prophylaxi
may
reduc
risk
sepsi
hematopoiet
stem
cell
transplant
report
patient
fadd
defici
consid
patient
rational
hcuvp
patient
productintroduct
program
provid
immun
globulin
subcutan
human
solut
free
charg
first
infus
elig
patient
primari
immunodefici
diseas
pid
use
patient
data
ongo
program
analysi
describ
clinic
characterist
infus
paramet
pediatr
adolesc
patient
initi
hcuvp
method
hcuvp
elig
criteria
patient
age
year
old
primari
code
verifi
diagnosi
pid
current
prior
use
program
initi
data
patient
receiv
first
infus
januari
septemb
includ
data
patient
receiv
infus
octob
censor
descript
statist
calcul
patient
demograph
clinic
characterist
prescrib
actual
infus
characterist
age
group
year
year
result
total
patient
complet
infus
includ
analysi
age
year
among
previous
receiv
immunoglobulin
ig
therapi
greater
percentag
patient
age
year
treat
intraven
ig
therapi
compar
adult
patient
initi
nine
patient
age
year
treatment
mean
infus
volum
per
site
lower
among
patient
age
year
year
ml
year
ml
year
ml
among
patient
age
year
year
ml
year
ml
howev
mean
infus
rate
per
site
similar
patient
age
year
xmen
diseas
xlink
immunodefic
magnesium
defect
epsteinbarr
viru
infect
neoplasia
primari
immun
defici
caus
mutat
character
chronic
infect
epsteinbarr
viru
ebv
ebvdriven
lymphoma
tcell
lymphopenia
dysgammaglobulinemia
gene
codifi
protein
transport
express
human
immun
system
specif
spleen
thymu
function
studi
establish
key
role
cell
natur
killer
nk
cell
activ
upon
tcell
receptor
stimul
mediat
transient
influx
necessari
phospholipas
c
gamma
activ
drive
rise
downstream
signal
influx
also
regul
cytotox
function
nk
cell
reason
patient
impair
cytolyt
respons
ebv
eleven
male
xmen
patient
describ
present
case
old
hispan
infant
pathogen
variant
gene
clinic
manifest
earli
pneumocysti
jirovecii
cytomegaloviru
cmv
interstiti
pneumonia
ebv
chronic
infect
good
respons
intraven
immunoglobulin
supplement
without
hematopoiet
stem
cell
transplant
gene
therapi
laboratori
studi
highlight
low
level
ligand
object
case
report
broaden
spectrum
clinic
present
xmen
diseas
manifest
initi
combin
immun
defici
cid
evolv
favor
cours
diseas
intraven
immunoglobulin
supplement
therapi
chemoprophylaxi
trimethoprimsulfamethoxazol
introduct
lysinur
protein
intoler
lpi
recess
inherit
disord
cation
amino
acid
transport
subunit
caus
variant
gene
diseas
character
proteinrich
food
intoler
heterogen
present
clinic
find
result
deplet
lysin
ornithin
arginin
symptom
includ
hyperammonemia
failur
thrive
protein
avers
neurolog
diseas
lung
diseas
also
evid
inflammatori
manifest
mediat
upregul
nfb
tnf
occur
independ
intracellular
arginin
level
lead
lifethreaten
episod
hemophagocyt
lymphohistiocytosi
hlh
case
present
male
present
histori
anxieti
depress
eat
disord
delay
puberti
complex
partial
seizur
due
poor
nutrit
failur
thrive
gastrostomi
tube
place
follow
commenc
enter
feed
present
alter
mental
statu
bilater
mydriasi
hyperreflexia
agit
lead
picu
admiss
ammonia
peak
high
episod
ceas
cessat
enter
feed
prior
enter
feed
selfrestrict
protein
diet
biochem
test
consist
lpi
illumina
nextgener
sequenc
reveal
compound
heterozyg
variant
hyperammonemia
resolv
quickli
cessat
protein
intak
high
rate
dextros
infus
without
need
ammonia
scaveng
agent
subsequ
start
proteinrestrict
enter
feed
diagnosi
respiratori
symptom
ct
scan
chest
show
patchi
area
groundglass
opacif
suggest
earli
pulmonari
alveolar
proteinosi
pap
bronchoalveolar
lavag
demonstr
foami
cloudi
pink
fluid
elev
bronchioalveolar
macrophag
cell
differenti
clinic
cours
genotyp
led
suspicion
smolder
hlh
find
elev
ferritin
hypertriglyceridemia
decreas
fibrinogen
splenomegali
elev
receptor
decreas
nk
cell
function
along
hemophagocytosi
bone
marrow
biopsi
confirm
diagnosi
pap
hlh
addit
dietari
modif
trial
beta
inhibit
anakinra
mgkgday
initi
follow
ct
scan
chest
month
initi
anakinra
show
complet
resolut
pulmonari
groundglass
opacif
pap
bone
marrow
evalu
show
continu
hemophagocytosi
spite
normal
ferritin
solubl
receptor
nk
function
triglycerid
level
overal
significantli
improv
daili
anakinra
longer
meet
criteria
hlh
pap
discuss
recent
data
shown
model
macrophag
airway
epitheli
cell
upregul
tnf
regardless
intracellular
arginin
content
suggest
inflammatori
manifest
may
continu
independ
dietari
modif
present
year
old
patient
newli
diagnos
lpi
treat
dietari
modif
therapi
result
resolut
hlh
pap
research
need
see
longterm
blockad
consist
control
immunolog
pulmonari
manifest
lpi
posit
impact
morbid
mortal
learn
object
recogn
symptom
bartonella
endocard
associ
complic
share
featur
certain
immunocompromis
condit
case
descript
caucasian
boy
histori
repair
pulmonari
atresia
aortic
root
dilat
diagnos
pancytopenia
splenomegali
brief
hospit
atyp
pneumonia
pancytopenia
persist
splenomegali
worsen
five
month
present
develop
hypertens
renal
insuffici
diagnos
hypocomplementem
diffus
scleros
crescent
glomerulonephr
start
mycophenol
mofetil
improv
kidney
function
stabil
cytopenia
part
comprehens
immun
workup
alp
autoimmun
lymphoprolif
syndrom
panel
sent
demonstr
elev
doubleneg
dnt
cell
posit
immunolog
criteria
alp
neither
target
sequenc
alp
alpslik
disord
whole
exom
sequenc
reveal
pathogen
mutat
age
patient
remain
mycophenol
develop
failur
thrive
weight
drop
percentil
less
percentil
hospit
lowgrad
fever
increas
work
breath
left
shoulder
pain
fatigu
found
right
lower
lobe
pneumonia
pancytopenia
worsen
start
cefepim
azithromycin
without
improv
symptom
echocardiogram
reveal
veget
pulmonari
conduit
bilater
branch
pulmonari
arteri
multipl
blood
cultur
neg
upon
histori
patient
report
contact
kitten
bartonella
hensela
titer
polymeras
chain
reaction
pcr
blood
sent
posit
complet
cours
gentamicin
cours
ceftriaxon
transit
doxycyclin
rifabutin
initi
antimicrobi
therapi
weight
energi
significantli
improv
blood
bartonella
pcr
becam
neg
splenomegali
resolv
approxim
one
year
later
patient
underw
pulmonari
arteri
conduit
replac
bartonella
pcr
test
tissu
specimen
posit
sustain
weight
increas
resolut
hypocomplementemia
splenomegali
decreas
dnt
cell
frequenc
improv
though
resolut
cytopenia
current
remain
doxycyclin
rifabutin
continu
treatment
mycophenol
discuss
alp
character
defect
lymphocyt
apoptosi
clinic
featur
lymphadenopathi
splenomegali
hepatomegali
cytopenia
glomerulonephr
hallmark
laboratori
find
expans
dnt
patient
met
criteria
probabl
alp
diagnosi
base
presenc
requir
criteria
chronic
splenomegali
elev
dnt
cell
secondari
addit
criteria
typic
immunolog
find
note
alp
panel
pediatr
case
bartonella
hensela
endocard
associ
splenomegali
cytopenia
glomerulonephr
mimic
mani
featur
monogen
immun
dysregulatori
disord
diagnosi
bartonella
endocard
patient
therefor
rais
question
whether
immunosuppress
predispos
infect
entir
clinic
present
explain
bartonella
endocard
physician
take
care
patient
immun
dysregulatori
disord
consid
bartonella
endocard
differenti
diagnosi
onset
exacerb
immun
dysregul
rational
fever
consid
sign
infect
mani
individu
primari
immunodefici
pi
anecdot
report
lower
normal
averag
bodi
temperatur
immun
defici
foundat
idf
friend
idf
pi
connect
research
forum
onlin
pi
patient
report
diminish
fever
respons
even
sign
infect
present
limit
knowledg
averag
bodi
temperatur
person
pi
howev
implic
miss
infect
pi
well
establish
method
studi
investig
partner
patient
investig
design
prospect
cohort
studi
determin
whether
bodi
temperatur
differ
person
live
without
pi
three
hundr
fifti
adult
pi
recruit
idf
one
adult
household
member
without
pi
also
recruit
mckesson
digit
oral
thermomet
model
provid
use
record
temperatur
particip
three
time
day
five
consecut
day
descript
statist
calcul
median
bodi
temperatur
compar
two
cohort
time
point
use
mannwhitney
test
result
data
household
use
analysi
particip
rate
pi
popul
larg
femal
median
age
year
larg
caucasian
popul
nonpi
popul
larg
male
median
age
year
larg
caucasian
popul
pi
diagnos
includ
cvid
hypogammaglobulinemia
igg
subclass
defici
select
iga
defici
specif
antibodi
defici
agammaglobulinemia
chronic
granulomat
diseas
combin
immunodefici
complement
defici
total
individu
pi
report
lower
normal
nonsick
bodi
temperatur
individu
pi
report
normal
nonsick
bodi
temperatur
total
individu
pi
report
absenc
fever
infect
individu
report
normal
fever
respons
infect
median
bodi
temperatur
significantli
higher
pi
patient
morn
even
bedtim
read
day
monday
pi
vs
nonpi
p
tuesday
pi
vs
nonpi
p
wednesday
pi
vs
nonpi
p
thursday
pi
vs
nonpi
p
friday
pi
vs
nonpi
p
conclus
despit
limit
nonclin
studi
individu
pi
knowledg
condit
offer
uniqu
insight
direct
research
studi
demonstr
collabor
patient
advocaci
group
may
facilit
patientcent
patientdriven
research
high
particip
among
target
popul
introduct
famili
mediterranean
fever
fmf
hereditari
condit
character
recurr
episod
pain
inflamm
caus
mutat
pyrin
mefv
gene
alter
mefv
gene
affect
pyrin
product
lead
recurr
fever
pain
inflamm
peritoneum
synovium
pleura
amyloidosi
may
also
develop
complic
arab
turkish
armenian
sephard
jewish
popul
commonli
affect
homozygos
mefv
mutat
associ
sever
cours
pauciti
inform
regard
pediatr
fmf
literatur
case
present
case
male
minor
speech
delay
diagnos
compound
heterozyg
fmf
patient
initi
refer
due
recurr
fever
infect
month
age
hospit
septic
shock
requir
intub
secondari
adenoviru
month
age
patient
began
recurr
fever
everi
week
lead
multipl
blood
draw
cours
antibiot
prior
referr
month
age
develop
three
separ
episod
febril
seizur
total
lifetim
episod
acut
otiti
media
occur
prior
bilater
myringotomi
tube
placement
four
episod
streptococcu
pyogen
pharyng
confirm
throat
cultur
preced
tonsillectomi
oral
ulcer
joint
pain
abdomin
pain
report
infect
pneumonia
sinus
uti
nonvir
gastroenter
fungal
infect
skin
infect
report
parent
ashkenazi
jewish
matern
histori
earli
miscarriag
note
famili
histori
neg
immunodefici
malign
autoimmun
patient
vital
sign
physic
exam
unremark
serolog
indic
leukocytosi
kl
elev
monocyt
cellsl
elev
eosinophil
cellsl
slightli
elev
cell
count
cellsl
neutrophil
cell
b
cell
nk
cell
enumer
immunoglobulin
panel
normal
age
tetanu
diphtheria
rubella
streptococcu
pneumonia
haemophilu
influenza
b
titer
protect
genet
analysi
identifi
patient
compound
heterozyg
mutat
mefv
gene
famili
instruct
keep
fever
diari
colchicin
day
given
initi
increas
day
inadequ
respons
loos
stool
observ
patient
maintain
lactos
free
diet
switch
colchicin
bid
resolut
loos
stool
apart
two
occas
colchicin
dose
miss
patient
remain
afebril
follow
visit
conclus
present
pediatr
case
compound
heterozyg
fmf
mefv
mutat
otherwis
healthi
male
ashkenazi
jewish
background
initi
symptomat
month
age
individu
compound
heterozyg
second
mevf
mutat
gener
symptomat
although
sever
predict
addit
pediatr
research
symptomat
heterozyg
compound
heterozyg
fmf
recommend
natur
killer
nk
cell
innat
lymphocyt
play
key
role
defens
virallyinfect
cell
tumor
surveil
nk
cell
divid
two
subset
major
nk
cell
peripher
blood
express
intermedi
level
refer
dim
nk
cell
respons
nk
cell
cytotox
minor
popul
nk
cell
express
high
express
refer
bright
nk
cell
respons
cytokin
product
precursor
dim
nk
cell
immunodefici
describ
abnorm
nk
cell
subset
autosom
domin
defici
bright
nk
cell
absent
pauciti
dim
nk
cell
rel
expans
bright
nk
cell
present
patient
absenc
bright
nk
cell
secondari
defici
patient
african
american
femal
born
nonconsanguin
parent
patient
past
medic
histori
signific
chronic
lung
diseas
secondari
prematur
recurr
acut
otiti
media
failur
thrive
congenit
hypothyroid
famili
histori
signific
older
sister
present
age
ebvassoci
hodgkin
lymphoma
whose
treatment
complic
chronic
activ
ebv
infect
ultim
underw
hematopoiet
stem
cell
transplant
hsct
patient
present
pancytopenia
fever
lymphadenopathi
splenomegali
found
ebv
viremia
greater
copi
whole
blood
pcr
treat
two
dose
rituximab
follow
etoposid
dexamethason
bridg
hsct
whole
exom
sequenc
demonstr
homozyg
mutat
member
tumor
necrosi
factor
receptor
famili
influenc
function
cell
b
cell
nk
cell
nk
cell
primarili
express
bright
nk
cell
defici
autosom
recess
disord
associ
persist
symptomat
ebv
viremia
includ
ebvdriven
hemophagocytosi
lymphoma
hypogammaglobulonemia
specif
antibodi
defici
patient
immun
evalu
prior
initi
chemotherapi
immunosuppress
notabl
elev
igg
iga
igm
despit
hypergammaglobulonemia
patient
protect
titer
streptococcu
pneumonia
patient
panlymphopenia
appropri
percentag
lymphocyt
subset
assess
b
cell
subset
show
slight
increas
percentag
transit
b
cellsplasmablast
nearli
complet
absenc
b
cell
nk
cell
phenotyp
demonstr
complet
loss
bright
nk
cell
reduc
nk
cell
cytotox
compar
previous
report
patient
defici
previou
report
patient
defici
denot
normal
nk
cell
number
normal
moder
reduc
nk
cell
cytotox
howev
defici
caus
specif
loss
bright
nk
cell
subset
previous
report
defici
consid
patient
ebv
driven
diseas
abnorm
nk
cell
studi
introductionbackground
transcript
factor
ikaro
encod
gene
play
crucial
role
lymphopoiesi
somat
recent
also
germlin
mutat
associ
hematolog
malign
notabl
bcell
precursor
acut
lymphoblast
leukemia
germlin
mutat
first
report
monogen
caus
human
diseas
character
marrow
failur
immun
defici
singl
neonat
subsequ
mutat
lead
haploinsuffici
discov
underli
proport
patient
cvid
low
b
cell
number
dominantneg
mutat
observ
caus
sever
combin
immun
defici
phenotyp
time
littl
known
regard
allogen
hematopoiet
cell
transplant
hct
outcom
patient
sever
dominantneg
mutat
concerningli
ikaro
defici
observ
neg
impact
graft
versu
host
diseas
mous
model
object
describ
allogen
stem
cell
transplant
outcom
patient
dominantneg
ikaro
mutat
method
collect
transplant
data
patient
underw
allogen
hct
transplant
center
around
world
result
patient
underw
allogen
hct
use
varieti
condit
regimen
patient
receiv
bone
marrow
cord
blood
graft
hlamatch
sibl
donor
singl
allel
hlamismatch
unrel
donor
neutrophil
engraft
occur
day
posttranspl
platelet
engraft
occur
day
except
one
patient
return
normal
platelet
count
due
underli
liver
dysfunct
patient
document
greater
whole
blood
donor
chimer
median
day
rang
day
follow
transplant
maintain
donor
chimer
last
followup
one
patient
develop
grade
ii
acut
gvhd
patient
develop
chronic
gvhd
one
patient
die
approxim
year
post
transplant
relat
cryptosporidium
cholang
exist
prior
hct
recent
follow
surviv
patient
rang
ivig
discontinu
antimicrobi
prophylaxi
stop
patient
receiv
routin
vaccin
excel
perform
statu
conclus
allogen
hct
may
safe
option
consid
patient
dominantneg
ikaro
mutat
appear
increas
risk
death
gvhd
moreov
transplant
patient
aliv
well
show
featur
diseas
howev
limit
number
patient
evalu
retrospect
natur
analysi
data
allow
firm
conclus
made
studi
need
evalu
outcom
larger
cohort
introduct
evalu
patient
tcell
lymphopenia
often
concern
defect
lymphocyt
product
function
especi
set
frequent
infect
outlin
case
demonstr
tcell
lymphopenia
due
increas
loss
consid
differenti
diagnosi
case
report
report
male
initi
present
recurr
rightsid
pneumonia
requir
frequent
hospit
admiss
includ
sever
episod
necessit
intens
care
unit
admiss
work
pneumonia
includ
bronchoscopi
reveal
normal
anatomi
minim
inflamm
chest
ct
mild
peribronchi
wall
thicken
pulmonari
diseas
progress
develop
persist
product
cough
expector
mucou
plug
plasticlik
appear
pulmonari
symptom
respond
steroid
mucou
plug
product
persist
sputum
cultur
intermitt
posit
isol
cryptococcu
neoforman
aspergillu
niger
underw
vat
wedg
biopsi
concern
recurr
aspir
immunolog
evalu
initi
demonstr
normal
tand
bcell
count
serial
evalu
lymphocyt
popul
demonstr
low
cell
rang
cellscumm
low
normal
cell
rang
cellscumm
normal
band
nkcell
number
tcell
evalu
reveal
normal
ratio
naiv
memori
p
p
u
l
n
c
c
r
c
c
r
normal
trec
copi
per
cell
normal
thymic
emigr
normal
indic
suffici
thymopoiesi
mitogen
antigen
stimul
assay
demonstr
normal
respons
phytohemagglutin
concanavalin
pokewe
mitogen
low
lymphocyt
respons
candida
normal
quantit
immunologlobulin
normal
diphtheria
tetanu
streptococcu
pneumonia
titer
dihydrorhodamin
flow
cytometri
fish
chromosom
delet
neg
given
normal
function
thymic
output
immunolog
profil
concern
tcell
loss
patient
regist
undiagnos
diseas
network
second
review
lung
biopsi
concern
plastic
bronchiti
subsequ
lymphat
imag
demonstr
abnorm
lymphat
within
bilater
clavicular
space
right
greater
left
question
partial
thorac
duct
explain
unilater
symptom
diagnos
plastic
bronchiti
secondari
abnorm
lymphat
drainag
lymphat
fluid
fill
airway
secondari
tcell
loss
discuss
plastic
bronchiti
rare
potenti
fatal
disord
seen
commonli
fontan
procedur
congenit
heart
diseas
process
result
tcell
loss
airway
subsequ
tcell
lymphopenia
patient
fontanrel
protein
lose
enteropathi
multipl
immun
abnorm
describ
includ
reduc
immunoglobulin
lymphopenia
select
lymphocyt
defici
similar
find
report
patient
lymphat
malform
although
impact
tcell
loss
adapt
immun
entir
known
indic
increas
risk
atyp
infect
given
normal
mitogen
assay
patient
start
prophylact
antibiot
continu
symptomat
episod
lymphopenia
opportunist
infect
remain
stabl
aggress
pulmonari
regimen
conclud
reiter
import
consid
tcell
loss
patient
present
lymphopenia
particularli
evid
normal
thymopoeisi
tcell
function
introduct
granulomat
diseas
gd
describ
variabl
incid
patient
common
variabl
immunodefici
cvid
increas
malign
report
cvid
patient
cohort
particularli
lymphoma
report
cvid
patient
depend
cohort
prior
analysi
cohort
cvid
patient
includ
patient
gd
gd
suggest
case
lymphoma
compar
case
without
gd
although
differ
statist
signific
object
compar
frequenc
lymphoma
gd
gdpatient
cvid
patient
cohort
usidnet
registri
method
submit
queri
usidnet
registri
request
deidentifi
data
patient
diagnosi
cvid
august
statist
analysi
perform
spss
comparison
done
pearson
chisquar
fisher
exact
test
depend
sampl
size
use
alpha
level
result
cohort
cvid
patient
usidnet
registri
analyz
ninetyon
patient
gd
overal
patient
malign
diagnosi
lymphoma
lymphoma
present
gd
patient
versu
gdpatient
overal
malign
present
gd
versu
discuss
cohort
cvid
patient
usidnet
registri
found
frequenc
lymphoma
rang
previous
describ
cohort
frequenc
lymphoma
patient
gd
higher
frequenc
gdpatient
differ
statist
signific
identifi
frequenc
lymphoma
gd
patient
lower
one
previous
identifi
cvid
patient
cohort
similar
proport
differ
gd
gdpatient
despit
statist
signific
frequenc
lymphoma
shown
elsewher
higher
cvid
patient
gd
gdin
studi
full
understand
increas
risk
lymphoma
expand
analysi
larger
group
cvid
patient
may
help
confirm
deni
robust
associ
may
meaning
impact
outcom
particular
popul
introduct
patient
refractori
pericard
treat
intraven
immunoglobulin
ivig
interleukin
receptor
antagonist
anakinra
limit
transient
benefit
separ
combin
therapi
subcutan
immunoglobulin
scig
interleukin
il
inhibitor
rilonacept
refractori
pericard
cohort
patient
previous
describ
case
descript
patient
refer
recurr
pericard
refractori
tradit
therapi
age
rang
year
multipl
seriou
sequela
pericard
abnorm
immun
paramet
includ
hypogammaglobulinemia
poor
respons
vaccin
poor
mitogen
induc
lymphocyt
prolifer
andor
b
cell
lymphopenia
patient
vari
past
medic
histori
associ
condit
patient
start
ig
initi
ivig
though
transit
hyaluronidasefacilit
scig
hyqvia
patient
start
either
anakinra
rilonacept
patient
continu
rilonacept
remain
anakinra
patient
complet
near
complet
resolut
pericard
dual
therapi
greater
year
markedli
elev
prior
therapi
seen
patient
normal
posttherapi
patient
elev
prior
therapi
also
improv
posttherapi
patient
also
diagnos
famili
mediterranean
fever
fmf
stop
therapi
greater
year
episod
pericard
discuss
patient
recurr
refractori
pericard
sign
immunodefici
autoinflammatori
diseas
laboratori
test
respond
dual
therapi
hyqvia
rilonacept
anakinra
result
resolut
pericard
inflammasom
immun
abnorm
may
implic
associ
recurr
pericard
may
respond
target
therapi
chief
laboratori
clinic
immunolog
microbiolog
idg
dir
niaid
nih
bethesda
md
usa
hypomorph
recombin
activ
gene
mutat
result
residu
tand
bcell
develop
human
mice
found
patient
present
delayedonset
combin
immun
defici
granuloma
andor
autoimmun
cidgai
recent
studi
shed
light
hypomorph
mutat
alter
primari
repertoir
b
cell
less
known
effect
immun
dysregul
target
organ
order
investig
role
mutat
determin
intestin
diseas
set
evalu
gut
immun
microbiota
interplay
mutant
hypomorph
mice
evalu
two
mous
model
carri
homozyg
mutat
correspond
human
mutat
respect
describ
patient
cidgai
mutat
fall
code
flanksensit
region
ctermin
domain
basi
aminoacid
properti
vitro
studi
mutat
demonstr
moder
effect
protein
stabil
mutat
result
highli
disrupt
analysi
intestin
patholog
mutant
mice
niaid
anim
protocol
lcim
reveal
differ
degre
spontan
coliti
sever
inflammatori
infiltr
observ
mice
carri
disrupt
mutat
colon
inflamm
character
crypt
elong
epitheli
hyperplasia
abund
inflammatori
infiltr
extend
colon
lamina
propria
occasion
crypt
abscess
signific
increas
activ
cell
express
gut
home
receptor
observ
mesenter
lymph
node
mln
mutant
strain
especi
promin
mutant
mice
addit
proport
mln
regulatori
treg
cell
increas
mous
model
final
mln
mutant
mice
contain
high
number
myeloid
cell
along
decreas
number
b
cell
abnorm
also
promin
mice
summari
shown
mutant
hypomorph
mice
present
differ
degre
inflammatori
bowel
diseas
mous
model
carri
disrupt
mutat
present
sever
phenotyp
current
perform
studi
evalu
impact
mutat
microbiom
composit
divers
mous
model
cidgai
background
hypogammaglobulinemia
low
serum
immunoglobulin
g
igg
level
either
inherit
primari
acquir
secondari
associa
e
w
h
n
c
r
e
e
n
f
e
c
n
r
e
p
r
r
hypogammaglobluinemia
caus
mani
primari
immun
defici
pid
includ
combin
variabl
immun
defici
cvid
secondari
hypogammaglobluinemia
caus
mani
acquir
condit
lymphoma
leukemia
chemotherapi
immunosuppress
drug
immunoglobulin
replac
therapi
irt
mainstay
treatment
patient
hypogammaglobulinemia
reduc
infect
replenish
quantit
igg
applic
ig
therapi
autoimmun
diseas
mechan
action
thought
ig
mediat
immunomodul
innat
immun
cell
shown
involv
mechan
whether
irt
modul
adapt
immun
cell
patient
hypogammaglobulinemia
well
known
hypothesi
irt
immunomodulatori
effect
tcell
function
prolifer
patient
hypogammaglobulinemia
method
blood
thirti
patient
hypogammaglobulinemia
recruit
immunodefici
clinic
ottawa
hospit
drawn
peripher
blood
mononuclear
cell
pbmc
isol
start
irt
minimum
week
start
irt
data
regard
igg
level
number
type
infect
receiv
irt
collect
pbmc
analyz
use
flow
cytometri
quantit
tcell
subset
cultur
stimul
pbmc
also
analyz
extracellular
intracellular
cytokin
product
measur
e
l
n
f
l
w
c
e
r
r
e
p
e
c
v
e
l
c
b
n
e
cytomegaloviru
epsteinbarr
viru
influenza
viru
cef
peptid
use
studi
specif
tcell
respons
stimul
pbmc
use
celltrac
tcell
prolifer
w
g
r
u
p
e
b
e
n
n
u
r
e
f
hypogammaglobulinemia
ie
result
compar
irt
use
wilcoxon
matchedpair
sign
rank
test
result
irt
found
significantli
alter
proport
treg
tcell
popul
activ
state
measur
express
howev
irt
found
significantli
increas
express
intracellular
ifni
tcell
stimul
p
ypogammaglobulinemia
patient
chang
extracellular
cytokin
product
group
contrast
tcell
patient
show
significantli
higher
express
intracellular
ifni
tnfa
postcef
viral
peptid
stimul
p
tcell
prolifer
stimul
found
decreas
irt
group
p
p
conclus
result
suggest
irt
alter
tcell
function
differenti
effect
patient
r
addit
replenish
serum
igg
level
experi
assess
cytotox
tcell
conduct
studi
tcell
subset
function
well
bcell
function
laboratori
result
analyz
associ
clinic
outcom
upload
file
upload
background
sever
congenit
neutropenia
scn
rare
immunodefici
disord
characteris
extrem
low
absolut
neutrophil
count
anc
less
clinic
featur
scn
recurr
bacteri
infect
patient
risk
leukemia
develop
incid
scn
estim
individu
mutat
gene
describ
caus
scn
either
recess
domin
xlink
inherit
case
present
describ
year
old
malaysian
girl
present
recurr
abscess
whole
part
bodi
recurr
oral
candidiasi
growth
failur
recurr
pneumonia
sinc
month
old
also
histori
episod
acut
tonsil
chronic
suppur
otiti
media
herp
zoster
infect
throughout
age
persist
neutropenia
less
occas
anc
elev
treat
autoimmun
neutropenia
respect
due
posit
result
autoimmun
workout
antinuclear
antibodi
ana
doubl
strand
dna
dsdna
eventu
later
neg
later
age
year
old
whole
exom
sequenc
perform
confirm
sanger
e
q
u
e
n
c
n
g
f
u
n
h
e
e
r
z
g
u
v
r
n
n
e
l
n
e
gene
autosom
domin
describ
caus
scn
parent
carri
mutat
henc
de
novo
mutat
current
recurr
infect
despit
rel
well
prophylaxi
antibiot
conclus
knowledg
report
first
time
malaysian
girl
scn
confirm
mutat
analysi
elan
gene
delay
diagnosi
might
due
insuffici
awar
phenotyp
present
rare
diseas
moreov
genet
analysi
avail
malaysia
need
done
outsid
countri
case
demonstr
import
genet
analysi
may
help
improv
diagnosi
manag
patient
submiss
id
professor
paediatr
immunolog
univers
colleg
london
great
ormond
street
hospit
nh
trust
orchard
therapeut
london
uk
background
adascid
rare
genet
disord
caus
sever
combin
immunodefici
histor
adascid
treat
use
enzym
replac
therapi
ert
follow
allogen
hematopoiet
stem
cell
hsc
transplant
hsct
match
relat
donor
mrd
none
identifi
nonmrd
matchedmismatch
unrel
mismatch
relat
donor
develop
selfinactiv
lentivir
vector
lv
codon
optim
human
ada
cdna
driven
short
form
elong
ef
promot
efsada
lv
drug
product
compos
autolog
hsc
transduc
ex
vivo
efsada
lv
evalu
prospect
historicallycontrol
phase
iii
clinic
trial
adascid
pediatr
subject
report
safeti
efficaci
month
adascid
subject
treat
lentivir
gene
therapi
gt
compar
histor
cohort
adascid
patient
treat
hsct
method
twenti
subject
male
femal
mo
yr
treat
gt
autolog
hsc
isol
bone
marrow
prestimul
cytokin
transduct
efsada
lv
busulfan
administ
singl
dose
mgkg
prior
infus
control
group
includ
patient
mo
yr
treat
allogen
hsct
mrd
nonmrd
great
ormond
street
hospit
uk
duke
univers
children
hospit
usa
result
month
overal
surviv
os
eventfre
surviv
evf
defin
surviv
absenc
ert
reinstitut
rescu
allogen
hsct
statist
significantli
higher
gt
group
compar
hsct
group
tabl
success
engraft
genet
modifi
hsc
observ
gt
subject
month
persist
month
base
vector
gene
mark
granulocyt
median
copiescel
rang
month
peripher
blood
mononuclear
cell
median
copiescel
rang
month
associ
increas
red
blood
cell
ada
enzym
activ
metabol
detoxif
deoxyadenosin
nucleotid
month
none
gt
subject
requir
pegada
ert
reinstitut
abl
stop
receiv
immunoglobin
replac
therapi
igrt
wherea
hsct
patient
requir
rescu
hsct
reinstitut
pegada
ert
abl
stop
receiv
igrt
tabl
nine
subject
gt
group
experienc
seriou
advers
event
sae
frequent
infect
gastrointestin
event
one
consid
treatmentrel
gt
group
event
autoimmun
studi
due
autolog
natur
product
incid
graft
vs
host
diseas
gvhd
gt
group
wherea
patient
hsct
group
experienc
acut
gvhd
experienc
chronic
gvhd
event
one
die
conclus
treatment
lentivir
gt
adascid
well
toler
favor
benefitrisk
profil
month
base
sustain
gene
correct
restor
immun
function
well
improv
os
evf
compar
hsct
mrd
nonmrd
month
background
adascid
rare
genet
disord
caus
sever
combin
immunodefici
minim
absent
b
cell
function
prior
often
treatment
allogen
hematopoiet
stem
cell
hsc
transplant
hsct
autolog
ex
vivo
hsc
gene
therapi
gt
patient
manag
enzym
replac
therapi
ert
immunoglobulin
ig
replac
therapi
igrt
evalu
gt
treatment
autolog
hsc
transduc
ex
vivo
selfinactiv
lentivir
vector
lv
codon
optim
human
ada
cdna
driven
intern
short
form
elong
ef
promot
efsada
lv
month
followup
pediatr
adascid
subject
treat
gt
compar
histor
cohort
adascid
patient
treat
hsct
report
b
cell
reconstitut
cohort
method
twenti
subject
male
femal
age
mo
yr
receiv
gt
autolog
hsc
isol
bone
marrow
prestimul
cytokin
transduct
efsada
lv
genet
modifi
cell
administ
condit
singl
dose
busulfan
mg
kg
control
group
includ
patient
age
mo
yr
treat
hsct
great
ormond
street
hospit
uk
duke
univers
children
hospit
us
hsct
patient
receiv
allogen
transplant
match
relat
donor
mrd
nonmrd
subject
continu
receiv
igrt
postgt
clinic
decis
made
stop
factor
b
cell
reconstitut
gener
medic
condit
season
infect
result
month
gt
group
stop
treatment
igrt
compar
hsct
group
overal
month
higher
proport
gttreat
subject
stop
igrt
respect
compar
mrd
hsct
patient
respect
nonmrd
hsct
patient
timepoint
tabl
gt
group
vector
gene
mark
detect
peripher
blood
mononuclear
cell
within
month
persist
month
postinfus
median
copiescel
rang
suggest
success
gene
modif
evid
b
cell
reconstitut
iga
igm
level
peripher
blood
sera
doubl
month
mgdl
rang
mgdl
rang
mgdl
rang
mgdl
rang
respect
addit
antibodi
respons
follow
tetanu
vaccin
evalu
subject
subject
mount
protect
respons
vaccin
median
antibodi
respons
iuml
rang
base
normal
threshold
iuml
hammarlund
clin
infect
di
laboratori
refer
rang
iuml
conclus
gt
autolog
hsc
transduc
ex
vivo
efsada
lv
result
b
cell
reconstitut
evidenc
doubl
iga
igm
product
month
cessat
igrt
patient
month
protect
specif
antibodi
respons
tetanu
vaccin
patient
evalu
background
xlink
chronic
granulomat
diseas
xcgd
result
mutat
cybb
encod
subunit
phagocyt
nadphoxidas
attempt
treat
xcgd
gene
therapi
gt
use
transduc
autolog
hematopoiet
stem
cell
hsc
transduc
ex
vivo
gammaretrovir
vector
met
limit
efficaci
due
transient
engraft
gene
correct
hsc
gene
silenc
vector
insertionmedi
activ
oncogen
lead
myelodysplasia
develop
novel
selfinactiv
sin
lentivir
vector
lv
chimer
cathepsin
gcfe
myeloidspecif
promot
drive
express
codon
optim
cdna
follow
transplant
lv
ex
vivo
transduc
autolog
hsc
busulfancondit
xcgd
patient
longterm
restor
oxidas
activ
peripher
blood
polymorphonuclear
neutrophil
pmn
month
sever
affect
xcgd
patient
without
evid
genotox
present
data
multipl
assay
use
assess
qualiti
quantiti
restor
pmn
oxidas
activ
method
similar
trial
gt
lv
initi
uk
plu
compassion
use
patient
usa
patient
histori
inflammatori
diseas
sever
persist
infect
nonrespons
convent
therapi
time
gt
gcsf
plu
plerixaformobil
hsc
transduc
ex
vivo
subject
receiv
myeloabl
condit
singleag
busulfan
target
net
areaunderthecurv
ngml
hr
freshli
prepar
cryopreserv
qualitytest
geneticallymodifi
hsc
manufactur
onsit
administ
intraven
pmn
oxidas
activ
postgt
assess
pnitroblu
tetrazolium
nbt
reduct
dihydrorhodamin
dhr
flow
cytometri
assay
quantit
ferricytochrom
c
assay
ferric
measur
superoxid
gener
result
report
result
patient
age
year
year
followup
two
addit
patient
treat
die
within
three
month
gt
complic
deem
relat
preexist
diseaserel
comorbid
sever
pulmonari
diseas
antiplatelet
antibodi
within
month
postgt
oxidas
pmn
present
peripher
blood
base
nbt
test
dhr
flow
cytometri
express
correct
transgen
confirm
flow
cytometri
use
antibodi
detect
quantit
biochem
measur
oxidas
activ
also
confirm
sampl
use
ferric
assay
demonstr
quantit
level
superoxid
product
per
correct
cell
within
normal
rang
function
test
oxidas
burst
activ
use
dhr
fluoresc
assay
appli
serial
follow
level
correct
pmn
oxidas
activ
per
correct
cell
also
normal
rang
patient
pmn
dhr
within
one
month
remain
stabl
patient
followup
period
figur
followup
demonstr
sustain
stabl
persist
oxidas
burst
posit
neutrophil
surviv
subject
month
restor
clinic
benefici
level
defin
pmn
dhr
patient
decemb
conclus
result
demonstr
correct
pmn
function
within
month
xcgd
patient
treat
autolog
gt
pmn
oxidas
activ
sustain
level
restor
biochem
function
provid
clinic
benefici
level
immun
month
patient
formul
igsc
develop
base
knowledg
acquir
formul
grifol
current
licens
immun
globulin
human
howev
protein
concentr
increas
facilit
effici
subcutan
administr
gamunexc
extens
record
safeti
toler
administ
intraven
subcutan
greater
year
divers
patient
popul
igsc
manufactur
process
employ
purif
step
gamunexc
demonstr
robust
provid
igg
product
requir
potenc
puriti
qualiti
formul
excipi
characterist
compat
drug
product
well
establish
glycin
excipi
intramuscular
immun
globulin
human
fifti
year
intraven
immun
globulin
igiv
twenti
year
igsc
formul
low
buffer
capac
low
ph
select
achiev
product
low
aggreg
low
fragment
viscos
suitabl
subcutan
administr
improv
visual
clariti
igsc
formul
contain
small
amount
polysorb
wide
use
biopharmaceut
product
subcutan
administr
igsc
formul
well
toler
clinic
studi
object
goal
provid
pid
popul
new
immunoglobulin
liquid
product
subcutan
administr
igsc
method
igsc
manufactur
use
current
manufactur
process
gamunexc
follow
addit
concentr
step
product
formul
higher
protein
concentr
igsc
gamunexc
batch
produc
full
industri
scale
subject
seri
analyt
test
includ
assess
puriti
composit
neutral
activ
result
igsc
gamunexc
manufactur
process
formul
preserv
igg
integr
molecular
characterist
potenc
manufactur
process
elimin
lipid
alcohol
acet
coagul
factor
impur
includ
fxia
undetect
either
specif
global
method
igsc
gamunexc
batch
gamma
globulin
agaros
membran
electrophoresi
subclass
distribut
similar
normal
plasma
accept
specif
antibodi
content
igsc
shown
primarili
monom
plu
dimer
igg
minim
aggreg
fragment
confirm
appropri
gentl
process
condit
use
concentr
igg
solut
igg
conclus
igsc
highli
concentr
igg
solut
characterist
compar
gamunexc
twice
igg
concentr
order
facilit
subcutan
administr
reduc
volum
shorter
infus
time
analyt
test
demonstr
suitabl
potenc
puriti
neutral
activ
number
specif
antigen
fund
studi
fund
conduct
grifol
manufactur
immunoglobulin
subcutan
administr
disclosur
author
employe
grifol
frequent
respiratori
tract
infect
seizur
caus
recurr
hospit
children
typic
consid
result
neurolog
impair
poor
airway
clearanc
evalu
patient
immunodefici
common
clinic
practic
report
combin
immun
defici
patient
md
recurr
respiratori
tract
infect
case
present
case
boy
md
initi
refer
age
month
abnorm
newborn
screen
low
cell
receptor
excis
circl
trec
sever
combin
immunodefici
scid
initi
evalu
reveal
moder
cell
lymphopenia
figur
initi
immunoglobulin
level
normal
place
antiseizur
medic
later
develop
recurr
sever
respiratori
tract
infect
start
infanc
month
age
develop
hypogammaglobulinemia
figur
addit
cell
count
progress
decreas
stay
around
cellsul
immunoglobulin
replac
therapi
start
month
age
hospit
due
respiratori
tract
infect
significantli
decreas
case
boy
md
recurr
bacteri
viral
respiratori
infect
requir
numer
hospit
includ
intens
care
unit
stay
newborn
screen
scid
neg
antiseizur
medic
immunolog
evalu
year
age
reveal
low
total
cell
cell
normal
rang
ul
normal
rang
hypogammaglobinemia
igg
normal
rang
nonprotect
igg
level
tetanu
varicella
pneumococcu
serotyp
immunoglobulin
replac
therapi
start
year
age
result
reduc
frequenc
sever
respiratori
infect
improv
qualiti
life
discuss
cell
lymphopenia
hypogammaglobulinemia
seen
case
millerdiek
syndrom
knowledg
immun
defici
never
report
md
one
case
suggest
low
cell
count
may
start
earli
birth
may
detect
newborn
screen
hypogammaglobulinemia
may
primari
secondari
due
antiepilept
children
reduc
frequenc
sever
respiratori
infect
improv
qualiti
life
immunoglobulin
replac
highlight
import
screen
earli
manag
immunodefici
conclus
millerdiek
syndrom
like
anoth
syndrom
primari
immun
defici
disord
high
index
suspicion
earli
screen
manag
immunodefici
may
benefici
children
millerdiek
syndrom
upload
file
upload
prospect
multicent
openlabel
studi
assess
pharmacokinet
pk
safeti
toler
immun
globulin
subcutan
human
caprylatechromatographi
purifi
igsc
subject
primari
immunodefici
pi
object
determin
weekli
subcutan
sc
dose
igsc
noninferior
intraven
iv
dose
immun
globulin
inject
human
caprylatechromatographi
purifi
igivc
determin
steadi
state
trough
igg
level
igsc
igivc
infus
possibl
phase
qualifi
igg
regimen
enrol
subject
requir
enter
runin
phase
receiv
igivc
achiev
steadyst
enter
iv
phase
determin
steadyst
areaunderthecurv
auc
iv
infus
subject
qualifi
igivc
regimen
mgkg
directli
enter
iv
phase
steadyst
iv
pk
assess
upon
complet
iv
pk
assess
subject
enter
sc
phase
receiv
weekli
dose
igsc
week
steadyst
auc
determin
dose
igsc
associ
report
seriou
local
infus
site
reaction
isr
major
local
isr
mildtomoder
igsc
dose
convers
factor
provid
equival
exposur
igivc
assess
steadyst
day
higher
mean
igg
trough
valu
lower
fluctuat
igg
concentr
flexibl
home
administr
igsc
well
toler
safeti
profil
compar
igivc
clinicaltrialsgov
identifi
disclosur
kecia
courtney
elsa
mondou
jiang
lin
employe
grifol
manufactur
igsc
grifol
sponsor
studi
background
two
report
describ
defici
adenosin
deaminas
earlyonset
lacunar
stroke
intermitt
fever
livedoid
rash
earli
onset
polyarter
nodosa
pan
sinc
first
report
clinic
spectrum
dramat
expand
includ
antibodi
defici
liver
diseas
vasculopathi
pure
red
cell
aplasia
cytopenia
lymphoprolif
diseas
method
fortytwo
patient
enrol
irb
approv
studi
nih
sequenc
gene
encod
adenosin
deaminas
perform
patient
inform
obtain
chart
review
clinic
serolog
radiograph
test
result
patient
germlin
biallel
loss
function
mutat
lead
absent
significantli
decreas
protein
express
function
cohort
compris
femal
male
sibl
pair
famili
affect
individu
twentyseven
patient
histori
least
one
ischem
stroke
experienc
hemorrhag
stroke
averag
age
time
first
stroke
year
rang
month
year
averag
number
stroke
rang
new
stroke
occur
patient
antitnf
therapi
skin
manifest
occur
patient
includ
livedo
cutan
vascul
resembl
pan
raynaud
hepatomegali
splenomegali
also
notabl
portal
hypertens
observ
patient
patient
requir
splenoren
shunt
massiv
varic
bleed
abdomin
mra
reveal
arter
aneurysm
patient
evalu
patient
develop
bowel
necrosi
peripher
vasculopathi
seen
patient
one
requir
amput
gangren
digit
common
immun
abnorm
seen
cohort
hypogammaglobulinemia
patient
low
igg
patient
low
igm
patient
low
iga
ten
patient
immunoglobulin
replac
specif
antibodi
respons
vaccin
inadequ
patient
challeng
lymphocyt
phenotyp
reveal
decreas
classswitch
memori
b
cell
patient
test
howev
relationship
absolut
number
class
switch
memori
b
cell
hypogammaglobulinemia
infect
frequenc
hematolog
abnorm
includ
transfus
depend
anemia
neutropenia
lymphopenia
thrombocytopenia
seven
patient
develop
pancytopenia
present
pure
red
cell
aplasia
develop
aplast
anemia
three
patient
undergon
bone
marrow
transplant
two
patient
requir
second
transplant
graft
failur
conclus
spectrum
expand
stroke
intermitt
fever
cutan
manifest
includ
portal
system
hypertens
immun
defici
cytopenia
vascular
abnorm
bone
marrow
failur
initi
antitnf
therapi
improv
inflammatori
marker
new
stroke
occur
therapi
cytopenia
seem
improv
bone
marrow
transplant
consid
patient
find
bone
marrow
failur
although
transplant
patient
complic
immun
mediat
neutropenia
diseas
manifest
heterogen
make
comprehens
evalu
critic
understand
diseas
given
increas
neonat
diagnosi
athymia
clinic
care
provid
refer
medic
center
prior
implant
patient
return
refer
center
earlier
creat
need
clear
concis
guidelin
care
patient
primari
goal
pretransplant
clinic
care
manag
preexist
medic
need
feed
difficulti
airway
obstruct
congenit
cardiac
defect
development
disabl
manag
symptom
relat
oligoclon
recipi
cell
expans
autolog
gvhdatyp
complet
digeorg
anomali
prevent
infect
death
pre
earli
posttransplant
period
secondari
preexist
infect
necessari
surgic
medic
procedur
ie
cardiac
surgeri
hear
aid
delay
first
month
patient
profoundli
low
cell
number
may
requir
immunosuppress
prevent
reject
oligoclon
recipi
cell
immunosuppress
need
close
monitor
titrat
desir
effect
minim
side
effect
renal
toxic
electrolyt
abnorm
hypertens
cell
count
perform
everi
month
use
guid
wean
immunosuppress
patient
success
transplant
develop
greater
cell
month
post
infect
prevent
clinic
stabil
optim
nutrit
critic
last
engraft
clinic
guidelin
develop
address
immunosuppress
manag
autolog
gvhd
symptom
gut
skin
liver
preserv
renal
function
development
consider
develop
cell
patient
continu
monitor
regularli
immunologist
patient
may
develop
autoimmun
complic
thyroid
diseas
transient
cytopenia
risk
complic
relat
viral
infect
greatli
decreas
develop
cell
patient
comorbid
central
venou
access
devic
depend
tracheostomi
chronic
lung
diseas
continu
requir
complex
care
multidisciplinari
team
medic
condit
associ
athymia
allevi
thymu
transplant
hypoparathyroid
cardiac
defect
may
requir
lifelong
medic
care
lastli
patient
must
evalu
readi
kill
live
vaccin
transplant
outcom
influenc
clinic
condit
time
implant
optim
immunosuppress
nutrit
clinic
stabil
first
month
follow
clinic
care
maintain
wellnourish
clinic
stabl
infect
free
patient
yield
best
chanc
success
cell
develop
guidanc
document
support
goal
ensur
patient
best
prepar
receiv
develop
long
last
thymic
function
hemophagocyt
lymphohistiocytosi
hlh
lifethreaten
diseas
immun
dysregul
character
uncheck
inflammatori
respons
lead
endorgan
dysfunct
primari
hlh
result
inherit
mutat
impair
capac
immun
regul
wherea
secondari
hlh
aris
inappropri
respons
immun
stimulu
infect
malign
autoimmun
report
male
present
symptom
hlh
initi
manifest
congenit
disord
glycosyl
cdg
due
mutat
gene
compon
oligomer
golgi
complex
result
cdgiij
male
histori
mild
motor
delay
present
day
fever
vomit
diarrhea
initi
evalu
identifi
highli
elev
ferritin
triglycerid
transamin
coagulopathi
hyperammonemia
subsequ
develop
gener
seizur
liver
bone
marrow
biopsi
demonstr
erythrophagocytosi
consist
hlh
immunolog
evalu
notabl
mild
hypogammaglobulinemia
neutropenia
thrombocytopenia
anemia
serum
level
nk
function
studi
later
found
normal
patient
initi
treat
ammoniascaveng
therapi
fresh
frozen
plasma
ffp
coagulopathi
subsequ
intraven
immunoglobulin
dexamethason
sever
day
later
within
hour
start
ffp
patient
ferritin
level
declin
sharpli
hyperammonemia
transamin
also
resolv
fever
curv
improv
addit
immunosuppress
consid
initi
due
patient
ongo
clinic
improv
next
month
patient
experienc
two
acut
episod
fever
liver
dysfunct
coagulopathi
sepsi
physiolog
second
episod
success
treat
ffp
though
clear
infecti
trigger
identifi
third
episod
occur
day
routin
vaccin
patient
prolong
hypotens
requir
ionotrop
support
resolv
receiv
daili
ffp
hypoxia
pleural
effus
resolv
singl
treatment
protein
c
concentr
patient
met
clinic
diagnost
criteria
hlh
also
histori
hyperammonemia
underw
concurr
biochem
genet
evalu
primari
hlh
inborn
error
metabol
whole
exom
sequenc
identifi
compound
heterozyg
mutat
part
oligomer
protein
complex
involv
golgi
apparatu
structur
function
mutat
previous
report
two
patient
autosom
recess
cdgiij
describ
similar
clinic
symptom
hypotonia
seizur
coagulopathi
liver
dysfunct
well
recurr
infect
subsequ
immun
phenotyp
patient
healthi
notabl
slightli
low
number
nk
cell
normal
mobil
perforingranzym
b
express
vitro
patient
repres
novel
present
cdg
due
defect
associ
immun
dysfunct
manifest
recurr
episod
inflammatori
crisi
featur
hlh
cdg
inborn
error
metabol
consid
diagnost
evalu
patient
hlh
symptom
cdg
patient
may
develop
acut
episod
sever
inflamm
absenc
cellular
regulatori
defect
ffp
protein
c
concentr
may
therapeut
valu
death
identifi
caus
relat
infect
rate
death
per
personyear
common
autoimmunityrel
complic
sweet
syndrom
seen
patient
antiifng
autoantibodi
sixteen
patient
recur
sweet
syndrom
addit
patient
develop
lymphat
obstruct
continu
recur
patient
seven
patient
studi
antiifng
autoantibodi
median
iqr
age
autoantibodyneg
patient
year
patient
femal
none
autoantibodyneg
patient
develop
new
infect
followup
end
followup
period
none
patient
activeprogress
diseas
patient
die
conclus
ninetyon
percent
hiv
uninfect
thai
patient
dissemin
ntm
infect
without
opportunist
infect
detect
antiifng
autoantibodi
one
third
patient
autoantibodi
ifng
recurr
infect
followup
approxim
year
followup
patient
antiifng
autoantibodi
inact
diseas
follow
multidrug
antibiot
therapi
activeprogress
diseas
die
patient
antiifng
autoantibodi
risk
recurr
infect
autoimmunityrel
complic
therefor
longterm
followup
recommend
lifelong
secondari
antibiot
prophylaxi
may
requir
prevent
recurr
infect
set
persist
antiifng
autoantibodi
studi
earli
cell
develop
patient
sever
cell
immunodefici
challeng
rariti
diseas
difficulti
obtain
hematopoiet
stem
cell
hsc
limit
assay
assess
vitro
differenti
hsc
matur
cell
recent
develop
serumfre
system
allow
faith
analysi
sequenti
step
cell
differenti
system
artifici
thymic
organoid
ato
gener
base
aggreg
cultur
deltalik
canon
notch
ligand
express
stromal
cell
line
cell
isol
bone
marrow
bm
sampl
normal
donor
nd
project
set
evalu
possibl
use
ato
system
studi
cell
differenti
patient
carri
cell
defect
order
defin
exact
step
cell
develop
affect
differ
genet
defect
use
ato
system
studi
vitro
cell
differenti
cell
obtain
patient
carri
defect
intrins
hematopoiet
cell
affect
thymu
develop
digeorg
syndrom
dg
patient
show
markedli
decreas
viabil
cell
earli
defect
cell
develop
alreadi
prot
cell
stage
defect
similar
observ
patient
carri
null
mutat
report
show
autolog
reconstitut
uncondit
haploident
hsc
transplant
contrast
cell
patient
carri
missens
mutat
leaki
scid
phenotyp
capabl
differenti
matur
cell
vitro
although
decreas
effici
compar
normal
donor
nd
interestingli
patient
carri
null
mutat
notic
cell
could
reach
full
matur
absolut
number
tcrab
cell
around
less
nd
varianc
prot
cell
fail
express
gc
protein
matur
cell
express
normal
level
gc
suggest
may
deriv
residu
cell
bm
donor
addit
cell
patient
carri
hypomorph
mutat
abl
differenti
doubl
posit
cell
cell
final
dg
patient
show
complet
normal
vitro
cell
differenti
confirm
cell
defici
reflect
thymic
abnorm
summari
data
show
ato
system
could
extrem
use
determin
whether
lack
cell
patient
unknown
gene
defect
reflect
hematopoiet
thymic
intrins
problem
may
therefor
provid
critic
evid
decid
whether
hsc
thymu
transplant
warrant
even
without
know
actual
gene
defect
introduct
ataxiatelangiectasia
autosom
recess
disord
caus
mutat
ataxia
telangiectasia
mutat
atm
gene
aid
detect
repair
dna
damag
character
progress
cerebellar
ataxia
oculomotor
apraxia
choreoathetosi
conjunctiv
telangiectasia
variabl
degre
tcell
lymphopenia
tcl
immun
compromis
patient
increas
risk
malign
particularli
leukemia
lymphoma
unusu
sensit
ioniz
radiat
advent
trecbas
newborn
screen
nb
scid
patient
recogn
asymptomat
tcl
earli
infanc
object
present
older
child
chronic
granulomat
lesion
discuss
may
avoid
individu
diagnos
follow
abnorm
nb
case
report
yo
male
born
term
follow
uncompl
twin
pregnanc
deliveri
prior
institut
scid
nb
demonstr
mild
gross
motor
speech
delay
infant
diagnos
age
receiv
routin
immun
includ
live
vaccin
develop
granulomat
skin
lesion
age
initi
small
papul
cheek
ear
subsequ
form
larg
disfigur
plaqu
sunexpos
areascheek
arm
hand
fig
follow
extens
workup
lesion
found
secondari
mutat
vaccinestrain
rubella
base
genotyp
previous
describ
immunocompromis
individu
perelyginasullivan
et
al
jaci
lesion
refractori
multipl
treatment
includ
nitazoxanid
current
daili
oral
topic
steroid
tmpsmx
ivig
retriev
nb
trec
determin
reveal
would
screen
posit
mallotpuck
et
al
j
clin
immunol
first
measur
age
tcell
low
b
nk
cell
number
normal
sinc
april
case
seen
ucsf
infant
nonscid
tcl
nb
male
femal
born
term
discharg
wellinf
nurseri
diagnos
month
age
initi
trec
rang
normal
perkinelm
enlit
kit
low
tcell
initi
flow
cytometri
ref
rang
decreas
tcell
howev
tcell
present
rule
typic
scid
rais
concern
nonscid
tcl
three
infant
also
demonstr
low
bcell
nk
cell
normal
two
current
receiv
ivig
one
also
tmpsmx
avoid
rotaviru
also
mmr
varicella
live
vaccin
conclus
often
diagnos
infant
low
trec
scid
nb
prior
neurolog
manifest
benefit
earli
diagnosi
includ
avoid
live
vaccin
includ
mmr
led
debilit
granuloma
older
patient
addit
patient
receiv
prompt
immunolog
monitor
treatment
avoid
unnecessari
radiat
specialti
referr
famili
genet
counsel
cure
ongo
research
may
bring
neuroprotect
treatment
futur
introduct
subcutan
immun
globulin
well
toler
phase
north
american
studi
patient
primari
immunodefici
diseas
pidd
assess
comorbid
use
concomit
medic
infus
paramet
toler
advanc
age
patient
treat
north
american
studi
method
patient
age
year
pidd
receiv
weekli
infus
volum
mlsite
rate
mlhsite
year
north
american
studi
medic
histori
baselin
medic
condit
ongo
defin
comorbid
event
use
concomit
medic
advers
event
ae
toler
infus
paramet
assess
age
advanc
age
patient
adult
pediatricadolesc
patient
result
mean
number
medic
histori
event
baselin
higher
advanc
age
patient
eventspati
event
patient
versu
adult
eventspati
event
patient
pediatricadolesc
patient
eventspati
event
patient
medic
condit
ongo
baselin
comorbid
event
also
higher
advanc
age
patient
eventspati
event
patient
versu
adult
event
patient
event
patient
pediatricadolesc
patient
eventspati
event
patient
advanc
age
patient
neurolog
comorbid
event
common
follow
relat
eye
ear
nose
throat
event
gastrointestin
event
musculoskelet
comorbid
event
concomit
medic
given
treat
preexist
condit
patient
advanc
age
group
medic
patient
despit
higher
mean
number
comorbid
condit
infus
paramet
advanc
age
patient
compar
adult
age
group
median
maximum
infus
rate
infus
volumessit
compar
advanc
age
patient
mlhsite
mlsite
adult
mlhsite
mlsite
lower
infus
rate
volumessit
report
pediatricadolesc
patient
larger
infus
volum
faster
infus
rate
associ
increas
causal
relat
local
ae
advanc
age
group
consist
trend
seen
pediatr
adolesc
adult
patient
conclus
despit
higher
mean
number
comorbid
advanc
age
patient
pidd
infus
rel
high
rate
volum
well
toler
introduct
hyqvia
ighi
immunoglobulin
infus
recombin
human
hyaluronidas
immunoglobulin
ig
replac
therapi
approv
patient
primari
immunodefici
diseas
pidd
allow
larger
infus
volum
mlsite
improv
ig
bioavail
compar
convent
subcutan
ig
product
postauthor
safeti
studi
conduct
unit
state
acquir
longterm
safeti
data
ighi
assess
prescrib
administr
regimen
routin
clinic
practic
infus
characterist
treatmentrel
advers
event
interim
analysi
report
method
patient
age
year
pidd
receiv
ighi
includ
ongo
prospect
nonintervent
openlabel
uncontrol
multicent
studi
part
routin
clinic
practic
patient
treat
ighi
accord
standard
medic
care
treatment
regimen
discret
treat
physician
advers
event
ae
collect
enrol
studi
completiondiscontinu
use
subject
diari
assess
everi
studi
visit
everi
month
standard
practic
ae
assess
base
serious
sever
causal
related
ighi
presenc
antibodi
evalu
voluntari
basi
treatment
prefer
variou
attribut
ig
therapi
assess
annual
use
treatment
prefer
questionnair
result
total
patient
enrol
us
studi
site
data
cutoff
date
august
infus
selfadminist
home
clinic
site
commonli
use
infus
interv
mean
maximum
ig
infus
rate
mlh
mean
ig
dose
mgkg
mean
number
infus
site
use
administr
mean
infus
durat
hour
infus
administ
without
rate
reduct
interrupt
discontinu
due
ae
seriou
ae
sae
relat
ighi
sixteen
patient
experienc
causal
relat
nonseri
local
ae
eventspatientyear
event
per
infus
patient
experienc
causal
relat
nonseri
system
ae
eventspati
year
event
per
infus
seven
patient
test
antibodi
posit
bind
antibodi
test
titer
maximum
titer
enrol
studi
neutral
antibodi
detect
patient
respond
treatment
prefer
questionnair
end
year
major
prefer
receiv
ig
therapi
home
prefer
doctor
offic
patient
prefer
treatment
hospit
prefer
indic
almost
patient
indic
prefer
continu
treatment
ighi
conclus
interim
analysi
patient
pidd
treat
ighi
routin
clinic
practic
support
previou
observ
ighi
welltoler
prefer
therapi
report
treatmentrel
sae
neutral
antibodi
background
cartilag
hair
hypoplasia
chh
autosom
recess
chondrodysplasia
associ
variabl
immunodefici
pathogen
defect
rmrp
encod
untransl
rna
subunit
ribonucleoprotein
endoribonucleas
complex
rmrp
result
reduc
mrna
rrna
cleavag
rmrp
g
common
variant
increas
finnish
amish
popul
cellular
immunodefici
associ
increas
morbid
mortal
establish
correl
clinic
immunolog
phenotyp
lymphocyt
radiosensit
describ
case
fullterm
amish
femal
infant
low
trec
copi
newborn
scid
screen
flow
cytometri
monthsold
demonstr
sever
b
cell
lymphopenia
cellsmcl
rang
cellsmcl
cellsmcl
rang
cellsmcl
normal
nk
quantit
cellsmcl
rang
cellsmcl
memori
tcell
expans
rel
subset
tcell
function
mitogen
respons
normal
diagnos
chh
homozyg
rmrp
g
mutat
lymphocyt
subset
b
nk
cell
radiosensit
evalu
flow
cytometr
analysi
phosphoryl
p
atm
lowdos
irradi
increas
level
observ
subset
nonirradi
cell
v
nk
cell
v
patient
suggest
constitut
defect
dna
repair
rel
distribut
b
nk
cell
express
patm
hour
postirradi
ir
significantli
differ
experiment
healthi
control
ehc
pediatr
refer
rang
prr
howev
kinet
dephosphoryl
hour
postir
alter
residu
express
subset
patient
cell
delta
mode
ratio
mean
fluoresc
intens
mfi
ehc
delta
mode
ratio
prr
delta
mode
ratio
similar
find
observ
subset
patient
bcell
delta
mode
ratio
ehc
delta
mode
ratio
prr
delta
mode
ratio
frequenc
patient
lymphocyt
residu
persist
postir
promin
tcell
demonstr
persist
compar
ehc
prr
bcell
compar
ehc
prr
lack
followup
verbal
report
suggest
signific
immunolog
infecti
concern
year
age
discuss
lymphocyt
radiosensit
novel
find
chh
b
cell
lymphopenia
abil
rmrp
associ
telomeras
revers
transcriptas
tert
function
rnadepend
rna
polymeras
yield
distinct
silenc
rna
sequenc
may
underli
radiosensit
rmrp
mutant
systemat
character
lymphocyt
radiosensit
immunolog
phenotyp
could
provid
use
inform
whether
could
serv
biomark
magnitud
complex
immunodefici
assess
radiosensit
implic
condit
regimen
select
patient
requir
allogen
hematopoiet
cell
transplant
recommend
lymphocyt
radiosensit
assess
chh
infant
identifi
nb
scid
chh
patient
signific
immunodefici
andor
malign
novel
primari
immunodefici
lymphoprolif
diseas
due
biallel
defect
background
three
children
nonconsanguin
famili
differ
ethnic
background
develop
lymphoprolif
diseas
year
age
also
recurr
infect
includ
pneumonia
bronchiectasi
otiti
media
skin
pustul
immun
phenotyp
reveal
low
cell
percentag
accumul
memorylik
cell
impair
cell
prolifer
low
total
nk
cell
number
method
affect
individu
unaffect
parent
unaffect
famili
member
underw
exom
sequenc
result
affect
case
rare
bioinformat
damag
biallel
variant
appropri
famili
segreg
encod
essenti
compon
regulatori
complex
wrc
immunoblot
confirm
destabil
wrc
patient
immunofluoresc
microscopi
demonstr
defect
factin
local
immun
synaps
nk
cell
signific
abnorm
identifi
patient
lymphocyt
neutrophil
migrat
morpholog
consist
alter
wrcmediat
cytoskelet
dynam
patient
exhibit
impair
insideout
integrin
activ
knockdown
produc
defici
prolif
respons
akt
activ
control
cell
conclus
immunolog
clinic
phenotyp
affect
individu
recapitul
phenotyp
observ
mice
biallel
defect
therefor
result
novel
human
primari
immunodefici
diseas
character
lymphoprolifer
suscept
infect
background
concurr
existencesignific
immunodefici
new
onset
lymphoprolif
diseas
remain
understudi
two
studi
date
evalu
preval
hypogammaglobulinemia
chronic
lymphocyt
leukemia
cll
neither
studi
preval
impact
ige
defici
outcom
cll
therefor
object
studi
examin
preval
hypogammaglobulinemia
examin
isotyp
newli
diagnos
cll
patient
test
hypothesi
patient
hypogammaglobulinemia
distinct
clinic
profil
outcom
method
use
bank
sera
newli
diagnos
cll
adult
patient
lymphoma
molecular
epidemiolog
resourc
lmer
ig
igg
iga
igm
ige
level
measur
lmer
initi
observ
cohort
studi
prospect
enrol
newli
diagnos
lymphoma
patient
evalu
mayo
clinic
rochest
mn
univers
iowa
iowa
citi
ia
iggam
level
measur
use
immunoturbidimetr
assay
wherea
ige
level
determin
use
electrochemiluminesc
immunoassay
associ
ig
defici
clinic
factor
evalu
wilcoxon
rank
sum
chisquar
fisher
exact
appropri
test
cox
regress
model
use
assess
effect
clinic
variabl
overal
surviv
os
time
calcul
biopsi
death
due
caus
patient
still
aliv
censor
last
contact
test
twosid
assess
signific
level
use
sa
sa
institut
cari
nc
result
mean
age
sd
select
cll
cohort
year
male
predomin
patient
white
median
followup
five
year
death
hypogammaglobulinemia
newli
diagnos
cll
common
cohort
patient
measur
isotyp
defici
common
ig
defici
igm
ci
follow
igg
ci
ige
ci
iga
ci
multipl
defici
patient
common
figur
iga
ige
defici
associ
higher
rai
stage
grade
system
cll
present
p
respect
well
higher
white
blood
cell
count
present
respect
higher
proport
iga
defici
patient
need
second
treatment
followup
compar
compar
predictor
overal
surviv
higher
rai
stage
vs
hazard
ratio
hr
ci
age
hr
ci
p
correl
wors
overal
surviv
individu
immunoglobulin
defici
correl
overal
surviv
conclus
signific
proport
patient
cll
underli
ig
deficienciesboth
isol
combin
differ
isotyp
defici
iga
ige
associ
sever
diseas
present
underli
relationship
two
immunolog
disord
deserv
studi
background
patient
primari
immunodefici
pid
increas
risk
develop
autoimmun
diseas
includ
rheumatoid
arthriti
ra
manag
patient
challeng
immunomodul
increas
risk
infect
addit
patient
ra
undergo
therapi
drug
modifi
antirheumat
drug
dmard
may
develop
secondari
immunodefici
studi
review
characterist
patient
pid
later
develop
ra
studi
report
compar
patient
develop
immunodefici
start
dmard
therapi
ra
method
patient
identifi
inflammatori
arthriti
concomit
immunodefici
id
institut
use
code
manual
chart
review
perform
confirm
identifi
time
diagnosi
disord
patient
exclud
either
definit
diagnosi
id
ra
clinic
diagnos
practic
allergistimmunologist
meet
acr
criteria
ra
score
higher
respect
rituximab
administ
prior
diagnosi
id
clinic
symptom
treatment
laboratori
data
extract
fisher
exact
test
use
compar
categor
variabl
group
ttest
use
compar
continu
variabl
result
patient
met
inclus
criteria
patient
diagnos
id
develop
ra
later
life
group
patient
diagnos
ra
subsequ
develop
clinic
signific
id
group
mean
age
diagnosi
id
ra
group
patient
year
sd
year
sd
respect
group
mean
age
diagnosi
ra
sd
compar
year
sd
diagnosi
id
patient
group
femal
group
group
patient
group
humor
id
includ
common
variabl
immunodefici
cvid
group
patient
specif
antibodi
defici
sad
group
group
patient
hypogammaglobulinemia
group
group
patient
patient
group
seroposit
rheumatoid
factor
rf
anticycl
citrullin
peptid
anticcp
wherea
patient
group
posit
rf
anticcp
tabl
patient
group
treat
immunoglobulin
replac
therapi
treatment
ra
group
similar
combin
dmard
therapi
use
group
patient
contrast
group
patient
conclus
studi
indic
even
though
clinic
characterist
manag
similar
patient
coexist
id
ra
rf
anticcp
usual
neg
patient
develop
ra
id
possibl
due
impair
antibodi
product
immunodefici
patient
assist
professor
allergi
immunolog
arkansa
children
hospit
univers
arkansa
medic
scienc
introductionbackground
complement
defici
rel
rare
compris
less
primari
immunodefici
associ
increas
risk
infect
encapsul
organ
autoimmun
complement
defici
rarest
defect
altern
complement
pathway
properdin
defici
commonli
describ
altern
pathway
defici
factor
b
factor
defici
rare
describ
fewer
patient
factor
defici
report
report
case
children
consanguin
parent
succumb
meningococc
sepsi
object
describ
case
factor
defici
associ
recurr
respiratori
infect
streptococcu
pneumonia
pneumonia
associ
lung
abscess
empyema
method
retrospect
chart
review
conduct
laboratori
investig
includ
lymphocyt
immunophenotyp
flow
cytometri
lymphocyt
prolifer
mitogen
quantit
serum
immunoglobulin
vaccin
titer
complement
assay
function
evalu
genet
evalu
next
gener
sequenc
result
year
old
marshalles
male
transfer
outsid
hospit
facil
evalu
worsen
pneumonia
found
rightsid
pleural
effus
pulmonari
abscess
right
lower
lobe
abscess
drain
found
posit
streptococcu
pneumonia
via
polymeras
chain
reaction
improv
chest
tube
placement
treatment
intraven
antibiot
medic
histori
signific
recurr
acut
otiti
media
prior
hospit
outofst
pneumonia
empyema
secondari
streptococcu
pneumonia
requir
chest
tube
placement
admiss
pediatr
intens
care
unit
month
age
immunolog
work
reveal
ageappropri
lymphocyt
subpopul
lymphocyt
prolif
respons
mitogen
quantit
immunoglobulin
level
pneumococcaltetanusdiphtheria
titer
complement
assay
complement
assay
decreas
unitsml
complement
test
repeat
normal
unitsml
evalu
reveal
normal
level
factor
b
h
properdin
factor
level
mcgml
factor
function
decreas
unitsml
indic
diagnosi
factor
defici
sequenc
cfd
gene
reveal
previous
undescrib
homozyg
delet
parent
agreeabl
person
undergo
genet
evalu
determin
de
novo
mutat
patient
manag
pneumococc
meningococc
immun
prophylact
amoxicillin
intraven
gamma
globulin
ivig
without
infect
unfortun
two
ivig
infus
lost
follow
conclus
factor
defici
extrem
rare
altern
complement
pathway
defici
describ
less
patient
infect
describ
thu
far
secondari
neisseria
meningitidi
case
repres
novel
mutat
cfd
gene
lead
factor
defici
also
first
descript
patient
factor
defici
develop
invas
infect
secondari
streptococcu
pneumonia
background
viral
infect
signific
caus
morbid
mortal
patient
primari
immunodefici
disord
follow
hematopoiet
stem
cell
transplant
adopt
immunotherapi
use
viru
specif
tcell
vst
shown
prevent
treat
viral
infect
immunocompromis
host
human
parainfluenza
common
caus
sever
respiratori
ill
immunocompromis
patient
approv
antivir
therapi
previous
use
target
cell
therapeut
introduct
previous
report
fatigu
increas
common
variabl
immunodefici
cvid
howev
previou
studi
fatigu
defin
use
valid
tool
aim
studi
identifi
preval
patientreport
fatigu
use
valid
questionnair
determin
factor
predispos
fatigu
cvid
method
data
cvid
respond
idf
patient
nation
survey
analyz
fatigu
measur
use
brief
fatigu
inventori
bfi
questionnair
includ
seven
item
identifi
fatigu
measur
fatigu
sever
total
patient
cvid
respons
bfi
enrol
demograph
comorbid
immunoglobulin
replac
therapi
iggrt
rout
dose
comorbid
infect
depress
qualiti
life
qol
use
disabl
compar
fatigu
nonfatigu
logist
regress
use
identifi
signific
variabl
ebv
reactiv
without
ptld
treat
rituximab
aliv
well
j
clin
immunol
suppl
granuloma
signific
daytoday
problem
cvid
patient
manag
current
limit
option
treatment
optim
therapi
unknown
case
report
small
seri
infliximab
report
effect
other
found
useless
describ
white
male
refer
monthli
ivig
august
age
develop
larg
area
erythemat
polymorph
plaqu
cheek
arm
leg
skin
biopsi
show
tuberculoid
granuloma
neg
bacteria
baar
fungi
infiltr
lymphocyt
prolong
cours
steroid
improv
skin
also
multipl
pneumonia
bronchiectasi
oral
candidiasi
receiv
vaccin
includ
bcg
complic
low
immunoglobulin
poor
respons
pneumococc
polysaccharid
tetanu
toxoid
diagnos
cvid
place
ivig
excel
infecti
control
sinc
age
skin
lesion
persist
deepen
bone
left
leg
broad
spectrum
antibiot
month
unsuccess
skin
graft
perform
arm
leg
cheek
two
ulcer
persist
left
leg
august
increas
size
deepen
becam
erythemat
extrem
pain
fig
septemb
two
new
ulcer
appear
right
cheek
right
gluteu
respect
one
week
later
third
ulcer
found
left
calf
septemb
infliximab
administ
second
infliximab
dose
octob
pain
complet
gone
ulcer
shrink
one
cheek
gluteu
calf
almost
complet
resolv
third
dose
novemb
ulcer
right
leg
almost
close
fig
infliximab
treatment
continu
everi
week
lab
test
remain
unchang
till
wound
got
worsen
tabl
granulomat
diseas
cvid
challeng
b
cell
direct
therapi
encourag
add
new
case
infliximab
respons
patient
other
alreadi
report
gene
report
caus
monogen
cvid
year
old
girl
present
recurr
pneumonia
diagnosi
cvid
parent
sought
second
opinion
born
week
gestat
age
alway
smaller
sicker
friend
prior
month
episod
pneumonia
fever
requir
emerg
depart
treatment
two
associ
rsv
metapneumoviru
respect
laboratori
evalu
confirm
low
level
igg
mgdl
iga
igm
congenit
tuberculosi
ctb
rare
diseas
often
associ
matern
genitourinari
gu
tuberculosi
tb
dissemin
tb
due
infertil
caus
gu
tb
ctb
rare
report
even
endem
countri
infant
acquir
tb
hematogen
via
placenta
umbil
vein
fetal
aspir
infect
amniot
fluid
present
symptom
includ
respiratori
distress
fever
hepatosplenomegali
poor
feed
lethargi
low
birth
weight
report
prematur
femal
infant
conceiv
via
vitro
fertil
ivf
born
indian
immigr
parent
week
gestat
due
preterm
prematur
ruptur
membran
matern
histori
signific
pulmonari
tb
year
age
deni
abdomin
gu
symptom
infant
nicu
cours
complic
opacif
right
lung
leukocytosi
neutrophil
predomin
identifi
evalu
frequent
apnea
bradycardia
episod
month
age
clinic
improv
note
treatment
vancomycin
amikacin
piperacillintazobactam
howev
leukocytosi
unknown
etiolog
persist
month
age
discharg
inpati
rehabilit
month
age
readmit
fever
respiratori
distress
admiss
immun
evalu
undertaken
due
persist
symptom
along
unresolv
leukocytosi
peak
cellsl
neutrophilia
cellsl
chest
ct
evid
progress
multifoc
lung
diseas
wors
right
upper
lobe
despit
empir
treatment
broadspectrum
antibiot
infecti
workup
neg
includ
acidfast
bacilli
test
bronchoalveolar
lavag
due
pronounc
persist
leukocytosi
neutrophilia
primari
immun
defect
suspect
immun
evalu
includ
normal
immunoglobulin
ig
g
e
elev
igm
vaccinespecif
antibodi
titer
protect
diphtheria
streptococcu
pneumonia
strain
mildli
elev
b
cell
normal
flow
cytometri
dihydrorhodamin
myeloperoxidas
stain
dehydrogenas
level
well
peripher
smear
giant
azurophil
granul
primari
immunodefici
genet
panel
unrev
underw
lung
biopsi
via
videoassist
thoracoscop
surgeri
show
noncas
granuloma
eventu
growth
multidrugresist
mycobacterium
tuberculosi
mtb
upon
treatment
appropri
adjust
antituberculosi
regimen
show
rapid
clinic
laboratori
improv
endometri
sampl
obtain
mother
show
gu
tb
confirm
diagnosi
ctb
slowgrow
natur
mtb
result
delay
diagnosi
along
presenc
noncas
granuloma
persist
neutrophilia
prompt
immun
work
complet
normal
case
demonstr
import
consid
ctb
differenti
diagnosi
infant
present
sever
lung
infect
persist
neutrophilia
suboptim
respons
broadspectrum
antibiot
relev
epidemiolog
risk
factor
furthermor
set
appropri
parent
exposur
infertil
prompt
use
ivf
maintain
high
level
suspicion
ctb
aid
earlier
diagnosi
affect
neonat
caucasian
male
initi
present
recurr
otiti
media
persist
hsm
lad
hypogammaglobinemia
igg
mgdl
year
age
diagnos
common
variabl
immunodefici
cvid
chronic
arthriti
year
age
respect
subsequ
develop
hepat
recurr
pneumonia
mycobacterium
avium
complex
mac
arthriti
partial
respond
antitumor
necrosi
factor
tnf
agent
tofacitinib
respond
treatment
combin
antitnf
inhibitor
tofacitinib
low
dose
prednison
requir
control
arthriti
hypogammaglobulinemia
igg
mgdl
recurr
otiti
media
pneumonia
crohn
diseas
celiac
diseas
lad
failur
thrive
year
age
recent
develop
hsm
requir
immunoglobulin
replac
therapi
case
caucasian
male
halfbroth
case
initi
present
recurr
pleural
effus
bilater
pulmonari
infiltr
hsm
lad
abdomin
distens
ascit
year
age
transbronchi
lung
biopsi
reveal
chronic
eosinophil
pneumon
liver
biopsi
show
increas
eosinophil
sinusoid
diffus
enlarg
hepatocyt
without
hepat
colon
biopsi
reveal
minim
colon
eosinophilia
pulmonari
infiltr
pleural
effus
respond
prednison
requir
addit
treatment
past
year
conclus
clinic
manifest
genet
variant
may
variabl
unpredict
even
famili
gof
syndrom
consid
children
multisystem
autoimmun
diseas
lad
hsm
low
switch
memori
b
cell
regardless
presenc
hypogammaglobulinemia
histori
recurr
infect
background
patient
primari
immun
defici
character
sever
lymphopenia
andor
poor
cell
function
patient
posthematopoiet
cell
transplant
high
risk
sever
viral
infect
antivir
medic
expens
alway
effect
associ
signific
toxic
andor
longterm
side
effect
increas
interest
use
donorderiv
thirdparti
virusspecif
cell
vst
sever
studi
demonstr
efficaci
vst
gener
use
variou
manufactur
strategi
howev
depth
immunolog
metabol
character
vst
report
limit
correl
investig
efficaci
method
ebvvst
gener
apheresi
cell
collect
healthi
donor
use
three
method
stimul
expans
hlamatch
ebvlymphoblastoid
cell
line
lcl
purchas
astart
biolog
sigmaaldrich
period
week
stimul
ebv
peptiv
miltenyi
follow
expans
day
differ
cytokin
stimul
ebv
peptiv
follow
isol
activ
cell
use
ifngamma
captur
system
miltenyi
immunophenotyp
flow
cytometri
perform
use
miltneyi
macsquant
analyz
nanostr
ncounter
system
use
measur
gene
express
metabol
pathway
analysi
agil
seahors
xf
cell
mito
stress
test
system
use
measur
mitochondri
respir
result
ebvvst
gener
use
lcl
peptiv
plu
result
high
percentag
cell
skew
effector
memori
termin
effector
memori
phenotyp
high
express
exhaust
marker
convers
ebvvst
gener
use
peptiv
plu
ifngamma
captur
system
result
mix
cell
popul
high
number
central
memori
cell
lower
percentag
cell
posit
stimul
peptiv
follow
expans
result
intermedi
immunophenotyp
nanostr
result
demonstr
upregul
glycolyt
pathway
ebvvst
stimul
peptiv
follow
expans
compar
ebvvst
gener
use
manufactur
approach
seahors
mito
stress
test
demonstr
peptiv
plu
ebvvst
significantli
lower
spare
respiratori
capac
ebvvst
low
extracellular
acidif
rate
despit
upregul
glycolyt
pathway
peptiv
plu
ebvvst
highest
basal
oxygen
consumpt
rate
atplink
respir
extracellular
acidif
rate
conclus
manufactur
ebvvst
use
variou
approach
current
employ
clinic
result
cell
pool
differ
immunophenotyp
differ
metabol
profil
ebvvst
stimul
peptiv
follow
expans
ebvvst
isol
use
ifngamma
captur
system
immunophenotyp
metabol
phenotyp
suggest
potenti
greater
vivo
persist
wherea
ebvvst
expand
characterist
correl
increas
effector
function
howev
vst
like
shortliv
impair
metabol
fit
phenotyp
enabl
better
correl
clinic
result
suggest
combinatori
approach
depend
clinic
indic
introduct
major
patient
primari
immunodefici
pid
requir
lifelong
replac
therapi
immunoglobulin
ig
prevent
sever
infect
irrevers
complic
addit
safeti
efficaci
toler
conveni
administr
ig
product
essenti
factor
patient
new
ig
prepar
octanorm
octapharma
lachen
tradenam
north
america
develop
subcutan
administr
scig
deriv
establish
manufactur
process
octapharma
intraven
ig
ivig
brand
object
primari
outcom
assess
efficaci
octanorm
prevent
seriou
bacteri
infect
main
secondari
endpoint
includ
among
other
evalu
toler
safeti
octanorm
number
rate
infect
number
day
miss
work
use
antibiot
method
prospect
openlabel
noncontrol
singlearm
phase
studi
involv
adult
patient
pid
conduct
russian
center
patient
treat
least
infus
ivig
prior
enrol
igg
trough
level
gl
underw
washinwashout
period
follow
efficaci
period
studi
patient
receiv
weekli
administr
octanorm
monthli
dose
previou
ivig
treatment
monthli
ivig
dose
divid
weekli
dose
total
patient
receiv
scig
infus
result
twentyfour
patient
complet
studi
one
patient
termin
earli
infus
washinwashout
phase
person
reason
mean
age
year
rang
year
fifteen
patient
femal
patient
male
seriou
bacteri
infect
record
efficaci
period
total
nonseri
infect
observ
patient
seventeen
infect
patient
mild
infect
patient
moder
intens
infect
rate
per
personyear
total
patient
receiv
infus
studi
drug
averag
dose
gkgweek
entir
studi
system
advers
event
report
includ
infect
three
system
advers
event
rate
relat
studi
drug
nonseri
seriou
signific
advers
event
advers
event
lead
withdraw
infus
site
reaction
report
infus
serum
igg
trough
level
nearli
constant
efficaci
period
median
igg
trough
level
gl
screen
gl
end
washinwashout
period
gl
termin
visit
one
patient
trough
level
visit
efficaci
period
dose
subsequ
adjust
patient
primari
treatment
period
patient
use
antibiot
treatment
episod
total
treatment
day
rang
day
patient
absenc
work
school
due
infect
total
day
absenc
conclus
studi
demonstr
new
subcutan
human
normal
immunoglobulin
well
toler
safe
effect
adult
patient
pid
background
children
chronic
granulomat
diseas
cgd
high
risk
fungal
infect
especi
aspergillu
speci
infect
usual
contigu
site
involv
patient
pulmonari
present
infect
endocard
fungal
osteomyel
skull
distinctli
unusu
report
one
case
case
boy
born
nonconsanguin
marriag
present
soft
tissu
swell
skull
month
past
histori
signific
episod
pneumonia
year
recurr
soft
tissu
swell
bodi
sinc
year
age
examin
wast
sign
micronutri
defici
ricket
pallor
cervic
lymphadenopathi
two
abscess
cm
right
temporopariet
region
cm
left
frontal
region
also
found
hyperdynam
precordium
eject
systol
murmur
investig
reveal
hemoglobin
platelet
count
total
leukocyt
count
elev
creactiv
protein
mgl
rais
erythrocyt
sediment
rate
mm
chest
x
ray
reveal
cardiomegali
cardiothorac
ratio
echocardiographi
show
veget
mm
anterior
mitral
leaflet
suggest
infect
endocard
blood
urin
cultur
steril
cultur
pu
temporopariet
abscess
show
growth
aspergillu
fumigatu
human
immunodefici
viru
serolog
nonreact
immunoglobulin
profil
reveal
elev
igg
iga
gl
igm
gl
view
strong
suspicion
cgd
nitroblu
tetrazolium
dye
reduct
test
nbt
carri
outit
reveal
reduct
dihydrorhodamin
dhr
assay
show
low
stimul
index
flow
cytometri
gp
phox
gp
phox
normal
dhr
mother
reveal
x
link
carrier
state
contrast
enhanc
computer
tomographi
cect
head
show
osteomyel
calvari
bone
contrast
enhanc
magnet
reson
imag
cemri
brain
show
heterogen
enchanc
soft
tissu
lesion
scalp
right
frontopariet
region
left
frontal
region
underli
boni
destruct
suggest
osteomyel
given
intraven
antimicrobi
ceftriaxon
gentamycin
cloxacillin
voriconazol
week
therapi
show
resolut
find
mri
brain
repeat
echocardiographi
show
signific
decreas
size
mitral
leaflet
veget
conclus
case
highlight
rare
present
cgd
infect
endocard
skull
osteomyel
due
aspergillu
fumigatu
best
knowledg
report
previous
background
genet
defect
affect
cellular
immun
underli
mendelian
suscept
mycobacteri
diseas
msmd
inflammatori
bowel
diseas
ibd
differ
pathway
present
first
time
patient
defici
consanguin
famili
two
differ
phenotyp
initi
diagnos
crohn
diseas
prior
msmd
diagnosi
method
materi
patient
refer
clinic
immunolog
allergi
clinic
alzahra
univers
hospit
immunolog
genet
evalu
blood
sampl
patient
famili
healthi
donor
control
collect
upon
inform
consent
studi
investig
effect
mutat
evalu
patient
whole
blood
cell
respons
ifn
express
pbmc
cell
blast
also
wholeexom
sequenc
perform
result
discuss
year
old
male
consanguin
famili
histori
right
subaxillari
bcg
lymphaden
recurr
mouth
ulcer
chronic
diarrhea
childhood
appendectomi
age
investig
base
clinic
present
abdomin
pain
signific
weight
loss
chronic
bloodi
diarrhea
endoscop
patholog
find
treatment
crohn
diseas
cd
start
age
seven
unfortun
protract
patient
symptom
end
resect
colon
colostomi
two
year
later
present
multi
focal
osteomyel
age
although
bacteria
detect
pcr
tissu
cultur
bone
biopsi
patient
respond
antibacteri
dramat
respons
empir
anti
mycobacteri
treatment
sever
bone
pain
lesion
heal
even
though
bone
manifest
complet
control
continu
treatment
gastrointestin
symptom
genet
analysi
confirm
segreg
homozyg
mutat
site
exon
express
gene
complet
abolish
pbmc
patient
surfac
express
detect
cell
deriv
pbmc
patient
compar
healthi
control
furthermor
respons
stimul
sinc
could
detect
increas
infaft
stimul
bcg
patient
receiv
bcg
vaccin
birth
bcg
lymphaden
infant
cd
mycobacteri
multifoc
osteomyel
child
furthermor
evid
indic
role
atyp
mycobacteri
infect
trigger
cd
conclus
report
first
time
contemporari
msmd
ibd
year
old
patient
impair
signal
abolish
express
pbmc
cell
blast
howev
mycobacteri
osteomyel
typic
phenotyp
msmd
patient
defici
stat
mycobacteri
osteomyel
report
defici
patient
background
advanc
genet
studi
help
explain
occurr
mani
undiagnos
rare
condit
recent
nba
variant
identifi
caus
basi
recurr
liver
failur
infant
infantil
liver
failur
syndrom
nba
neuroblastoma
amplifi
sequenc
gene
encod
protein
involv
golgi
er
retrograd
transport
nba
function
seem
broad
loss
function
variant
nba
associ
multisystem
manifest
case
report
old
chilean
male
present
er
three
day
histori
vomit
diarrhea
one
day
fever
examin
pale
letharg
tachycard
chemistri
profil
reveal
markedli
elev
liver
enzym
increas
bilirubin
coagulopathi
consist
acut
hepat
failur
alt
ast
total
bilirubin
db
ggt
inr
hospit
given
vitamin
k
kept
intraven
fluid
ursodiol
antipyret
liver
function
improv
significantli
within
day
admiss
alt
ast
total
bilirubin
workup
possibl
etiolog
includ
autoimmun
infecti
hepat
neg
liver
sonogram
normal
liver
biopsi
consist
acut
hepat
necrosi
urin
organ
acid
plasma
amino
acid
screen
consist
inherit
metabol
disord
parent
recal
two
previou
episod
liver
failur
age
year
preced
mild
febril
ill
nonspecif
symptom
includ
fever
cough
vomit
diarrhea
lethargi
decreas
po
intak
subsequ
follow
jaundic
mark
elev
liver
enzym
flu
adenoviru
identifi
caus
febril
ill
two
previou
episod
admiss
adenoviru
found
respiratori
secret
mild
ebv
viremia
also
detect
genet
evalu
chile
reportedli
normal
literatur
review
obtain
sequenc
nba
reveal
two
variant
nba
g
variant
previous
report
patient
infantil
onset
recurr
liver
failur
syndrom
clinic
featur
includ
development
speech
delay
failur
thrive
facial
dysmorph
also
histori
recurr
ear
infect
set
tympanostomi
tube
test
limit
due
lack
insur
coverag
conclus
nba
defici
newli
describ
syndrom
recurr
acut
liver
failur
occur
earli
life
individu
surviv
adulthood
seem
develop
liver
failur
ill
typic
liver
crisi
trigger
common
childhood
febril
ill
mechan
diseas
thought
thermal
instabl
hepatocyt
improv
time
case
howev
although
spontan
recoveri
occur
follow
crise
episod
fatal
result
perman
liver
damag
requir
liver
transplant
increas
awar
diseas
lead
earli
establish
diagnosi
appropri
time
manag
fever
onset
ill
significantli
improv
outcom
potenti
fatal
diseas
associ
prof
infecti
diseas
tropic
medicin
research
center
isfahan
univers
medic
scienc
isfahan
iran
background
preeclampsia
pregnancyspecif
complic
shown
associ
cytomegaloviru
cmv
infect
cmv
specif
tcell
respons
play
major
role
cmv
infect
diseas
explor
whether
chang
cmvspecif
cellmedi
immun
cmi
relat
develop
preeclampsia
method
cmvspecif
cmi
assess
use
cmvquantiferon
qfcmv
assay
serum
women
preeclampsia
well
normal
pregnanc
control
retrospect
particip
match
gestat
age
individu
proport
reactiv
result
mean
valu
interferonlevel
produc
mitogen
antigen
tube
compar
case
control
via
chisquar
wilcoxon
ranksum
test
respect
odd
ratio
confid
interv
ci
calcul
well
result
signific
differ
observ
demograph
characterist
case
control
group
qfcmv
assay
turn
reactiv
qfcmv
patient
vs
control
p
women
preeclampsia
lower
mean
ifnlevel
antigen
tube
compar
normal
pregnanc
control
p
statist
signific
differ
valu
mitogen
tube
case
control
p
women
suppress
cmvcmi
time
like
manifest
preeclampsia
ci
result
even
strengthen
adjust
age
gestat
age
gravid
ci
conclus
find
support
associ
suppress
cmv
specif
cmi
preeclampsia
introduct
triad
suscept
infect
autoinflamm
cancer
patient
person
famili
histori
alway
suggest
underli
primari
immunodefici
howev
case
diagnosi
might
delay
year
furthermor
result
immunolog
inflammatori
evalu
also
affect
ongo
immunomodulatori
therapi
initi
differ
specialist
upon
clinic
diagnosi
object
describ
uniqu
present
autoinflammatori
diseas
combin
immunodefici
adult
patient
case
present
report
case
year
old
male
long
histori
infect
includ
recurr
sinopulmonari
bacteri
infect
start
childhood
osteomyel
year
age
recurr
tonsil
requir
tonsillectomi
year
age
recurr
cellul
episod
prostat
septicaemia
well
recurr
varicella
zoster
wart
patient
also
diagnos
scleros
mesenther
reynaud
phenomenon
recurr
oral
ulcer
arthriti
uveiti
autoimmun
thyroid
lung
fibrosi
suffer
repeat
episod
abdomin
pain
furthermor
famili
histori
earli
childhood
death
multipl
soft
tissu
cancer
crohn
diseas
autoimmun
thyroid
upon
physic
examin
patient
multipl
telangiectasia
baselin
erythroderma
flush
immunolog
evalu
show
lymphopenia
signific
reduct
circul
b
cell
howev
assess
humor
immun
reveal
low
igg
decreas
igm
normal
iga
level
time
evalu
low
dose
daili
prednison
colchicin
methotrex
immunomodifi
therapi
genet
evalu
reveal
heterozyg
mutat
well
compound
heterozyg
mutat
mefv
gene
discuss
mutat
describ
associ
blau
syndrom
multisystem
autoinflammatori
syndrom
may
explain
mani
featur
experienc
patient
surpris
next
gener
sequenc
reveal
second
aberr
mefv
gene
caus
familiar
mediterranean
fever
anoth
multisystem
autoinflammatori
diseas
might
lead
phenotyp
observ
patient
conclus
first
report
genet
lesion
two
differ
gene
lead
sever
cours
auto
inflamm
monogen
autoinflammatori
syndrom
mai
divers
group
disord
character
primari
overactiv
innat
immun
system
induct
inflammasom
complex
innat
immun
sensor
increas
product
implic
pathogenesi
mai
macrophag
activ
syndrom
ma
lifethreaten
ill
defin
acut
hyperinflamm
unoppos
cytokin
releas
consid
acquir
condit
secondari
infect
rheumatoid
diseas
malign
earli
therapeut
use
inhibit
profoundli
improv
prognosi
ma
recent
shown
increas
free
level
blood
caus
link
develop
ma
signific
overlap
clinic
present
laboratori
marker
patient
mai
ma
led
us
explor
role
free
therapeut
use
inhibit
patient
mutat
report
case
monthsold
femal
present
hydrop
fetali
utero
later
develop
failuretothr
splenomegali
anemia
thrombocytopenia
arthralgia
rash
frequent
febril
episod
mild
facial
dysmorph
along
massiv
increas
crp
esr
ferritin
whole
exom
sequenc
we
identifi
heterogen
like
pathogen
de
novo
variant
cell
divis
control
protein
homolog
encod
small
rho
famili
gtpase
regul
multipl
signal
pathway
control
cell
polar
migrat
endocytosi
cell
cycl
progress
singl
allel
mutat
gene
recent
report
caus
takenouchikosaki
syndrom
manifest
growth
retard
development
delay
facial
dysmorph
thrombocytopenia
howev
system
autoinflamm
describ
close
interact
wiskottaldrich
syndrom
protein
littl
known
mechan
underli
immun
abnorm
associ
mutat
patient
inflammamosopathylik
syndrom
signific
clinic
overlap
ma
measur
free
bind
protein
significantli
increas
increas
free
heighten
risk
develop
ma
level
normal
increas
hardli
ever
detect
serum
despit
play
critic
role
type
inflamm
inde
chronic
excess
tissu
promot
system
inflamm
associ
chronic
elev
crp
esr
rational
start
receptor
antagonist
anakinra
within
hour
start
anakinra
parent
observ
increas
appetit
resolut
arthralgia
improv
mobil
cours
follow
week
fever
anemia
thrombocytopenia
rash
disappear
spleen
massiv
decreas
size
patient
start
meet
development
mileston
crp
esr
eventu
normal
ferritin
free
still
trend
conclus
signific
increas
free
extrem
encourag
clinic
respons
therapi
anakinra
patient
novel
mutat
suggest
link
ma
defect
elucid
mechan
inflammasom
activ
driver
increas
ma
mai
broadli
may
shed
light
novel
therapeut
target
like
use
human
recombin
bind
protein
j
clin
immunol
suppl
mainten
enrich
cell
maintain
telomer
via
altern
lengthen
telomer
pathway
cell
demonstr
telomer
instabl
replic
fork
collaps
increas
telomereassoci
dna
damag
telomer
analysi
siod
patient
includ
one
patient
receiv
hematopoiet
stem
cell
transplant
hsct
year
prior
well
heterozyg
famili
member
reveal
significantli
shorter
telomer
siod
patient
compar
heterozyg
famili
member
compar
agematch
healthi
control
method
peripher
blood
mononuclear
cell
isol
use
ficollhypaqu
densiti
gradient
cryopreserv
sent
repeat
diagnost
north
vancouv
bc
telomer
length
measur
perform
singlecel
level
use
flowfluoresc
situ
hybrid
previous
describ
telomer
length
measur
total
lymphocyt
naiv
memori
enrich
cell
b
cell
nk
cell
compar
refer
sampl
agematch
healthi
individu
result
compar
agematch
healthi
control
three
siod
individu
mean
telomer
length
mtl
less
percentil
age
across
lymphocyt
subset
total
lymphocyt
b
cell
nk
cell
memori
cell
comparison
three
unaffect
famili
member
normal
mtl
percentil
x
percentil
across
subset
two
unaffect
famili
member
low
mtl
x
percentil
subset
siod
individu
receiv
matcheds
hsct
year
prior
normal
mtl
nk
cell
x
percentil
low
mtl
x
percentil
subset
conclus
data
show
siod
patient
significantli
impair
telomer
length
across
multipl
lymphocyt
lineag
support
limit
role
defici
telomer
mainten
comparison
unaffect
famili
member
heterozyg
mutat
mean
telomer
length
normal
slightli
low
age
suggest
abnorm
short
telomer
seen
individu
homozyg
heterozyg
mutat
individu
receiv
hsct
pre
posthsct
telomer
data
result
support
obtain
pre
posthsct
telomer
length
analysi
futur
case
abnorm
short
telomer
link
widespread
perturb
gene
express
hypothes
defici
effect
stall
fork
shorten
telomer
lead
perturb
transcriptom
affect
tissu
shorten
telomer
may
explain
reduc
hematopoiet
bone
marrow
product
siod
bone
marrow
failur
cardin
featur
dyskeratosi
congenita
disord
impair
telomer
mainten
futur
studi
investig
role
telomer
mainten
siod
includ
measur
telomeras
activ
polyclon
activ
cell
transcriptom
analysi
use
rnaseq
background
yellow
fever
potenti
fatal
diseas
support
treatment
avail
vaccin
primari
strategi
prevent
diseas
vaccin
extrem
effect
specif
popul
contraind
regard
iga
defici
frequent
primari
immunodefici
current
recommend
literatur
controversi
specif
studi
diseas
case
seri
address
safeti
possibl
advers
event
vaccin
essenti
decisionmak
epidem
scenario
experienc
brazil
last
year
context
studi
aim
describ
advers
event
use
yellow
fever
vaccin
iga
defici
patient
method
retrospect
crosssect
studi
conduct
includ
iga
defici
patient
follow
special
pediatr
outpati
clinic
patient
least
one
year
followup
immunoglobulin
level
antibodi
respons
vaccin
lymphocyt
subset
count
evalu
exclud
immunodefici
presenc
abnorm
could
contraind
vaccin
demograph
data
presenc
infect
comorbid
use
immunosuppress
medic
advers
event
vaccin
administr
vaccin
describ
result
thirtyeight
patient
iga
defici
includ
studi
receiv
vaccin
vaccin
patient
mean
age
time
studi
year
sd
six
present
comorbid
thyroid
type
diabet
mellitu
celiac
diseas
juvenil
rheumatoid
arthriti
patient
atop
one
recurr
infect
last
year
despit
use
antibiot
prophylaxi
patient
normal
igg
igm
level
age
posit
vaccin
respons
measl
rubella
mump
ageappropri
lymphocyt
subset
count
month
observ
immedi
late
advers
event
report
among
nonvaccin
patient
one
formal
contraind
system
erythematosu
lupu
use
immunosuppress
therapi
five
nonvaccin
patient
report
afraid
receiv
vaccin
still
intend
receiv
patient
data
regard
vaccin
unavail
conclus
despit
small
number
patient
absenc
advers
event
case
seri
suggest
immun
yellow
fever
vaccin
may
safe
iga
defici
patient
exclud
contraind
studi
essenti
confirm
safeti
help
decisionmak
process
regard
vaccin
administr
iga
defici
patient
especi
yellow
fever
outbreak
scenario
introductionbackround
immunodefici
centromer
instabl
facial
anomali
syndrom
icf
rare
group
autosom
recess
disord
involv
triad
hypogammaglobulinemia
centromer
instabl
facial
anomali
major
patient
hypoor
agammaglobulinemia
cell
defect
also
report
present
case
child
present
nk
defici
ultim
develop
ebvdriven
malign
success
treat
bone
marrow
transplant
method
whole
exom
sequenc
nk
cell
function
via
cytotox
assay
phenotyp
via
flow
cytometri
perform
baylor
colleg
medicin
texa
children
hospit
centromer
band
studi
perform
univers
pittsburgh
medic
center
result
femal
patient
present
month
age
cmv
pneumon
persist
cmv
viremia
requir
treatment
follow
prophylaxi
valgancyclovir
initi
hypogammaglobulinemia
low
b
nk
cell
normal
trec
lymphocyt
mitogen
prolifer
respons
zap
mhci
mhcii
express
hypogammaglobulinemia
tand
bcell
lymphopenia
resolv
within
month
initi
present
clinic
improv
cmv
infect
found
nk
cell
defici
three
separ
commerci
test
sampl
whole
exom
sequenc
reveal
homozyg
variant
indic
syndrom
confirm
sanger
sequenc
repeat
nk
cell
studi
confirm
impair
function
phenotyp
show
increas
decreas
cell
suggest
either
impair
transit
immatur
matur
nk
cell
impair
surviv
matur
cell
karyotyp
centromer
band
studi
normal
centromer
instabl
studi
later
develop
memori
bcell
defect
present
month
age
persist
fever
respiratori
distress
loss
vaccin
titer
hypogammaglobulinemia
low
b
cell
found
ebv
viremia
eberposit
diffus
larg
bcell
lymphoma
right
lung
due
tenuou
clinic
statu
receiv
rituximab
treatment
ebv
prior
definit
lymphoma
diagnosi
treat
chemotherapi
per
protocol
group
b
prephas
cop
cours
copadm
cours
cym
cours
complic
seizur
attribut
methotrex
toxic
ultim
underw
reduc
intens
condit
hydroxyurea
alemtuzumab
fludarabin
mephalan
thiotepa
follow
select
hlamatch
unrel
donor
peripher
blood
stem
cell
transplant
earli
posttranspl
cours
complic
adeno
ebv
cmv
viremia
success
treat
antivir
donor
lymphocyt
infus
greater
month
posttranspl
immunosuppress
donor
engraft
evid
organ
toxic
gvhd
excel
immun
reconstitut
conclus
first
report
case
impair
nk
cell
function
phenotyp
ebvdriven
malign
patient
case
expand
phenotyp
suggest
earli
bone
marrow
transplant
consid
children
also
demonstr
novel
requir
human
nk
cell
matur
function
rational
common
variabl
immunodefici
cvid
disord
affect
product
immunoglobulin
associ
develop
autoimmun
multipl
mutat
describ
associ
cvid
mutat
describ
patient
phospholipas
c
gamma
associ
antibodi
defici
immun
dysregul
plaid
autoinflammatori
associ
antibodi
defici
immun
dysregul
aplaid
present
case
yo
male
cvid
patient
recurr
upper
respiratori
tract
infect
steroiddepend
autoimmun
thrombocytopenia
low
b
cell
count
hepatosplenomegali
restrict
lung
diseas
found
variant
unknown
signific
gene
contrast
plaid
patient
exhibit
cold
urticaria
method
case
present
cvid
patient
follow
clinic
patient
chart
previou
laboratori
review
sequenc
analysi
deletiondupl
cvid
panel
test
perform
use
discuss
genet
test
revolution
diagnosi
immun
defici
variant
unknown
signific
increasingli
report
case
variant
uncertain
signific
identifi
replac
threonin
alanin
codon
protein
codon
locat
domain
part
region
provid
autoinhibitori
enzymat
function
plaid
mutat
identifi
domain
known
domain
facilit
plcg
associ
protein
studi
delet
gene
shown
function
abnorm
b
cell
natur
killer
cell
mast
cell
knowledg
previou
report
cvid
patient
variant
mutat
domain
gene
without
diagnos
plaid
aplaid
patient
immunodefici
recurr
upper
respiratori
tract
infect
steroiddepend
recurr
autoimmun
thrombocytopenia
rheumatoid
arthriti
hepatosplenomegali
earlyosteoporosi
restrict
lung
diseas
cold
urticaria
seen
plaid
exhibit
autoimmun
observ
aplaid
conclus
conclus
import
protein
pathway
b
cell
develop
novel
mutat
domain
gene
may
associ
cvid
phenotyp
low
b
cell
autoimmun
could
lead
gainoffunct
mutat
seen
plaid
without
earlyonset
cold
urticaria
function
studi
requir
confirm
signific
mutat
primari
famili
hemophagocyt
lymphohistiocytosi
hlh
rare
lifethreaten
hyperinflammatori
diseas
affect
mainli
young
children
caus
mutat
gene
involv
granuledepend
cytotox
pathway
character
extrem
inflamm
massiv
tissu
infiltr
activ
cell
macrophag
day
hematopoiet
stem
cell
transplant
avail
cur
treatment
transplantrel
mortal
thu
develop
new
effici
antiinflammatori
treatment
would
signific
advanc
treatment
hlh
hypothes
combin
therapi
target
jakdepend
independ
cytokin
effect
either
one
alon
reduc
lifethreaten
symptom
induc
patholog
use
perforindefici
mous
model
hlh
first
compar
effect
target
individu
cytokin
block
antibodi
progress
diseas
show
block
ifng
significantli
reduc
sever
hlh
target
jakstat
signal
pathway
ruxolitinib
specif
inhibitor
downstream
ifng
similarli
benefici
importantli
combin
therapi
use
ruxolitinib
block
antibodi
either
ifng
show
synergist
effect
mitig
progress
diseas
result
suggest
jakdepend
independ
cytokin
drive
pathogen
hlh
perforindefici
mice
support
ruxolitinib
although
effect
reduc
symptom
hlh
use
combin
antiifng
andor
antibodi
prevent
hlh
progress
particular
relev
sinc
former
recent
approv
treatment
hlh
latter
bind
protein
clinic
trial
macrophag
activ
syndrom
despit
increas
risk
opportunist
lung
infect
patient
sever
cell
dysfunct
eg
defici
andor
sever
cell
lymphopenia
awar
report
dissemin
pneumocysti
jiroveci
infect
nonhuman
immunodefici
viru
hiv
patient
primari
immunodefici
pid
report
first
case
knowledg
dissemin
pjp
patient
cvid
haploinsuffici
diagnos
common
variabl
immunodefici
cvid
approxim
eight
year
prior
refer
us
intraven
immunoglobulin
ivig
also
diagnos
multilineag
evan
syndrom
medic
histori
also
signific
potenti
granulomat
lymphocyt
interstiti
lung
diseas
glild
lung
biopsi
remot
past
interstiti
diseas
signific
splenomegali
cm
sever
portal
hypertens
nodular
liver
diseas
like
nodular
regen
hyperplasia
complic
anasarca
histori
chronic
diarrhea
potenti
enteropathi
lymphadenopathi
sp
biopsi
nodular
lymphoid
hyperplasia
histori
multipl
pneumonia
develop
dissemin
pjp
lung
liver
bone
involv
vertebra
pjp
invas
confirm
bone
biopsi
gomori
methenamin
silver
stain
pcr
perform
conclud
pjp
treat
trimethoprim
sulfamethoxazol
tmpsmx
steroid
continu
tmpsmx
prophylaxi
due
liver
damag
chronic
neutropenia
tmpsmx
replac
atovaquon
secondari
prophylaxi
pjp
laboratori
studi
signific
absolut
neutrophil
count
kul
absolut
lymphocyt
count
kul
hemoglobin
gdl
platelet
kul
total
bilirubin
tcell
receptor
beta
chain
repertoir
analysi
show
oligoclon
distribut
sever
combin
immunodefici
panel
ambri
genet
test
neg
genet
test
defici
given
complex
clinic
histori
whole
exom
sequenc
obtain
detect
autosom
domin
heterozyg
missens
mutat
implic
haploinsuffici
previous
report
schwab
et
al
patient
current
undergo
therapi
abatacept
fusion
protein
report
improv
glild
splenomegali
enteropathi
patient
haploinsuffici
improv
regimen
met
stem
cell
transplant
team
point
time
due
abnorm
lung
function
liver
damag
signific
splenomegali
good
candid
defect
nfb
signal
pathway
implic
pathogenesi
sever
primari
immun
defici
human
clinic
featur
condit
vari
significantli
reflect
complex
pathway
broad
role
innat
adapt
immun
respons
develop
differenti
lymphoid
organ
report
first
case
human
pid
caus
homozyg
mutat
nfkbid
yearold
male
second
child
consanguin
parent
diagnos
possibl
cvid
age
recurr
episod
pneumococc
pneumonia
howev
clinic
featur
evolv
time
develop
sever
ebv
infect
age
caus
hepat
pancreat
age
present
ancaneg
system
vascul
manifest
pulmonari
haemorrhag
acut
necrot
pauciimmun
glomerulonephr
puls
methylprednisolon
cyclophosphamid
induc
initi
remiss
howev
relaps
year
later
led
endstag
renal
failur
dialysisdepend
due
underli
pid
chronic
cmv
viraemia
candid
renal
transplant
genom
dna
subject
wholeexom
sequenc
variant
filter
use
model
autosomalrecess
inherit
function
analysi
primari
cell
perform
identifi
novel
homozyg
singlebas
delet
result
frameshift
prematur
stop
nfkbid
nfkbid
encod
ibn
nonclass
inhibitor
nfb
signal
diagnosi
patient
reduc
level
iga
igm
elev
ige
absent
humor
immun
respons
pneumococc
polysaccharid
vaccin
intact
respons
tetanu
lymphocyt
number
initi
within
normal
refer
rang
albeit
increas
proport
cell
howev
time
signific
reduct
b
cell
cell
cell
demonstr
skew
toward
central
memori
phenotyp
cell
prolif
respons
pha
compar
healthi
control
function
analysi
primari
cell
proband
reveal
complet
absenc
bn
protein
express
dysregul
nfb
signal
elev
proinflammatori
cytokin
product
patient
current
receiv
trial
target
therapi
modul
aberr
immun
respons
novel
pid
highlight
import
regul
nfb
signal
orchestr
appropri
immun
respons
mainten
selftoler
protect
viral
pathogen
primari
immunodefici
diseas
pid
heterogen
group
condit
variabl
clinic
featur
frequent
associ
signific
diagnost
delay
accur
diagnosi
signific
therapeut
benefit
may
lead
person
therapi
establish
immunolog
flagship
melbourn
genom
health
allianc
australia
determin
clinic
util
genom
sequenc
diagnosi
manag
individu
suspect
confirm
case
pid
adult
children
suspect
confirm
pid
autoinflammatori
diseas
hereditari
angioedema
hae
recruit
melbourn
genom
immunolog
flagship
wholeexom
sequenc
we
perform
target
gene
analysi
variant
curat
report
perform
accord
american
council
medic
genet
guidelin
overal
we
diagnost
confirm
preexist
diagnosi
offer
new
specif
diagnosi
variant
uncertain
signific
identifi
patient
gene
known
associ
clinic
diagnosi
warrant
function
valid
hae
group
diagnosi
confirm
patient
suggest
we
may
appropri
techniqu
genet
diagnosi
condit
higher
diagnost
rate
observ
autoinflammatori
disord
compar
pid
receiv
diagnosi
immedi
chang
patient
manag
treatment
occur
patient
includ
hsct
specif
target
therapi
individu
demonstr
util
we
accur
diagnosi
complex
immun
diseas
potenti
chang
diagnos
guid
therapeut
intervent
provid
opportun
genet
counsel
longitudin
analysi
determin
clinic
outcom
health
econom
implic
genom
sequenc
diagnosi
manag
immunolog
condit
australia
birth
neonat
asphyxia
cerebr
palsi
year
old
present
involuntari
movement
left
paresi
bilater
horizont
nystagmu
year
age
right
nasal
obstruct
resect
otorhinolist
inform
biopsi
inflammatori
polyp
chronic
sinus
pneumonia
sinus
diarrhea
age
year
ataxia
telangiectasia
confirm
sequenc
pcr
exon
bp
atm
gene
transit
g
nucleotid
posit
codon
affect
splice
alpha
fetoprotein
uml
brain
mri
say
cerebellar
atrophi
igg
mg
dl
mg
dl
iga
mg
dl
mg
dl
igm
mg
dl
mg
dl
ige
iu
ml
subclass
igg
g
dl
grdl
low
igg
anti
hepat
b
seroconvers
hiv
neg
lymphocyt
cell
cel
cell
common
variabl
immunodefici
diagnos
receiv
human
immunoglobulin
arriv
hospit
due
fever
respiratori
distress
lymphadenopathi
neck
ct
show
ganglion
conglomer
right
side
neck
lymph
node
biopsi
strong
tumor
weak
moder
diffus
neg
cell
prolifer
index
diagnosi
diffus
larg
b
cell
lymphoma
treat
rituximab
chemotherapi
lymphoma
complet
remit
conclus
associ
ataxia
telangiectasia
lymphoma
frequent
contrast
cvid
ataxia
telangiectasia
extraordinarili
rare
introduct
chronic
granulomat
diseas
cgd
primari
immunodefici
wherein
affect
patient
suscept
recurr
infect
caus
specif
bacteria
fungi
result
defect
nadph
activ
addit
inflammatori
complic
involv
bowel
lung
caus
signific
morbid
current
proven
perman
cure
cgd
remain
hematopoiet
stem
cell
transplant
case
patient
diagnos
infanc
xlink
cgd
age
receiv
nonmyeloabl
peripher
blood
stem
cell
transplant
noncarri
sister
previous
report
nejm
condit
cyclophosphamid
mgkg
daili
fludarabin
antithymocyt
globulin
posttranspl
immunosuppress
consist
cyclosporin
receiv
peripher
blood
stem
cell
tcell
deplet
add
back
cell
day
day
neutropenia
anc
sign
engraft
per
protocol
receiv
donor
peripheralblood
lymphocyt
contain
cellskg
transplant
sinc
donor
cell
constitut
less
percent
circul
cell
graft
versushost
diseas
receiv
cellskg
discontinu
cyclosporin
receiv
total
three
donorlymphocyt
infus
cellskg
interv
achiev
cell
myeloid
engraft
month
posttranspl
acut
chronic
gvhd
last
followup
year
posttranspl
lymphoid
myeloid
peripher
chimer
respect
patient
famili
declin
period
followup
octob
present
malais
cough
fever
eventu
found
larg
consolid
bal
grew
burkholderia
cepacia
dhr
show
activ
peripher
blood
myeloid
lymphoid
chimer
respect
discuss
late
graft
failur
follow
peripher
blood
transplant
occur
follow
condit
regimen
current
standard
transplant
cgd
case
seri
patient
transplant
report
nejm
anoth
patient
myeloid
chimer
fell
year
posttranspl
remain
stabl
level
chimer
without
seriou
infect
regular
period
follow
present
time
current
regimen
typic
includ
busulfan
enhanc
engraft
prevent
graft
failur
case
reinforc
need
prolong
monitor
primari
immun
defici
patient
transplant
introduct
introduct
sever
combin
immunodefici
scid
newborn
screen
nb
state
kansa
case
complet
digeorg
syndrom
dg
discov
infant
born
diabet
mother
atyp
featur
first
dg
case
diagnos
ad
scid
nb
emphas
need
establish
scid
nb
state
case
present
femal
infant
born
via
spontan
vagin
deliveri
week
year
old
mother
matern
histori
signific
chronic
hypertens
obes
insulin
depend
type
diabet
anxieti
depress
scoliosi
infant
note
left
side
abdomin
wall
defect
hernia
imag
identifi
left
renal
agenesi
initi
suspici
vater
syndrom
fortun
infant
scid
nb
reveal
low
cell
receptor
excis
circl
trec
initi
white
blood
cell
count
absolut
lymphocyt
count
kul
ebv
pcr
cmv
pcr
hiv
studi
neg
chest
imag
discov
absent
thymu
abnorm
vertebra
rib
right
rib
left
abnorm
form
thorac
vertebra
echocardiogram
detect
atrial
septal
defect
measur
cm
possibl
pfo
versu
secundum
asd
endocrinolog
consult
manag
labil
calcium
phosphoru
level
fish
neg
delet
microarray
r
eveal
variant
unknown
signif
icanc
arr
sequenc
analysi
combin
sever
immun
defici
gene
show
variant
uncertain
signific
manag
outcom
addit
evalu
includ
cellsul
normal
cd
cd
normal
immunoglobulin
g
level
normal
dihydrorhodamin
assay
skelet
survey
ct
abdomen
chest
hla
type
perform
prepar
thymic
transplant
discuss
patient
complet
dg
form
scid
found
less
percent
patient
absent
thymu
cell
count
standard
deviat
normal
age
typic
larg
seri
patient
complet
dg
percent
identifi
delet
infant
diabet
mother
variou
genet
syndrom
associ
includ
diabet
embryopathi
despit
import
immunolog
aspect
pregnanc
studi
report
cellular
immun
modif
diabet
embryopathi
diabet
pregnanc
may
affect
develop
thymu
thu
matur
immun
system
offspr
recent
addit
trec
assay
newborn
screen
identifi
subset
infant
atyp
present
scid
nb
use
assay
trec
biomark
cell
develop
initi
present
place
immunologist
role
first
respond
regard
diagnosi
manag
patient
may
present
atyp
featur
newer
genet
molecular
techniqu
allow
earlier
identif
immun
defect
disord
lifelong
clinic
concern
refer
introductionbackground
good
syndrom
rare
caus
combin
band
tcell
immunodefici
occur
associ
thymoma
affect
patent
suscept
bacteri
fungal
viral
opportunist
infect
associ
autoimmun
also
report
current
knowledg
good
syndrom
primarili
limit
case
report
small
seri
object
examin
spectrum
clinic
laboratori
featur
major
cohort
good
syndrom
patient
us
method
conduct
retrospect
analysi
patient
good
syndrom
usidnet
registri
mount
sinai
hospit
msh
cohort
r
e
u
l
e
n
f
e
p
e
n
w
h
h
n
hypogammaglobulinemia
usidnet
msh
median
age
year
femal
repres
data
patient
year
median
age
diagnosi
thymoma
hypogammaglobulinemia
year
rang
year
rang
respect
two
patient
deceas
age
year
caus
unspecifi
patient
low
igg
median
rang
iga
igm
reduc
patient
respect
low
b
cell
median
rang
report
avail
record
absenc
b
cell
observ
year
postthymectomi
wide
rang
addit
laboratori
abnorm
identifi
low
cell
low
cell
low
ratio
low
nk
cell
absent
peripher
eosinophil
common
site
infect
lower
respiratori
upper
respiratori
gastrointestin
addit
sepsi
meningoenceph
osteomyel
urinari
tract
infect
also
observ
identifi
infecti
agent
includ
bacteria
viru
fungu
parasit
protozoa
opportunist
infect
record
patient
opportunist
infect
significantli
associ
absolut
lymphopenia
fisher
exact
test
enteroviru
identifi
previous
unreport
caus
meningoenceph
popul
autoimmun
manifest
report
patient
higher
preval
inflammatori
coliti
previous
report
hashimoto
thyroid
fibromyos
bronchiol
obliteran
organ
pneumonia
identifi
previous
unreport
autoimmuneinflammatori
condit
popul
case
alopecia
areata
also
observ
addit
bronchiectasi
record
patient
patient
initi
immunoglobulin
replac
antibiot
prophylaxi
immunosuppress
medic
employ
patient
post
diagnosi
immunodefici
conclus
good
syndrom
combin
immunodefici
wide
rang
autoimmun
subset
patient
expand
upon
spectrum
associ
infecti
inflammatori
complic
major
us
cohort
persist
immun
dysregul
observ
decad
postthymectomi
introduct
primari
immunodefici
pid
constitut
larg
group
rare
disord
affect
immun
system
function
pid
patient
develop
autoimmun
addit
increas
suscept
infect
due
impair
immun
case
present
manag
year
old
caucasian
femal
histori
bipolar
disord
factor
v
leiden
defici
anti
thrombin
defici
pulmonari
embol
endometriosi
season
allergi
evalu
chronic
granulomat
diseas
cgd
main
symptom
inflammatori
breast
lesion
necessit
surgeri
right
breast
back
facial
genit
ocular
mouth
scalp
sore
biopsi
cultur
wound
posit
corynebacterium
coagulaseneg
staphylococcu
enterococcu
bacteroid
speci
provatella
neutrophil
oxid
burst
order
infecti
diseas
specialist
show
normal
abnorm
neutrophil
popul
find
consist
cgd
carrier
patient
start
interferon
fail
multipl
cours
antibiot
symptom
well
control
interferon
sq
everi
day
trimethoprim
tab
tab
pm
cefixim
daili
topic
mupirocin
need
except
recurr
genit
ulcer
cgd
rare
associ
oral
ulcer
howev
limit
literatur
describ
associ
genit
ulcer
accord
intern
studi
group
diagnost
criteria
publish
patient
diagnos
rheumatologist
behcet
diseas
bd
pathognomon
laboratori
test
bd
result
diagnosi
made
clinic
patient
fail
trial
colchicin
later
start
cyclosporin
result
decreas
mouth
genit
ulcer
discuss
bd
rare
diseas
mostli
seen
along
silk
road
preval
report
usa
singl
villag
northern
turkey
inhabit
cgd
primari
immunodefici
caus
defect
five
subunit
nadph
oxidas
complex
respons
respiratori
burst
phagocyt
leukocyt
patient
cgd
increas
risk
lifethreaten
infect
catalaseposit
bacteria
fungi
inflammatori
complic
cgd
coliti
report
cgd
femal
carrier
discoid
lupu
erythematosu
photosensit
rash
autoimmun
phenomena
publish
best
knowledg
first
case
report
bd
affect
cgd
carrier
treatment
inflammatori
diseas
patient
cgd
pose
difficult
balanc
therapeut
immunosuppress
increas
risk
sever
infect
high
dose
intraven
immunoglobulin
target
therapi
cell
mediat
patholog
rituximab
bcell
mediat
patholog
antitnf
ibd
may
prefer
broad
immunosuppress
activ
glucocorticoid
addit
emerg
evid
suggest
hematopoiet
stem
cell
transplant
indic
case
difficult
control
use
immunosuppress
given
case
emphas
need
maintain
suspicion
autoimmun
disord
immun
dysregul
patient
pid
introduct
defici
xlink
combin
immunodefici
character
suscept
infect
often
associ
neutropenia
malign
autoimmun
central
nervou
system
cn
manifest
less
commonli
report
respiratori
gastrointestin
complic
often
attribut
infect
herein
describ
challeng
case
gradual
onset
episod
memori
loss
confus
unilater
hemiplegia
young
male
defici
case
present
patient
male
defici
immunoglobulin
replac
therapi
present
recurr
episod
alter
mental
statu
am
gradual
neurocognit
declin
initi
neurolog
symptom
began
age
year
includ
fever
nausea
eyelid
flutter
initi
comprehens
infecti
workup
time
includ
blood
urin
cultur
lyme
antibodi
serum
pcr
hsv
cmv
ebv
respiratori
viral
pcr
includ
atyp
virus
csf
studi
includ
cultur
lyme
eia
pcr
enterov
r
u
v
z
v
e
b
v
c
v
h
v
w
e
r
e
u
n
r
e
v
e
l
n
g
electroencephalogram
eeg
mri
display
gener
slow
global
atrophi
respect
definit
diagnosi
made
patient
continu
declin
worsen
development
delay
memori
loss
one
year
later
age
year
recurr
episod
am
repeat
neg
infecti
workup
includ
blood
urin
cultur
respiratori
viru
pcr
includ
atyp
virus
csf
cultur
includ
acid
fast
bacillu
fungi
cryptococc
antigen
viral
enceph
panel
pcr
serum
pcr
ebv
eeg
time
show
left
hemispher
epileptogen
potenti
consist
seizur
activ
present
age
year
notabl
rightsid
hemiplegia
facial
numb
dysarthria
nausea
fever
found
anello
viru
pcr
csf
abnorm
left
tempor
region
eeg
global
atrophi
stabl
diffus
gener
volum
loss
mri
diagnos
occult
anello
virusinduc
enceph
hemipleg
migrain
discharg
valproat
discuss
present
first
report
case
anello
viru
detect
pcr
defici
male
neurocognit
manifest
attribut
primarili
hemipleg
migrain
given
anello
viru
preval
rel
avirul
charact
presum
unlik
culprit
enceph
howev
signific
find
yet
unknown
case
highlight
diagnost
challeng
immunodefici
infect
may
go
undetect
standard
diagnost
techniqu
howev
signific
infect
identifi
advanc
techniqu
may
yet
understood
background
purpura
hsp
igamedi
small
vessel
vascul
present
tetrad
abdomin
pain
arthriti
glomerulonephr
purpura
hsp
typic
selflimit
diseas
childhood
follow
viral
ill
univers
treatment
patient
chronic
recurr
hsp
report
chronic
refractori
case
hsp
success
treat
tumor
necrosi
factor
inhibitor
tnfi
etanercept
etanercept
function
recombin
protein
consist
tnfalpha
receptor
ligandbind
region
link
fc
portion
human
igg
current
approv
use
diseas
juvenil
rheumatoid
arthriti
rheumatoid
arthriti
ankylos
spondyl
plaqu
psoriasi
psoriat
arthriti
tnfi
categor
two
broad
categori
recombin
receptor
etanercept
neutral
antibodi
ex
infliximab
adalimumab
prior
case
report
hsp
associ
tnfi
agent
treatment
autoimmun
condit
adult
popul
knowledg
prior
etanercept
relat
hsp
report
one
report
associ
adalimumab
one
infliximab
howev
prior
report
etanercept
use
success
treat
chronic
refractori
hsp
case
present
nativ
american
male
year
histori
chronic
hsp
posit
enthes
relat
arthriti
initi
treat
steroid
sulfasalazin
methotrex
symptom
joint
pain
purpura
iga
level
mgdl
prior
therapi
despit
treatment
one
month
steroid
eight
month
sulfasalazin
exclus
eight
month
methotrex
sulfasalazin
continu
persist
purpura
bilater
extrem
without
improv
subsequ
initi
etanercept
weekli
methotrex
discontinu
approxim
one
month
later
rash
significantli
improv
rash
joint
pain
recur
miss
dose
etanercept
punch
biopsi
taken
month
initi
etanercept
biopsi
lesion
left
arm
show
earli
leukocytoclast
vascul
left
leg
show
weak
granular
deposit
iga
igm
within
vessel
wall
controversi
whether
true
iga
vascul
howev
believ
clinic
present
deposit
iga
within
blood
vessel
wall
seen
biopsi
correl
chronic
purpura
conclus
standard
treatment
chronic
hsp
report
benefit
nsaid
corticosteroid
per
literatur
review
prior
report
etanercept
use
treatment
chronic
hsp
tnf
inhibitor
etanercept
consid
treatment
chronic
refractori
hsp
pediatr
popul
show
rapid
resolut
purpura
case
report
studi
etanercept
treatment
chronic
hsp
conduct
given
controversi
literatur
antitnf
ab
induc
hsp
treatment
autoimmun
diseas
although
clinic
manifest
iron
overload
appear
quit
uncommon
patient
heterozyg
carrier
hfa
mutat
present
case
appear
suggest
increas
risk
non
allerg
rhinosinus
case
report
present
year
old
gentleman
perenni
color
rhinorrhea
facial
pressur
tender
constant
post
nasal
drip
dri
cough
bilater
congest
go
past
sever
year
also
frequent
urg
clear
throat
frequent
episod
sore
throat
despit
histori
gerd
lpr
report
multipl
sinu
infect
everi
year
would
progress
pneumonia
eventu
requir
long
cours
oral
antibiot
start
intensifi
recent
past
sibl
one
die
due
liver
complic
hh
carrier
sister
brother
hx
sino
nasal
problem
exactli
similar
patient
exam
remark
bilater
narrow
nasal
passag
moder
edema
mucosa
rhinolaryngoscopi
show
signific
edema
purul
drainag
notabl
bilater
middl
meati
skin
test
neg
cbc
show
wbc
count
eosinophil
immunoglobulin
panel
show
iga
mgdl
igg
mgdl
ige
mgdl
patient
place
alkalol
sinu
rins
azelastin
nasal
spray
report
work
pretti
well
left
costa
rica
expect
return
back
sibl
clinic
come
month
discuss
hh
one
common
inherit
disord
peopl
northern
european
descent
incid
carrier
rate
affect
hh
patient
homozyg
mutat
design
hfe
gene
locat
chromosom
unlik
hereditari
hemochromatosi
clinic
manifest
iron
overload
appear
quit
uncommon
patient
heterozyg
carrier
hh
patient
risk
number
infect
bacteria
whose
virul
increas
presenc
excess
tissu
iron
hh
also
risk
factor
acut
fulmin
fr
mechan
postul
due
quantit
qualit
neutrophil
defect
condit
mostli
seen
patient
dm
aplast
anemia
happen
patient
undergo
antineoplast
chemotherapi
known
increas
suscept
infect
either
mechan
postul
patient
heterozyg
carrier
state
present
hh
carrier
patient
present
recurr
rhinosinus
allergen
sensit
normal
ige
level
sinc
fungal
immun
tissu
level
cytokin
driven
specul
increas
tissu
level
iron
might
interfer
mechan
innat
immun
chief
human
immunolog
diseas
section
laboratori
clinic
immunolog
microbiolog
niaid
nih
bethesda
md
background
dedic
cytokinesi
mutat
associ
combin
immunodefici
disord
mark
atop
featur
infecti
suscept
strike
preponder
cutan
viral
diseas
risk
develop
malign
includ
lymphoma
almost
case
diagnos
document
loss
protein
express
method
describ
male
diagnosi
preb
cell
acut
lymphoblast
leukemia
follow
epsteinbarr
viru
ebv
associ
diffus
larg
b
cell
lymphoma
dlbcl
compound
heterozyg
mutat
document
follow
complet
whole
exom
sequenc
we
pathogen
variant
assess
flow
cytometr
quantif
intracellular
protein
complet
protein
function
assess
evalu
morpholog
patient
lymphocyt
migrat
collagen
matrix
result
concern
primari
immunodefici
rais
due
histori
recurr
otiti
media
began
month
age
year
age
numer
wart
note
finger
howev
transient
durat
year
atop
featur
appreci
year
age
diagnosi
preb
cell
made
therapi
infecti
complic
sever
includ
intestin
perfor
osteomyel
sepsi
year
age
still
ongo
remiss
incident
find
lung
nodul
led
diagnosi
ebvassoci
dlbcl
therapi
howev
infecti
complic
sever
includ
soft
tissu
infect
sepsi
we
perform
compound
heterozyg
mutat
c
document
flow
cytometr
quantif
intracellular
protein
normal
compar
normal
control
nevertheless
addit
function
assess
protein
complet
migrat
collagen
matrix
patient
lymphocyt
studi
demonstr
abnorm
elong
stretch
ratio
defin
lengthwidth
compar
lymphocyt
normal
control
evalu
hematopoiet
stem
cell
transplant
conclus
autosom
recess
mutat
rare
caus
combin
immunodefici
mark
atop
featur
infecti
suscept
strike
preponder
cutan
viral
diseas
risk
develop
malign
includ
lymphoma
preb
cell
follow
develop
subsequ
malign
neoplasm
ebvassoci
dlbcl
led
discoveri
defici
henc
case
underscor
rare
instanc
high
clinic
suspicion
despit
normal
protein
express
addit
function
test
crucial
make
definit
diagnosi
plan
treatment
understand
spectrum
mutant
phenotyp
improv
understand
defici
background
autosom
domin
hyperimmunoglobulin
e
syndrom
adhi
rare
primari
immunodefici
caus
heterozyg
lossoffunct
mutat
signal
transduc
activ
transcript
gene
adhi
classic
character
recurr
cold
staphylococc
abscess
pneumonia
eczema
elev
ige
level
addit
clinic
manifest
hie
recogn
includ
skelet
dysplasia
scoliosi
patholog
fractur
delay
dental
decidu
pneumatocel
coronaryarteri
aneurysm
brain
lesion
chiari
malform
object
describ
uniqu
case
abdomin
abscess
patient
adhi
method
femal
known
adhi
c
complic
histori
earli
pneumococc
pneumonia
meningococcemia
result
bilater
amput
knee
along
loss
sever
digit
present
evalu
skin
infect
histori
recurr
staphylococc
skin
abscess
present
inabl
use
prosthes
due
pain
inflamm
around
amput
site
underw
imag
found
bilater
extrem
abscess
associ
osteomyel
l
tibia
found
mrsa
incis
drainag
receiv
intraven
antibiot
osteomyel
develop
intract
abdomin
pain
imag
show
thickwal
multisept
paranephr
abscess
well
sever
smaller
abscess
scatter
throughout
abdomen
underw
multipl
drain
placement
drainag
retroperiton
fluid
collect
via
intervent
radiolog
ir
purul
fluid
abdomin
abscess
drainag
grew
mrsa
patient
continu
reaccumul
abscess
despit
multipl
drainag
repeat
imag
note
increas
paranephr
abscess
commun
drain
given
lack
respons
sever
irplac
abdomin
drain
week
intraven
antibiot
open
surgic
washout
minim
improv
hospit
cours
complic
develop
left
lower
lung
lobe
consolid
subsegment
pulmonari
embol
necessit
treatment
heparin
final
sever
week
escal
antimicrobi
therapi
addit
drain
placement
retroperiton
abscess
start
reced
repeat
abdomin
imag
sever
month
later
asymptomat
reveal
slow
continu
resolut
abscess
conclus
present
case
rais
awar
unusu
locat
infect
patient
adhi
although
major
complic
adhi
sinopulmonari
skin
infect
recalcitr
intraabdomin
abscess
consid
differenti
infect
hie
introductionbackground
recent
epidemiolog
studi
reveal
primari
immunodefici
pid
common
previous
thought
howev
data
epidemiolog
pid
korea
object
attempt
estim
pid
epidemiolog
diseas
burden
korea
provid
background
inform
pid
registri
futur
method
review
previous
report
scientif
studi
pubm
koreanm
googl
scholar
search
studi
pid
report
scientif
journal
korean
intern
januari
novemb
search
korean
english
report
search
diagnosi
pid
categor
group
group
xi
accord
iui
phenotyp
classif
studi
period
divid
two
period
period
period
multicent
studi
estim
pid
epidemiolog
addit
number
pid
patient
cost
care
estim
among
patient
request
reimburs
health
insur
review
assess
servic
hira
korea
one
year
result
total
pid
patient
identifi
report
one
hundr
ninetynin
patient
report
patient
report
found
period
period
respect
pid
report
patient
immunodefici
affect
cellular
humor
immun
patient
combin
immunodefici
associ
syndrom
featur
patient
predominantli
antibodi
defici
patient
diseas
immun
dysregul
patient
congenit
defect
phagocyt
patient
defect
intrins
innat
immun
patient
autoinflammatori
disord
patient
complement
defici
none
phenocopi
pid
hira
reimburs
data
number
pid
patient
combin
immunodefici
predominantli
antibodi
defici
common
variabl
immunodefici
function
defect
neutrophil
immunodefici
associ
major
defect
immunodefici
total
pid
patient
treat
day
reimburs
conclus
perform
systemat
review
publish
studi
pid
medic
journal
nation
open
data
system
hira
estim
pid
diseas
burden
first
time
korea
obtain
inform
true
pid
epidemiolog
diseas
burden
korea
nation
multicent
studi
pid
registri
requir
futur
microthrombocytopenia
one
seriou
challeng
wiskottaldrich
syndrom
xlink
thrombocytopenia
xlt
patient
thrombocytopenia
lead
sever
potenti
lifethreaten
bleed
episod
requir
frequent
transfus
account
death
patient
experienc
mutat
gold
standard
treatment
patient
hematopoiet
stem
cell
transplant
hsct
hlaident
donor
recent
number
gene
therapi
gt
trial
europ
usa
show
promis
result
particular
shown
patient
receiv
lentivir
mediat
gt
consist
autolog
cell
transduc
lentivir
vector
encod
human
gene
control
endogen
promot
combin
reduc
intens
condit
regimen
signific
increas
platelet
plt
count
even
though
plt
count
reach
normal
level
treat
patient
decreas
sever
frequenc
bleed
cohort
xlt
patient
fifteen
treat
gt
plt
phenotyp
function
analyz
electron
microscopi
flow
cytometri
proteom
profil
aim
project
assess
presenc
plt
defect
untreat
patient
impact
gt
treatment
correct
plt
behavior
demonstr
plt
untreat
patient
reduc
size
abnorm
ultrastructur
along
hyperactiv
phenotyp
steadi
state
show
increas
express
activ
integrin
convers
activ
respons
agonist
aggreg
capac
decreas
analyz
plt
sampl
isol
treat
patient
found
gt
restor
plt
size
ultrastructur
earli
treatment
reduc
hyperactiv
phenotyp
proport
protein
wasp
express
followup
length
plt
isol
gt
treat
patient
show
normal
activ
respons
agonist
restor
aggreg
capac
analys
patient
proteom
variou
protein
pathway
found
downregul
untreat
plt
sampl
mainli
involv
cytoskeletalrearrang
protein
integrin
signal
transduct
molecul
vesiclestransport
protein
addit
decreas
metabol
capac
observ
result
line
function
defect
observ
plt
term
activ
aggreg
convers
express
proteinpathway
found
downregul
untreat
patient
compar
healthi
control
gttreat
plt
sampl
reflect
amelior
plt
phenotyp
function
overal
studi
highlight
coexist
multipl
defect
activ
aggreg
respons
occur
patient
plt
absenc
wasp
gt
abl
normal
plt
proteom
profil
follow
consequ
restor
plt
ultrastructur
phenotyp
suggest
gt
respons
observ
reduct
bleed
episod
treat
patient
introduct
autosom
domin
genet
disord
immun
system
result
persist
activ
signal
essenti
immun
cell
regul
metabol
migrat
prolifer
differenti
lead
patient
present
lymphadenopathi
immunodefici
senesc
cell
mutat
protein
caus
cell
activ
matur
quickli
lead
death
activ
also
block
matur
b
cell
case
present
femal
childhood
histori
failur
thrive
asthma
chronic
rhiniti
common
variabl
immunodefici
intraven
immunoglobulin
replac
seen
immunolog
clinic
establish
care
report
frequent
episod
pneumonia
bronchiti
childhood
famili
histori
signific
famili
member
leukopenia
diagnos
immunodefici
patient
son
report
symptom
concern
immunodefici
physic
exam
within
normal
limit
lymphadenopathi
laboratori
examin
exhibit
normal
iga
mgdl
igg
mgdl
igm
mgdl
flow
cytometri
show
normal
absolut
cellsul
cellsul
nk
cell
cellsul
cellsul
cellsul
cellsul
cellsul
hladr
cellsul
nonswitch
memori
cell
cellul
classswitch
memori
cell
cellsul
cellsul
vaccin
respons
pursu
patient
ivig
genet
test
pursu
reveal
mutat
gene
specif
mutat
variant
mutat
though
seen
databas
current
report
medic
literatur
associ
condit
base
ct
chest
order
screen
bronchiectasi
adenopathi
lymphoma
ct
show
cardiopulmonari
diseas
adenopathi
show
incident
adren
mass
work
pattern
inherit
mutat
autosom
domin
son
asymptomat
test
son
pursu
though
advis
cousin
given
histori
leukopenia
patient
continu
igg
replac
therapi
conclus
recent
public
clinic
immunolog
societi
suggest
consider
next
gener
sequenc
affect
futur
famili
plan
treatment
prognost
implic
case
highlight
aspect
import
genet
test
part
diagnosi
cvid
sinc
affect
progeni
offer
possibl
treatment
immun
modul
agent
implic
screen
sinc
patient
increas
risk
malign
background
abnorm
v
j
recombin
activ
patient
mutat
recombinationactiv
gene
result
markedli
reduc
usag
distal
vand
j
gene
cell
receptor
alpha
tra
locu
mucosaassoci
invari
mait
cell
express
semiinvari
cell
receptor
contain
distal
gene
mait
cell
identifi
flow
cytometri
use
mab
direct
valpha
recogn
product
gene
perform
high
throughput
sequenc
ht
tra
rearrang
flow
cytometri
confirm
lack
cell
use
distal
valpha
gene
patient
known
rag
mutat
report
flow
cytometri
mab
valpha
success
identifi
rag
defici
two
patient
atyp
present
method
tra
rearrang
analyz
ht
use
gdna
sort
cell
subset
ragmut
patient
healthi
donor
distal
valpha
usag
measur
whole
blood
flow
cytometr
analysi
antivalpha
antibodi
rag
mutat
detect
sanger
sequenc
patient
enrol
niaid
protocol
result
ht
tra
rearrang
reveal
lack
distal
trav
traj
gene
usag
patient
mutat
presenc
circul
mait
cell
control
patient
known
mutat
variou
clinic
phenotyp
analyz
flow
cytometri
use
mab
valpha
found
virtual
lack
valpha
express
rag
mutat
patient
compar
control
use
valpha
assay
test
two
patient
unknown
immunodefici
manifest
skin
granuloma
autoimmun
cytopenia
found
nearli
absent
express
target
sequenc
reveal
patient
compound
heterozyg
mutat
respect
conclus
patient
mutat
demonstr
skew
tcralpha
repertoir
reduct
recombinas
activ
patient
allow
rearrang
distal
valpha
segment
rapid
identif
patient
lack
valpha
cell
flow
cytometri
may
prompt
sanger
sequenc
identif
mutat
matter
day
assay
repres
simpl
power
tool
reduc
cost
time
associ
analysi
method
acknowledg
support
dirniaidnih
director
centro
de
drabezrodnik
equipo
introduct
fate
effector
cell
strongli
depend
express
inhibit
reciproc
complex
signal
pathway
sever
studi
shown
key
transcript
factor
differenti
toward
follicular
helper
cell
tfh
lineag
abl
collabor
b
lymphocyt
bl
contrari
transcript
factor
highli
express
lymphocyt
treg
thu
regul
differenti
toward
tfh
materi
method
whole
fresh
blood
peripher
mononuclear
cell
patient
homozyg
mutat
analys
flow
cytometri
analysi
ctfh
bl
lb
memori
mbl
lb
igm
switch
mblsw
igdigm
plasmablast
pbc
cell
perform
immunoglobulin
measur
serum
result
patient
defici
show
increas
valu
ctfh
healthi
donor
present
activ
phenotyp
ico
skew
profil
consist
hipergammaglobulinemia
mark
sustain
increas
switch
mbl
pbc
subpopul
peripher
blood
year
discus
immunolog
phenotyp
describ
patient
defici
could
explain
part
pathophysiolog
autoimmun
disord
patient
well
two
patient
mutat
previous
describ
group
chronic
hypergammaglobulinemia
autoantibodi
consequ
autoimmun
process
psoriasi
hypothyroid
eczema
alopecia
celiac
diseas
among
other
believ
link
clinic
symptomatolog
molecular
defect
reli
fact
absenc
promot
greater
express
gener
bia
toward
product
ctfh
cell
give
rise
greater
activ
lb
gener
lbm
plasma
cell
dysregul
cg
event
manifest
hypergammaglobulinemia
autoimmun
summari
provid
promis
evid
mechan
lead
autoimmun
type
patient
could
also
consequ
defect
regul
gc
highlight
crucial
role
humor
immun
respons
mainten
toler
immun
system
backgroundintroduct
term
primari
immunodefici
pid
encompass
phenotyp
genet
divers
group
condit
genet
test
condit
guid
treatment
reduc
morbid
mortal
allow
genet
counsel
identif
addit
atrisk
famili
member
howev
test
complic
number
factor
includ
pseudogen
high
homolog
methodolog
limit
heterogen
natur
pid
method
mayo
clinic
laboratori
launch
first
set
nine
pid
next
gener
sequenc
ng
test
approxim
one
year
ago
test
includ
one
singl
gene
assay
defici
eight
target
next
gener
sequenc
panel
atyp
hemolyt
urem
syndrom
ahu
autoinflammatori
disord
bcell
disord
monogen
irrit
bowel
diseas
ibd
phagocyt
defect
sever
combin
immunodefici
scid
sever
cyclic
neutropenia
herein
summar
first
year
experi
ng
test
focu
eight
target
panel
test
result
march
novemb
perform
test
case
highest
volum
test
ahu
panel
case
variant
report
case
variant
includ
variant
uncertain
signific
like
pathogen
variant
pathogen
variant
indic
highest
percentag
case
variant
report
scid
case
number
case
consid
solv
genotyp
like
explain
patient
phenotyp
vari
wide
indic
twenti
case
found
pathogen
like
pathogen
variant
variant
howev
case
heterozygot
autosom
recess
condit
consid
solv
case
panel
highest
percentag
solv
case
scid
panel
case
convers
yet
solv
autoinflammatori
irrit
bowel
diseas
telomer
defect
case
howev
case
three
panel
variant
uncertain
signific
report
hypothes
one
reason
low
detect
rate
three
panel
inappropri
test
order
also
activ
look
way
updat
panel
increas
detect
rate
clinic
util
exampl
expand
gene
list
ibd
panel
includ
larg
deletiondupl
detect
includ
difficult
gene
captur
ng
phagocyt
panel
final
present
molecular
find
number
interest
case
solv
use
target
ng
panel
conclus
launch
pid
ng
test
march
allow
us
aid
patient
confirm
diagnos
provid
molecular
diagnos
enabl
accur
genet
counsel
risk
assess
also
uncov
area
improv
clinic
side
provid
educ
import
enabl
better
identif
patient
benefit
molecular
genet
test
pid
laboratori
side
introduct
expand
panel
addit
methodolog
progress
decreas
red
blood
cell
platelet
neutrophil
via
selfdirect
immun
process
jointli
term
autoimmun
cytopenia
autoimmun
cytopenia
includ
autoimmun
hemolyt
anemia
aiha
immun
thrombocytopen
purpura
itp
autoimmun
neutropenia
common
present
autoimmun
gener
popul
particularli
frequent
appear
first
sign
patient
primari
immunodefici
pid
possibl
caus
cytopenia
pid
compris
mainli
immun
dysregul
bone
marrow
failur
bmf
myelodysplasia
goal
investig
possibl
immun
mediat
mechan
underli
chronic
cytopenia
children
order
achiev
earli
diagnosi
consequ
offer
time
appropri
therapi
select
patient
affect
chronic
cytopenia
evalu
immunophenotyp
flowcytometri
data
subject
multivari
analysi
princip
compon
analysi
pca
next
gener
sequenc
ng
analysi
gene
frequent
implic
pid
perform
among
patient
affect
bone
marrow
failur
diagnos
fanconi
anemia
sever
congenit
neutropenia
affect
immunemedi
cytopenia
idiopath
cytopenia
immunephenotyp
show
typic
pattern
cell
subpopul
express
patient
compar
healthi
donor
increas
cell
reduct
central
memori
cm
effector
memori
em
cell
level
observ
decreas
total
b
cell
b
switch
b
memori
cell
increas
cell
pca
show
overlap
group
howev
reveal
peculiar
trend
singl
patient
suggest
pathway
involv
immun
defect
preliminari
result
ng
studi
reveal
genet
variat
gene
previous
associ
pid
patient
investig
particular
identifi
one
patient
mutat
fa
one
mutat
air
one
mutat
ikaro
concern
remain
patient
studi
ongo
valid
pathogen
genet
variat
pca
effect
tool
analyz
sever
paramet
time
highlight
patient
whose
phenotyp
show
main
peculiar
presenc
specif
lymphocyt
subpopul
pattern
import
indic
immunemedi
cytopenia
help
sign
specif
pid
promptli
investig
genet
analysi
rapid
discoveri
novel
monogen
primari
immunodefici
made
possibl
broad
avail
clinic
whole
exom
sequenc
we
howev
clinic
we
major
shortcom
understood
practic
immunologist
focus
iui
list
monogen
primari
immunodefici
gene
show
limit
coverag
could
significantli
impact
clinic
interpret
agil
whole
exom
captur
kit
common
we
platform
number
gene
exon
poorli
cover
specif
least
gene
less
exon
coverag
less
coverag
less
coverag
eg
ikbkb
taci
beyond
challeng
technic
issu
subtl
issu
well
includ
presenc
pseudogen
least
gene
eg
cftr
msn
ncstn
ikbkg
pten
rp
sbd
make
accur
sequenc
challeng
final
mani
known
caus
intron
eg
btk
wasp
copi
number
variant
mutat
eg
xiap
well
larg
delet
eg
expect
optim
cover
use
we
list
gene
requir
consider
even
neg
exom
may
requir
addit
approach
includ
whole
genom
sequenc
sanger
sequenc
cnv
array
andor
longread
ng
sequenc
we
power
genom
diagnost
tool
avoid
miss
key
diagnost
insight
use
altern
approach
may
critic
certain
gene
differenti
diagnosi
go
forward
pid
phenotyp
continu
broaden
issu
remain
fundament
import
even
gene
obvious
implic
given
clinic
phenotyp
physician
util
target
genet
panel
reach
definit
diagnosi
patient
immunodefici
howev
increas
test
also
led
discoveri
mani
variant
uncertain
signific
vu
gene
test
find
often
leav
patient
physician
question
answer
present
patient
recurr
infect
found
multipl
variant
uncertain
signific
sever
gene
associ
primari
immunodefici
femal
diagnos
crohn
diseas
age
intestin
perfor
jejun
resect
experienc
two
discret
episod
epstein
barr
viru
ebv
meningoenceph
septic
shock
first
episod
diagnos
patient
fever
alter
mental
statu
occur
prior
crohn
diseas
diagnosi
second
episod
complic
alter
mental
statu
dissemin
intravascular
coagul
dic
hypotens
requir
picu
admiss
asid
two
major
infect
famili
deni
infect
requir
antibiot
last
year
report
remot
histori
repeat
streptococc
pharyng
recur
immunolog
consult
time
second
episod
meningoenceph
work
mainli
unremark
normal
immunoglobulin
adequ
vaccin
respons
hib
tetanu
diphtheria
rubella
measl
pneumococcu
protect
titer
normal
cell
number
slightli
decreas
natur
killer
number
age
neutrophil
studi
show
normal
dihydrorhodamin
dhr
analysi
dehydrogenas
level
myeloperoxidas
mpo
stain
commerci
test
toll
like
receptor
show
normal
function
invita
primari
immunodefici
panel
demonstr
heterozyg
variant
well
heterozyg
variant
uncertain
signific
g
patient
variant
known
associ
increas
risk
crohn
diseas
even
patient
present
recurr
sever
viral
infect
ibd
immedi
clear
genet
result
explain
patholog
innat
immun
defect
probabl
contribut
present
current
unclear
combin
multipl
genet
variant
left
immunolog
vulner
use
case
demonstr
even
genet
test
elucid
clearcut
diagnosi
primari
immunodefici
still
provid
help
insight
patient
underli
immun
phenotyp
introduct
xiap
defici
rare
primari
immun
defici
character
hemophagocyt
lymphohistiocytosi
recurr
fever
inflammatori
syndrom
inflammatori
bowel
diseas
hypogammaglobulinemia
recurr
infect
manifest
loss
xiap
result
abnorm
tnf
receptor
signal
inflammasom
actviti
lead
dysregul
product
hypothes
suppress
inflammasom
either
target
delet
pharmacolog
inhibit
would
suppress
abnorm
product
secret
inflammatori
method
bone
marrow
deriv
macrophag
bmdm
control
xiapdefici
xiap
doubl
knockout
mice
deriv
week
cultur
condit
media
bmdm
stimul
varieti
tlr
agonist
tnfalpha
without
varieti
inhibitor
includ
inhibitor
cathepsin
b
inhibitor
quercetin
natur
flavonoid
antioxid
found
mani
fruit
veget
avail
nutrit
supplement
tnfalpha
measur
supernat
elisa
cell
death
evalu
flow
cytometri
use
pi
exclus
result
expect
bmdm
xiap
defici
mice
markedli
increas
tlragonistor
tnfalphainduc
product
compar
normal
bmdm
genet
delet
pretreat
cell
inhibitor
greatli
reduc
abnorm
product
residu
product
could
inhibit
inhibit
pretreat
cell
cathepsin
b
inhibitor
also
decreas
cytokin
product
toxic
higher
concentr
quercetin
reliabl
abrog
also
quercetin
found
inhibit
prime
inflammasom
decreas
upregul
also
decreas
tnfalpha
secret
follow
tlr
agonist
stimul
conclus
quercetin
suppress
inflammasom
may
promis
therapeut
option
patient
xiap
defici
prevent
secret
particularli
appeal
option
given
natur
occur
antioxid
great
safeti
profil
readili
avail
nutrit
supplement
human
studi
need
recent
singl
cell
rna
sequenc
scrnaseq
analysi
mice
disclos
unexpect
complex
thymic
stromal
cell
medullari
thymic
epitheli
cell
mtec
particular
howev
development
origin
hierarchi
function
subpopul
remain
illdefin
moreov
although
cortic
tec
ctec
thought
repres
homogen
popul
character
larg
restrict
adult
thymu
previous
shown
impair
lymphostrom
crosstalk
thymu
patient
combin
immunodefici
correspond
mous
model
associ
abnorm
thymic
architectur
tec
matur
sought
compar
tec
distribut
gene
express
wildtyp
wt
mice
carri
hypomorph
mutat
observ
patient
combin
immun
defici
immun
dysregul
method
multicolor
flow
cytometri
scrnaseq
use
analyz
composit
distribut
ctec
mtec
subpopul
wt
mutant
mice
variou
week
age
niaid
anim
protocol
result
observ
mutant
mice
excess
ctec
mtec
compart
predominantli
repres
cell
high
level
mhc
class
ii
mhcii
express
recapitul
phenotyp
neonat
wt
thymi
mhciihi
mtec
thought
repres
minor
fraction
mtec
adult
wt
mice
includ
matur
air
cell
rel
abund
mhciihi
mtec
observ
also
neonat
age
thought
repres
immatur
mtec
defin
precis
tec
matur
perform
scrnaseq
sort
cell
identifi
distinct
cluster
tec
wt
mutant
mice
respect
larg
proport
cell
mutant
mice
could
ascrib
ctec
compart
confirm
previou
flow
cytometri
histopatholog
result
furthermor
scrnaseq
analysi
also
disclos
differ
distribut
mtec
subset
wt
mutant
mice
address
hypothesi
differ
ctec
mtec
abund
subset
distribut
may
reflect
differ
matur
stage
tec
develop
wt
mutant
mice
perform
lineag
trace
transplant
experi
also
extend
tec
scrnaseq
analysi
wt
mutant
mice
embryon
neonat
age
parallel
evalu
contribut
thymocyt
matur
shape
stromal
popul
scrnaseq
perform
thymocyt
conclus
refin
complex
tec
shown
impair
develop
cell
combin
immun
defici
exemplifi
mutant
mice
profound
effect
composit
matur
tec
may
thu
contribut
abnorm
immun
toler
often
associ
condit
advent
nextgener
sequenc
ng
develop
wholeexom
sequenc
we
particular
allow
identif
unknown
genet
lesion
mani
diseas
implement
specif
therapeut
strategi
primari
immunodefici
pid
group
rare
diseas
benefit
ng
discoveri
molecular
character
previous
genet
undefin
diseas
identif
novel
molecul
involv
regul
immun
system
pid
often
associ
autoimmun
diseas
due
dysregul
immun
system
whole
clinic
phenotyp
heterogen
often
overlap
monogen
caus
diseas
identifi
subset
patient
recent
applic
wholegenom
sequenc
found
polygen
caus
like
aim
investig
genet
background
patient
immunedysregul
autoimmun
evalu
possibl
pathogen
identifi
gene
variant
extens
function
studi
select
patient
sign
immunedysregul
autoimmun
extend
immunophenotyp
nextgener
sequenc
ng
analysi
gene
frequent
implic
pid
perform
six
identifi
singl
gene
respons
clinic
featur
particular
identifi
two
patient
gain
function
mutat
one
patient
mutat
one
patient
activ
mutat
one
mutat
one
fa
mutat
variant
multipl
gene
detect
interestingli
find
gene
recurr
mutat
one
patient
studi
ongo
valid
effect
variat
identifi
result
strongli
suggest
old
hypothesi
base
singl
gene
mutat
caus
ill
revis
favor
concept
sum
caus
effect
differ
point
view
pid
seem
inevit
physician
omni
allergi
immunolog
asthma
introductionbackground
immunoglobulin
replac
therapi
igrt
may
optim
reduc
sever
incid
infect
potenti
delay
abrog
develop
pulmonari
complic
primari
immun
defici
pulmonari
complic
includ
bronchiectasi
common
common
variabl
immun
defici
cvid
contribut
significantli
morbid
mortal
patient
remain
unclear
whether
continu
obstruct
bronchial
chang
result
repeat
respiratori
infect
associ
inflamm
immun
dysregul
simpli
lungdamag
irrevers
time
therapi
initi
also
suggest
undertreat
addit
diagnost
delay
may
contribut
develop
bronchiectasi
patient
pid
lower
serum
igg
level
given
dose
immunoglobulin
replac
therapi
demonstr
patient
bronchiectasi
compar
pid
patient
without
complic
addit
earlier
studi
shown
greater
dose
ig
mgkg
month
may
reduc
frequenc
durat
infect
help
prevent
slow
progress
chronic
lung
diseas
object
evalu
preval
bronchiectasi
cohort
patient
diagnosi
cvid
identifi
associ
ig
dose
pattern
clinic
outcom
method
data
analyz
ideal
immunoglobulin
diagnosi
evalu
key
learn
patient
registri
prospect
longitudin
registri
studi
patient
receiv
ig
replac
therapi
home
ambulatori
infus
suit
one
nation
home
infus
provid
nurs
pharmaci
standard
care
form
collect
dose
infect
rate
preval
bronchiectasi
evalu
patient
diagnosi
cvid
code
result
patient
registri
cvid
bronchiectasi
also
observ
seventynin
percent
studi
popul
femal
case
bronchiectasi
observ
femal
mean
age
patient
concurr
bronchiectasi
start
care
compar
without
observ
bronchial
obstruct
bronchiectasi
patient
receiv
igrt
subcutan
everi
week
mean
dose
mgkgwk
mean
dose
ig
remain
patient
receiv
ig
intraven
mgkgmonth
averag
annual
rate
infect
ivig
scig
patient
bronchiectasi
respect
howev
mani
seriou
bacteri
infect
time
analysi
bronchiectasi
patient
remain
activ
registri
withdrawn
reason
withdraw
includ
stop
igrt
due
follow
patient
decis
physician
decis
insur
chang
patient
expir
conclus
document
case
bronchiectasi
cohort
cvid
registri
patient
dose
pattern
align
standard
dose
despit
presenc
bronchial
obstruct
studi
necessari
assess
evolut
lung
damag
respect
ig
dose
patient
cvid
background
activ
phosphoinositid
syndrom
type
combin
immunodefici
result
gainoffunct
gof
mutat
gene
encod
catalyt
subunit
phosphoinositid
form
pid
character
recurr
respiratori
tract
infect
suscept
herp
viru
infect
impair
antibodi
respons
lymphoprolifer
autoimmun
previou
studi
show
patient
b
cell
defect
contribut
clinic
phenotyp
furthermor
patient
display
cell
abnorm
includ
increas
number
memori
cell
follicular
helper
cell
tfh
reduct
cell
impair
regulatori
cell
treg
function
whether
cell
abnorm
also
associ
perturb
cell
repertoir
unknown
object
aim
investig
effect
increas
signal
tcell
repertoir
patient
apd
method
high
throughput
sequenc
use
studi
composit
divers
tcell
receptor
tra
tcell
receptor
trb
repertoir
sort
treg
tfh
convent
tconv
cell
patient
gof
mutat
healthi
control
result
treg
cell
patient
show
restrict
tra
trb
repertoir
divers
increas
clonal
repertoir
restrict
detect
tfh
tconv
cell
patient
howev
trb
repertoir
treg
cell
enrich
presenc
hydrophob
amino
acid
posit
biomark
selfreact
conclus
data
demonstr
tcell
repertoir
patient
character
molecular
signatur
may
contribut
increas
rate
autoimmun
associ
condit
furthermor
result
support
notion
pathway
key
regul
treg
cell
develop
homeostasi
human
j
clin
immunol
suppl
iii
predominantli
antibodi
defici
immunodefici
affect
cellular
humor
immun
vii
autoinflammatori
disord
ix
phenocopi
pid
two
non
relat
case
ataxiatelangiectasia
one
case
schimk
syndrom
compound
heterozyg
mutat
diagnos
last
year
observ
wide
rang
age
evalu
adult
pediatr
popul
male
femal
ratio
close
immunodefici
immun
dysregul
system
autoimmun
clinic
diagnosi
disord
complic
overlap
phenotyp
april
next
gener
sequenc
ng
panel
inclus
copi
number
variat
analysi
launch
commerci
laboratori
facilit
clinic
diagnosi
primari
immunodefici
pid
monogen
autoimmun
autoinflammatori
disord
assess
outcom
genet
test
util
panel
cohort
pediatr
patient
immunohematolog
phenotyp
evalu
tertiari
care
center
period
elig
subject
evalu
least
two
three
provid
multidisciplinari
pediatr
hematologyimmunolog
team
includ
hematolog
physician
immunolog
physician
geneticist
genet
counselor
twentythre
patient
met
inclus
criteria
caucasian
male
averag
age
year
two
common
phenotyp
diagnos
includ
cytopenia
singleor
multilineag
leukopenia
neutropenia
anemia
thrombocytopenia
primarili
attribut
autoimmun
caus
hypogammaglobulinemia
five
given
definit
genet
diagnosi
result
panel
test
though
two
case
caus
mutat
list
variant
uncertain
signific
vu
diagnos
includ
common
variabl
immunodefici
due
pathogen
variant
multiorgan
autoimmun
due
gainoffunct
mutat
famili
cold
autoinflammatori
syndrom
due
pathogen
mutat
biallel
vu
found
patient
whose
phenotyp
laboratori
studi
includ
karyotyp
consist
immunodeficiencycentromer
instabl
facial
anomali
syndrom
vu
identifi
patient
multiorgan
autoimmun
father
hypothyroid
studi
outsid
research
laboratori
consist
gainoffunct
variant
privat
commun
addit
three
patient
vu
identifi
suspect
relat
phenotyp
prompt
elig
research
studi
four
patient
increas
risk
allel
confer
increas
risk
crohn
diseas
three
patient
pathogen
like
pathogen
carrier
find
warrant
genet
counsel
addit
vu
averag
per
patient
thought
unrel
phenotyp
identifi
necessit
investig
counsel
use
ng
panel
cohort
pediatr
patient
immunohematolog
disord
led
definit
diagnosi
previous
undiagnos
patient
prompt
research
investig
sever
genet
test
also
led
identif
clinic
signific
carrier
find
risk
allel
vu
unrel
phenotyp
necessit
genet
counsel
experi
illustr
valu
genet
test
diagnosi
immunohematolog
disord
import
multidisciplinari
care
includ
genet
counsel
proper
evalu
manag
patient
background
allogen
hematopoiet
cell
transplant
allohct
cur
primari
immun
defici
pid
howev
mani
patient
lack
fullymatch
unaffect
sibl
may
unknown
underli
genet
defect
render
undesir
use
relat
donor
mani
pid
patient
signific
comorbid
time
refer
allohct
preclud
use
myeloabl
condit
use
altern
donor
reducedintens
condit
ric
histor
led
increas
rate
graft
failur
graftversushost
diseas
gvhd
transplantrel
mortal
trm
posttransplant
cyclophosphamid
ptci
gvhd
prophylaxi
immunomodul
graft
preferenti
spare
regulatori
cell
hematopoiet
stem
cell
cytotox
effect
thu
allow
robust
donor
engraft
overcom
hla
barrier
effect
prevent
sever
acut
chronic
gvhd
report
outcom
two
institut
use
ric
allohct
regimen
altern
donor
ptci
patient
pid
design
transplant
pid
patient
tabl
use
altern
donor
ric
either
serotherapyfre
alemtuzumabbas
patient
receiv
ptci
gvhd
prophylaxi
day
either
alon
combin
mycophenol
mofetil
either
sirolimu
tacrolimu
donor
includ
haploident
famili
member
match
unrel
mismatch
unrel
stem
cell
sourc
cellreplet
bone
marrow
peripher
blood
stem
cell
result
median
followup
month
rang
year
month
overal
surviv
eventfre
surviv
defin
aliv
without
graft
failur
median
day
neutrophil
platelet
engraft
rang
rang
respect
patient
develop
acut
gvhd
grade
grade
case
grade
agvhd
seven
eight
patient
treat
system
corticosteroid
respond
one
corticosteroiddepend
respond
secondlin
therapi
one
patient
develop
skinonli
chronic
gvhd
respond
corticosteroid
puva
light
therapi
five
patient
develop
graft
failur
either
primari
secondari
four
success
retranspl
remain
engraft
one
patient
secondari
graft
failur
autolog
recoveri
requir
second
allohct
given
durabl
infect
control
gain
initi
engraft
three
death
prior
day
due
infect
one
death
year
secondari
presum
overdos
ongo
followup
engraft
survivor
evid
phenotyp
revers
demonstr
patient
complet
ongo
resolut
underli
diseas
manifest
includ
infect
transfusiondepend
autoimmun
malign
andor
immun
dysregul
discuss
observ
high
rate
engraft
low
rate
sever
acut
chronic
gvhd
low
trm
patient
pid
transplant
use
altern
donor
ric
ptcybas
gvhd
prophylaxi
ric
allohct
ptci
show
promis
cure
pid
use
minim
toxic
wide
expand
donor
pool
thu
allow
us
offer
cur
therapi
mani
patient
pid
chronic
granulomat
diseas
cgd
primari
immun
disord
involv
mutat
nicotinamid
adenin
dinucleotid
nadph
oxidas
complex
deffert
cachat
kraus
twothird
cgd
case
caus
lossoffunct
mutat
cybb
gene
encod
subunit
nadph
increas
patient
life
expect
thank
progress
diagnosi
manag
underlin
burden
inflammatori
manifest
occur
independ
infecti
agent
dunogu
et
al
marciano
et
al
cgd
patient
develop
inflammatori
granulomat
disord
notabl
coliti
consequ
dysregul
inflammasom
activ
treatment
inflammatori
manifest
remain
challeng
associ
increas
risk
infect
thu
understand
pathophysiolog
mechan
autoinflamm
cgd
could
help
improv
therapeut
arsen
manag
manifest
reveal
precis
pathophysiolog
mechan
autoinflamm
cgd
develop
cellular
model
reproduc
cgd
phenotyp
phagocyt
cell
geneedit
gener
c
e
l
l
l
n
e
h
r
b
r
n
g
h
e
p
r
e
v
u
l
e
c
r
b
e
mu
n
cybb
gene
respons
knockout
earli
termin
translat
cell
line
recapitul
phenotyp
cgd
phagocyt
decreas
product
ii
enhanc
inflammatori
respons
pma
stimul
evidenc
increas
tnfa
secret
level
kuijper
lutter
featur
rescu
complement
lentivir
transduct
wild
type
cybb
gene
new
model
help
us
investig
autoinflamm
report
cgd
patient
also
propos
new
therapeut
target
inflammatori
manifest
disord
driven
respons
children
defici
predispos
recurr
invas
infect
secondari
streptococcu
pneumonia
staphylococcu
aureu
pyogen
bacteria
high
mortal
rate
earli
childhood
frequenc
sever
infect
thought
decreas
age
due
acquisit
humor
immun
immunolog
memori
howev
due
rariti
diseas
natur
histori
condit
beyond
earli
childhood
well
describ
object
present
three
unrel
defici
patient
persist
chronic
rhinosinus
nasal
polyposi
develop
childhood
case
patient
yo
male
compound
heterozyg
mutat
histori
recurr
pneumonia
osteomyel
left
hip
age
left
knee
age
c
septicum
sepsi
age
follow
acut
bowel
perfor
addit
experienc
recurr
aom
infanc
recurr
uti
sinc
age
despit
prophylact
antibiot
ivig
recurr
polymicrobi
mrsa
pneumonia
h
influenza
p
aeruginosa
fumigatu
rhinosinus
nasal
polyposi
sinc
age
refractori
medic
manag
requir
surgic
intervent
prolong
cours
iv
antibiot
patient
yo
femal
homozyg
delet
exon
histori
ruptur
append
complic
pseudomona
abscess
bacteremia
age
cultureneg
sepsi
septic
arthriti
osteomyel
right
leg
age
septic
shock
secondari
mssa
bacteremia
complic
rhabdomyolysi
dic
age
histori
chronic
rhinosinus
despit
ivig
prophylact
antibiot
develop
polymicrobi
h
influenza
b
fragili
rhinosinus
associ
nasal
polyposi
pend
surgic
manag
patient
yo
femal
homozyg
mutat
exon
histori
pneumonia
mening
month
catarrhali
epiglott
neck
cellul
month
rsv
bronchiol
month
enterococcu
bacteremia
month
pneumonia
sepsi
age
streptococcu
lymphaden
age
despit
ivig
prophylact
antibiot
develop
recurr
polymicrobi
h
influenza
b
fragili
mssa
v
cholera
p
aeruginosa
fumigatu
rhinosinus
refractori
medic
manag
requir
surgic
intervent
iv
antibiot
conclus
center
experi
defici
patient
continu
suffer
infecti
complic
promin
recurr
polymicrobi
sinu
infect
beyond
earli
childhood
consist
presenc
sinonas
polyp
children
unusu
typic
found
uncompl
pediatr
chronic
rhinosinus
infect
occur
despit
antimicrobi
prophylaxi
ivig
highlight
role
sinopulmonari
epithelium
addit
infecti
organ
identifi
patient
cohort
commonli
associ
defici
studi
chronic
rhinosinus
nasal
polyposi
larger
cohort
defici
patient
innat
immunodefici
may
help
identifi
pathway
target
treatment
patient
introduct
chronic
granulomat
diseas
cgd
inherit
phagocyt
defect
associ
inabl
clear
catalas
posit
organ
infect
patient
cgd
sever
recalcitr
commonest
infect
pulmonari
follow
soft
tissu
infect
suppur
lymphaden
osteomyel
uncommon
infect
patient
cgd
pose
sever
diagnost
therapeut
challeng
herein
report
experi
osteomyel
cgd
last
year
materi
method
review
record
carri
describ
profil
osteomyel
cohort
patient
cgd
pediatr
immunodefici
clinic
advanc
pediatr
centr
postgradu
institut
medic
educ
research
chandigarh
india
diagnosi
cgd
base
nitroblu
tetrazolium
dye
reduct
test
nbt
dihydrorhodamin
reduct
dhr
assay
result
patient
cgd
osteomyel
male
femal
age
rang
year
patient
first
episod
seriou
infect
earli
childhood
mean
age
year
stimul
index
si
dhr
assay
rang
mutat
analysi
done
patient
xlink
autosom
recess
site
involv
variabl
aspergillu
fumigatu
common
isol
other
aspergillu
flavu
aspergillu
terreu
serratia
marcescen
patient
rib
osteomyel
concurr
pneumonia
fungu
isol
aspergillu
aspergillu
zygomyc
antifung
intraven
amphotericin
b
given
durat
week
follow
oral
voriconazol
therapeut
dose
month
major
debrid
resect
rib
requir
one
patient
patient
manag
conserv
patient
succumb
pneumonia
respiratori
failur
conclus
osteomyel
context
cgd
usual
caus
aspergillu
spp
involv
rib
vertebra
usual
occur
contigu
spread
infect
lung
therapi
often
requir
prolong
durat
antimicrobi
may
requir
surgic
debrid
addit
woman
histori
hypogammaglobulinemia
acut
liver
failur
woman
histori
nausea
vomit
abdomin
pain
admit
outsid
hospit
new
onset
jaundic
anasarca
liver
biopsi
thought
consist
alcohol
steatohepat
discharg
counsel
alcohol
cessat
medic
manag
liver
diseas
present
facil
second
opinion
follow
day
develop
rise
direct
hyperbilirubinemia
mgdl
new
coagulopathi
inr
hypoalbuminemia
mg
dl
absenc
ongo
alcohol
consumpt
liver
sonographi
reveal
cours
echotextur
patent
vessel
pcr
direct
multipl
hepatotrop
virus
neg
copper
studi
normal
due
histori
moder
alcohol
consumpt
start
highdos
corticosteroid
due
presumpt
diagnosi
alcohol
hepat
addit
histori
rais
concern
possibl
primari
immunodefici
includ
idiopath
thrombocytopen
purpura
year
age
multipl
episod
sinus
treat
antibiot
sinu
surgeri
one
episod
suspect
bacteri
pneumonia
one
hospit
influenza
develop
neutropenia
develop
refractori
genit
wart
prompt
infecti
diseas
evalu
initi
immun
evalu
reveal
low
immunoglobulin
iga
mgdl
igg
mgdl
igm
mgdl
low
respons
tetanu
diphtheria
despit
recent
booster
dose
b
cell
lymphopenia
cd
antigen
mitogen
prolifer
assess
intraven
immunoglobulin
replac
initi
discontinu
patient
due
infusionrel
advers
effect
lost
follow
present
liver
failur
parent
deceas
cardiovascular
diseas
sibl
limit
knowledg
famili
histori
known
immun
diseas
due
suspicion
genet
etiolog
immun
disord
liver
diseas
perform
nextgener
sequenc
panel
gene
implic
primari
immun
defici
patient
heterozyg
nucleotid
substat
within
splice
site
exon
boundari
gene
hospit
immunoglobulin
replac
trimethoprimsulfamethoxazol
prophylaxi
initi
attempt
made
refer
patient
addit
immunolog
evalu
transplant
evalu
unfortun
develop
worsen
liver
failur
multipl
complic
includ
extendedspectrum
betalactamas
esbl
produc
e
coli
bacteremia
hypotens
requir
vasopressor
extens
bowel
ischemia
die
hospit
summari
case
highlight
risk
diagnost
delay
adult
patient
present
primari
immun
defici
potenti
genet
test
clarifi
diagnosi
particular
genet
chang
describ
splice
site
predict
lossoffunct
mutat
report
pathogen
gene
implic
autosom
domin
common
variabl
immunodefici
case
expand
genet
caus
spectrum
diseas
associ
chang
gene
introduct
malnutrit
micronutri
defici
underrecogn
caus
acquir
immunodefici
adult
may
occur
even
patient
high
bodi
mass
index
bmi
method
woman
medic
histori
signific
one
remot
urinari
tract
infect
present
emerg
depart
sudden
onset
sever
right
flank
pain
pain
accompani
urinari
frequenc
reliev
ibuprofen
deni
fever
chill
diagnos
pyelonephr
discharg
ciprofloxacin
later
chang
trimethoprimsulfamethoxazol
cultur
grew
resist
e
coli
pain
continu
despit
treatment
prompt
return
hospit
three
day
later
upon
present
afebril
blood
pressur
mmhg
heart
rate
bpm
bodi
mass
index
physic
exam
otherwis
notabl
right
costovertebr
angl
tender
laboratori
studi
reveal
leukocyt
count
neutrophil
alkalin
phosphatas
unitsl
albumin
gdl
otherwis
normal
liver
function
test
normal
lactic
acid
urinalysi
wbchpf
rbchpf
moder
bacteria
presenc
wbc
clump
ct
scan
abdomen
pelvi
demonstr
obstruct
mm
right
renal
stone
hydronephrosi
right
renal
abscess
contigu
rightsid
hepat
abscess
measur
x
x
cm
treat
ceftriaxon
metronidazol
underw
imagingguid
drainag
abscess
abscess
cultur
grew
resist
e
coli
discharg
hospit
drain
place
plan
continu
trimethoprimsulfamethoxazol
definit
manag
nephrolithiasi
ureteroscopi
lithotripsi
discuss
remain
question
ostens
immunocompet
patient
develop
sever
intraabdomin
infect
littl
system
inflammatori
respons
eg
fever
mild
leukocytosi
hiv
antibodi
screen
neg
interview
describ
intent
weight
loss
preced
year
accomplish
dietari
restrict
less
calori
per
day
nutrit
assay
reveal
prealbumin
vitamin
c
vitamin
level
threshold
detect
lownorm
concern
acquir
immunodefici
result
malnutrit
micronutri
defici
balanc
nutrit
discuss
patient
agre
liber
diet
background
past
decad
brought
dozen
new
mendelian
disord
immun
yet
genet
contribut
divers
disord
immun
system
remain
larg
unelucid
major
research
particip
refer
nation
institut
allergi
infecti
diseas
niaid
may
mendelian
disord
evad
molecular
diagnosi
make
progress
area
requir
coordin
systemat
transpar
approach
clinic
genom
research
leverag
uniqu
environ
nation
institut
health
clinic
center
nih
cc
methodsdesign
studi
design
systemat
appli
exom
sequenc
relat
technolog
clinic
grade
interpret
report
niaid
research
particip
nih
cc
singl
protocol
order
facilit
research
clinic
genet
care
across
niaid
recruit
approxim
particip
per
year
approxim
intramur
clinic
investig
gener
genom
data
collect
standard
phenotyp
report
clinic
interpret
medic
record
provid
link
genet
counsel
result
date
consent
particip
sent
sampl
exom
sequenc
sampl
underw
copi
number
variant
analysi
complet
analysi
famili
individu
final
result
case
present
case
seri
illustr
find
case
femal
refer
niaid
neonat
onset
multisystem
inflammatori
diseas
nomid
development
delay
mild
intellectu
disabl
appreci
clinic
evalu
exom
sequenc
detect
mosaic
novel
like
pathogen
variant
chromosom
microarray
analysi
cma
show
mb
interstiti
delet
chromosom
previous
associ
development
delay
intellectu
disabl
case
ukrainian
male
refer
niaid
clinic
diagnosi
autoimmun
polyendocrinopathycandidiasisectoderm
dystrophi
apec
exom
sequenc
cma
detect
pathogen
variant
air
find
de
novo
variant
defect
associ
poikiloderma
tendon
contractur
myopathi
pulmonari
fibrosi
poiktmp
clinic
featur
patient
consist
poikmp
case
man
histori
brain
liver
kidney
nocardiosi
dissemin
mac
infect
prostat
cancer
lymphoma
famili
histori
signific
prostat
cancer
exom
sequenc
show
heterozyg
pathogen
variant
associ
suscept
breastovarian
male
breast
pancreat
prostat
cancer
conclus
case
seri
illustr
multipl
diagnos
unexpect
diagnos
secondari
genom
find
data
share
help
identifi
variant
candid
gene
process
standard
support
data
integr
effici
accommod
need
investig
flexibl
provid
tailor
patient
care
rational
activ
kinas
delta
syndrom
apd
primari
immunodefici
caus
domin
mutat
increas
activ
catalyt
subunit
mainli
express
cell
hematopoiet
system
primarili
lymphocyt
myeloid
cell
mutat
affect
band
tcell
sought
evalu
role
tcell
receptor
tcr
repertoir
immun
dysregul
pathogenesi
autoimmun
lymphoprolifer
patient
apd
method
evalu
tcr
repertoir
peripher
blood
patient
mutat
compar
peripher
tcr
repertoir
patient
common
variabl
immunodefici
cvid
healthi
control
investig
role
tcr
diseas
tcr
repertoir
affect
tissu
patient
mutat
also
evalu
tissu
includ
lymph
node
patient
addit
gastrointestin
tract
lung
tissu
one
patient
fix
number
tcr
subsampl
blood
tissu
divers
calcul
use
gini
shannon
index
result
use
shannon
gini
divers
index
tcr
repertoir
patient
mutat
less
divers
increas
clonal
compar
healthi
control
cvid
figur
two
apd
patient
biopsi
tissu
avail
analysi
divers
tcr
tissu
increas
compar
peripher
blood
tcr
repertoir
figur
conclus
play
import
role
develop
function
band
tcell
patient
apd
found
decreas
tcr
repertoir
divers
circul
tcell
compart
compar
healthi
control
cvid
patient
increas
tcr
divers
affect
tissu
compar
peripher
blood
implic
signal
pathway
tcell
traffick
tissu
immun
homeostasi
suggest
pathway
may
play
role
develop
inflammatori
lymphoprolif
complic
patient
gainoffunct
mutat
result
human
primari
immunodefici
name
apd
activ
syndrom
character
lymphopenia
lymphoprolifer
respiratori
infect
ineffici
respons
vaccin
howev
promot
immun
disturb
cellular
molecular
level
remain
unknown
recent
publish
mous
model
recapitul
major
featur
diseas
use
model
patient
sampl
probe
hyperact
foster
aberr
humor
immun
found
mutant
alter
intrins
function
b
cell
lead
icosindepend
increas
follicular
helper
tfh
germin
center
gc
b
cell
disorgan
gc
poor
classswitch
antigenspecif
respons
immun
phenotyp
associ
increas
phosphoryl
akt
b
cell
lower
threshold
activ
alter
regul
famili
member
moreov
b
cell
show
enhanc
respons
prolifer
antigen
innat
stimuli
accompani
reduc
cell
death
strikingli
aberr
respons
accompani
increas
reactiv
gut
bacteria
broad
increas
autoantibodi
depend
commens
microbi
stimul
demonstr
strike
reduct
selfreact
upon
antibiot
treatment
mutant
mice
examin
b
cell
function
mice
demonstr
alter
play
major
role
disrupt
b
cell
function
provid
evid
alter
activ
metabol
pathway
b
cell
compar
wt
cell
may
contribut
dysregul
b
cell
reactiv
find
suggest
proper
regul
critic
ensur
optim
hostprotect
humor
immun
despit
tonic
stimul
commens
microbiom
research
support
part
intramur
research
program
nih
nhgri
niaid
autoimmun
cytopenia
seen
signific
proport
patient
immunodefici
affect
antibodi
product
previou
bcell
matur
studi
use
fluorescenceactiv
cell
sort
fac
associ
variou
phenotyp
primari
immunodefici
diseas
affect
antibodi
product
differ
level
bcell
differenti
studi
analyz
peripher
bcell
compart
patient
hypogammaglobulinemia
bcell
without
histori
autoimmun
cytopenia
bcell
isol
peripher
blood
use
monoclon
cell
gate
identifi
proport
memori
b
cell
igm
memori
b
margin
zone
bcell
igm
igd
isotypeswitch
memori
bcell
transit
cell
pid
patient
histori
aic
decreas
proport
total
bcell
vs
igm
memori
b
cell
vs
p
convers
proport
margin
zone
bcell
increas
group
vs
p
consist
previou
report
proport
isotypeswitch
memori
bcell
significantli
lower
aic
group
vs
p
statist
signific
intergroup
differ
seen
within
transit
bcell
subset
data
suggest
matur
arrest
margin
zone
igd
bcell
may
implic
develop
autoimmun
cytopenia
humor
immunodefici
submiss
id
taissa
de
mato
kasahara
sudhir
gupta
md
phd
student
state
univers
rio
de
janeiro
univers
californi
irvin
professor
univers
california
irvin
irvin
ca
usa
introductionbackground
common
variabl
immunodefici
cvid
frequent
form
primari
hypogammaglobulinemia
decreas
serum
igg
iga
level
variabl
level
igm
adult
addit
decreas
serum
immunoglobulin
cvid
patient
present
autoimmun
manifest
mechan
lead
breakdown
selftoler
cvid
complet
understood
howev
differ
b
cell
subset
autoreact
b
cell
detect
elev
express
surfac
igd
downregul
igm
receptor
hallmark
anerg
b
cell
contain
autoreact
receptor
human
peripher
blood
moreov
memori
b
cell
class
switch
igd
present
igdigmphenotyp
also
highli
reactiv
selfantigen
healthi
individu
role
autoreact
memori
b
cell
immunopathogenesi
cvid
evalu
investig
frequenc
b
cell
express
igd
igm
peripher
blood
cvid
patient
method
peripher
blood
mononuclear
cell
pbmc
cvid
patient
health
subject
separ
ficollhypaqu
incub
antihuman
igmapc
identifi
differ
subset
b
cell
flow
cytometri
igm
b
cell
sort
load
cfse
cultur
cpg
day
evalu
prolifer
result
among
compart
cell
cvid
patient
show
increas
frequenc
igdigm
cell
lower
frequenc
igdigmcel
compar
control
group
differ
observ
frequenc
igdigmcel
cell
cvid
patient
control
contrast
compart
b
cell
cvid
patient
show
increas
frequenc
igdigm
igd
igm
igdigm
cell
lower
frequenc
igdigmcel
compar
health
subject
patient
divid
two
group
base
autoimmun
manifest
group
autoimmun
diseas
show
increas
frequenc
igdigm
igdigm
cell
cell
compar
control
group
patient
group
show
increas
frequenc
igdigm
igdigm
igdigm
cell
lower
frequenc
igdigmcel
compar
health
subject
regard
prolifer
b
cell
cvid
patient
show
reduc
prolif
capac
respons
vitro
stimul
compar
b
cell
health
subject
conclus
result
suggest
increas
cell
relat
suscept
autoimmun
cvid
patient
introduct
immunoglobulin
diseas
group
immunemedi
condit
tissu
affect
dens
lymphoplasmacyt
infiltr
predomin
plasma
cell
storiform
fibrosi
usual
set
elev
serum
concentr
common
present
includ
autoimmun
pancreat
scleros
cholang
retroperiton
fibrosi
salivari
gland
diseas
orbit
diseas
among
other
symptom
asthma
allergi
present
approxim
percent
patient
typic
exhibit
good
initi
therapeut
respons
glucocorticoid
case
present
femal
histori
gastroparesi
cutan
lupu
erythematosu
suspect
autoimmun
pancreat
refer
allergyimmunolog
clinic
evalu
elev
report
histori
recurr
abdomin
pain
attribut
recurr
pancreat
base
previou
mild
lipas
elev
prior
endoscop
ultrasound
eu
pancrea
reveal
edema
concern
gallston
pancreat
ercp
follow
cholecystectomi
biliari
pancreat
sphincterotomi
chang
symptom
note
posit
ana
high
serum
per
patient
valu
osh
record
could
obtain
symptom
improv
cours
steroid
henc
suspicion
autoimmun
pancreat
develop
rash
arm
face
biopsi
affect
area
reveal
cutan
lupu
erythematosu
arm
basal
cell
carcinoma
face
excis
ana
time
visit
complain
sever
allerg
rhiniti
joint
pain
well
malar
rash
respond
intermitt
cours
prednison
prior
provid
laboratori
obtain
initi
visit
signific
thrombocytopenia
thoucu
mm
posit
lupu
anticoagul
sec
elev
mgdl
normal
rang
mgdl
ana
antidoubl
strand
dna
antismith
antibodi
antiphospholipid
panel
upep
spep
unremark
ct
chest
abdomen
also
normal
given
patient
histori
cutan
lupu
erythematosu
plaquenil
start
steroid
spare
agent
eu
pancrea
possibl
biopsi
order
attempt
obtain
histopatholog
diagnosi
conclus
case
exhibit
associ
elev
pancreat
unknown
origin
allerg
rhiniti
cutan
lupu
erythematosu
highlight
valu
identifi
patholog
connect
seemingli
unrel
disord
patient
elev
may
manifest
order
make
diagnosi
histopatholog
find
showcas
lymphoplasmacyt
tissu
infiltr
consist
mainli
plasma
cell
small
lymphocyt
essenti
major
patient
respond
glucocorticoid
durat
respons
variabl
patient
flare
glucocorticoid
taper
note
patient
rituximab
shown
effect
patient
consid
patient
symptom
persist
submiss
id
rational
pnp
defici
autosom
recess
disord
due
defect
purin
metabol
lead
sever
combin
immunodefici
scid
neurolog
deterior
newborn
screen
util
tcell
receptor
excis
circl
trec
assay
detect
affect
patient
complic
aris
herein
describ
infant
initi
identifi
newborn
screen
pnp
defici
congenit
cmv
previous
unreport
present
method
cmv
quantit
pcr
qpcr
perform
nebraska
medicin
pnp
enzym
activ
duke
genet
sequenc
invita
result
small
gestat
age
sga
male
infant
report
abnorm
trec
assay
day
life
dol
hospit
evalu
initi
studi
reveal
profound
lymphopenia
normal
lymphocyt
prolifer
mitogen
evid
matern
engraft
addit
dol
cmv
viremia
viruria
thu
sga
fail
unilater
hear
screen
head
ultrasound
bilater
parenchym
calcif
congenit
cmv
suspect
pnp
enzym
activ
abnorm
cmv
treatment
initi
ganciclovir
dol
foscarnet
ad
dol
cmv
qpcr
level
decreas
limit
detect
dol
genet
test
found
pathogen
homozyg
mutat
pnp
infant
hlamatch
unaffect
cmv
posit
sibl
proceed
hematopoiet
stem
cell
transplant
conclus
knowledg
first
report
case
pnp
defici
identifi
newborn
screen
novel
case
congenit
cmv
pnp
defici
highlight
import
cmv
screen
need
treatment
strategi
congenit
cmv
scid
despit
dramat
increas
use
next
gener
sequenc
last
decad
major
million
identifi
human
genom
variant
wellestablish
clinic
implic
progress
made
complex
challeng
multipl
approach
includ
data
share
maxim
understand
genom
data
platform
enabl
effect
respons
datashar
essenti
mean
genotyp
phenotyp
data
must
findabl
access
interoper
reusabl
condit
ethic
transpar
highlight
innov
datashar
potenti
advanc
discoveri
present
three
datashar
mechan
platform
present
case
highlight
key
function
discuss
opportun
challeng
may
aris
platform
scale
genom
research
integr
system
gri
collaborationengend
web
applic
facilit
identif
genet
variant
associ
rare
immunolog
disord
user
access
integr
standard
phenotyp
genom
data
analyz
within
platform
gri
enabl
systemat
autom
captur
link
patient
data
disconnect
system
paperbas
record
standard
annot
allow
comparison
data
differ
clinic
studi
main
goal
tool
discover
affect
individu
enrol
separ
protocol
within
niaid
intramur
research
program
intern
databas
use
find
second
famili
rare
variant
candid
gene
genom
ascertain
cohort
tgac
resourc
aim
improv
understand
phenotyp
consequ
genet
variat
provid
access
aggreg
deidentifi
genom
data
larg
nih
intramur
relat
cohort
particip
provid
inform
consent
recontact
addit
phenotyp
futur
main
goal
tool
enabl
studi
clinic
consequ
variant
larg
unbias
cohort
patient
ascertain
mani
indic
databas
use
investig
find
particip
previous
publish
pathogen
variant
gene
associ
primari
immun
defici
base
medic
record
review
clingen
dedic
build
authorit
central
resourc
defin
clinic
relev
gene
variant
precis
medicin
research
share
genet
health
data
clingen
seek
answer
whether
given
gene
associ
diseas
clinic
valid
whether
given
variant
caus
pathogen
whether
inform
action
clinic
util
resourc
meant
conven
diseaseand
genespecif
expert
group
curat
medic
literatur
mendelian
diseas
better
defin
genediseas
variantdiseas
relationship
use
mani
line
evid
resourc
use
clarifi
clinic
valid
diseasegen
assert
togeth
effort
help
creat
clinic
research
ecosystem
maxim
valu
clinic
research
data
ultim
improv
patient
care
research
support
intramur
research
program
nih
niaid
introduct
accord
popul
refer
bureau
number
elderli
american
defin
age
older
project
doubl
million
million
rise
total
popul
impact
immunodefici
import
segment
popul
remain
understudi
method
usidnet
registri
queri
obtain
demograph
clinic
data
elderli
patient
defin
age
older
descript
analys
perform
data
result
particip
elig
total
registri
particip
median
age
cohort
year
predominantli
femal
white
median
bmi
major
subject
live
humor
defici
compris
major
diagnos
common
variabl
immun
defici
frequent
remain
nonhumor
diagnos
immun
dysregul
immunodefici
myelodysplasia
frequent
major
subject
report
receiv
immunoglobulin
replac
therapi
igrt
point
report
via
iv
rout
infect
occur
cohort
sinopulmonari
infect
commonli
report
specif
sinus
pneumonia
upper
respiratori
infect
otiti
media
cohort
autoimmun
cardiovascular
granulomat
complic
report
number
patient
malign
patient
diagnos
multipl
malign
disord
report
malign
major
solid
tumor
conclus
compar
agematch
nonimmunodefici
unit
state
popul
cohort
femal
usidnet
versu
us
popul
fewer
white
usidnet
vs
us
popul
humor
immunodefici
specif
cvid
common
diagnos
similar
age
group
immunodefici
patient
major
patient
receiv
igrt
approxim
half
via
iv
rout
cohort
report
live
varieti
noninfecti
complic
includ
autoimmun
malign
research
specif
focus
elderli
patient
immunodefici
need
clinic
microbiologist
infecti
diseas
physician
univers
calgari
xlink
agammaglobulinemia
xla
primari
immunodefici
caus
mutat
bruton
tyrosin
kinas
gene
lead
b
cell
matur
failur
defect
antibodi
product
put
patient
risk
recurr
sinopulmonari
infect
gastrointestin
infect
recurr
skin
infect
includ
infect
caus
helicobact
sp
helicobact
sp
gram
neg
bacilli
commonli
found
gastrointestin
tract
variou
anim
helicobact
sp
link
gastriti
notabl
helicobact
pylori
caus
gastric
ulcer
human
helicobact
sp
found
rare
case
caus
dissemin
infect
includ
pyoderm
gangrenosum
cellul
notabl
patient
agammaglobulinemia
infect
caus
helicobact
bili
challeng
diagnosi
due
difficulti
cultur
pathogen
well
poor
guidelin
antimicrobi
manag
case
report
patient
diagnos
xlink
agammaglobulinemia
age
month
histori
recurr
sinus
start
ivig
despit
regular
ivig
develop
bronchiectasi
year
age
develop
chronic
rash
around
left
knee
resembl
erythema
nodosum
develop
left
knee
effus
associ
left
side
calf
pain
knee
pain
found
improv
cours
ciprofloxacin
treat
recurr
lung
infect
given
case
report
data
h
pylori
caus
erythema
nodosum
patient
agammaglobulinemia
treat
empir
h
pylori
infect
improv
found
progress
cellul
pyomyos
left
leg
skin
biopsi
calf
nodul
found
cultur
neg
pcr
posit
h
bili
start
treatment
ertapenem
levofloxacin
subsequ
resolut
rash
left
ankl
pain
progress
late
found
possibl
osteomyel
left
ankl
mri
found
bacterem
h
bili
due
progress
symptom
signific
impact
function
rise
inflammatori
marker
despit
month
antimicrobi
treatment
doxycyclin
flagyl
ad
lead
clinic
improv
normal
inflammatori
marker
continu
oral
doxycyclin
flagyl
month
chronic
osteomyel
discuss
h
bili
slow
grow
pathogen
challeng
cultur
laboratori
often
requir
special
agar
plate
prolong
incub
patient
agammaglobulinemia
associ
chronic
skin
infect
erythema
nodosuma
h
bili
suspect
possibl
pathogen
due
challeng
cultur
pcr
amplif
ribosom
subunit
consid
tri
identifi
pathogen
poorli
delin
clinic
antimicrobi
breakpoint
help
guid
therapi
minim
evid
case
report
suggest
prolong
therapi
aminoglycosid
penicillin
studi
success
treat
patient
carbapenem
azithromycin
levofloxacin
absenc
sensit
data
prolong
treatment
consid
combin
antimicrobi
patient
follow
close
recurr
infect
uncommon
chief
human
immunolog
diseas
section
laboratori
clinic
immunolog
microbiolog
niaid
nih
bethesda
md
introduct
defici
combin
immunodefici
character
eczema
recurr
sinopulmonari
infect
viral
skin
infect
malign
earli
mortal
recent
year
liver
diseas
vasculopathi
increasingli
recogn
complic
defici
clinic
character
cohort
defici
patient
specif
focu
newli
identifi
area
diseas
involv
method
chart
review
perform
patient
seen
nih
genet
clinic
diagnosi
defici
patient
enrol
irb
approv
niaid
protocol
result
identifi
patient
famili
defici
nih
cohort
rang
age
year
famili
homozyg
mutat
patient
food
allergi
diagnos
eczema
asthma
chronic
recurr
viral
skin
infect
seen
chronic
ebv
viremia
pcr
posit
seen
patient
patient
known
ebv
immun
without
viremia
cmv
viremia
infrequ
sinopulmonari
infect
common
bronchiectasi
occur
avail
imag
liver
diseas
diagnos
biliari
tract
abnorm
imag
stool
posit
cryptosporidia
patient
cryptosporidia
without
diarrhea
incid
cryptosporidia
like
underrepres
due
recent
avail
sensit
assay
cryptosporidia
detect
liver
abnorm
includ
fatti
liver
metastat
diseas
malign
medic
relat
hepat
vasculopathi
predominantli
aorta
cerebr
arteri
diagnos
patient
last
year
prospect
imag
autoimmun
rare
includ
autoimmun
cytopenia
hypothyroid
followup
aliv
age
rang
year
live
patient
hsct
caus
death
includ
malign
infect
hsct
complic
longterm
followup
patient
hsct
year
reveal
resolut
infect
suscept
eczema
new
cancer
stabil
vasculopathi
conclus
addit
well
describ
manifest
defici
includ
eczema
allergi
recurr
sinopulmonari
infect
skin
viral
infect
malign
cohort
reveal
rel
high
incid
liver
diseas
frequent
associ
stool
posit
cryptosporidia
well
vasculopathi
clinic
manifest
consid
prepar
hsct
may
affect
manag
transplant
autoimmun
like
overestim
prior
descript
defici
longterm
followup
hsct
need
determin
prognosi
vasculopathi
liver
diseas
malign
risk
submiss
id
yasuhiro
yamazaki
stefano
volpi
luigi
notarangelo
introductionbackground
exostosin
like
glycosyltransferas
exostosin
famili
member
initi
heparan
sulfat
hs
chain
biosynthesi
elong
report
homozyg
hypomorph
mutat
caus
immunoosseousdysplasia
syndrom
fourteen
patient
homozyg
mutat
report
far
eight
manifest
cell
lymphopenia
present
sever
combin
immunodefici
scid
omenn
syndrom
use
patientderiv
induc
pluripot
stem
cell
ipsc
model
previous
report
mutat
affect
differenti
thymic
epitheli
progenitor
cell
well
expans
hematopoiet
progenitor
cell
consist
latter
previou
studi
suggest
mutat
gene
involv
hs
biosynthesi
affect
hematopoiet
stem
cell
hsc
differenti
howev
exact
mechan
mutat
affect
hematopoiesi
known
object
tri
clarifi
gene
express
differ
hsc
deriv
wildtyp
hypomorph
knockout
ko
human
ipsc
method
control
bj
ipsc
line
engin
gene
target
ko
ipsc
obtain
carri
compound
heterozyg
mutat
hsc
differenti
induc
use
stemdiff
hematopoiet
kit
stemcel
technolog
bulk
rna
ip
cell
differenti
analyz
rna
sequenc
result
compar
control
ipsc
patientderiv
cell
show
slightli
lower
capac
gener
cell
hand
ko
cell
show
differenti
cell
gene
set
enrich
analysi
show
enrich
express
gene
involv
hematopoiet
progenitor
cell
differenti
regul
hemopoiesi
posit
regul
hemopoiesi
control
patientderiv
cell
compar
parent
ipsc
moreov
gene
set
abundantli
enrich
control
patientderiv
cell
gene
set
respons
type
interferon
significantli
enrich
control
versu
patientderiv
cell
conclus
result
confirm
play
import
role
hsc
homeostasi
human
cell
type
interferon
play
role
hsc
prolifer
decreas
type
interferon
signatur
may
account
reduc
number
hsc
previous
report
upon
vitro
differenti
versu
controlderiv
ipsc
studi
support
divis
intramur
research
niaid
nih
protocol
case
autoinflammatori
syndrom
osteoporosi
specif
antibodi
defici
autoinflammatori
syndrom
inherit
disord
exagger
inflammatori
respons
specif
trigger
clinic
phenotyp
variant
autoinflammatori
syndrom
may
overlap
report
case
year
old
male
prior
diagnosi
specif
antibodi
defici
period
fever
aphthou
stomat
pharyng
cervic
aden
pfapa
syndrom
arthralgia
moder
atop
dermat
diagnos
year
age
specif
antibodi
defici
base
persist
low
pneumococc
titer
repeat
immun
due
recurr
infect
place
immunoglobulin
replac
therapi
igrt
year
age
igrt
discontinu
year
age
due
full
resolut
infect
patient
demonstr
robust
respons
immun
patient
lifelong
histori
recurr
fever
everi
week
associ
pharyng
aphthou
ulcer
consist
diagnosi
pfapa
becam
older
episod
becam
less
frequent
last
episod
fever
year
ago
father
similar
symptom
recurr
fever
oral
ulcer
child
current
remain
asymptomat
patern
grandfath
die
kidney
diseas
patient
gener
good
health
recent
year
intermitt
abdomin
pain
arthralgia
sever
long
bone
fractur
histori
prior
trauma
bone
densiti
scan
reveal
osteopenia
osteoporosi
z
score
lumbar
spine
left
femor
neck
left
hip
given
histori
famili
autoinflammatori
diseas
antibodi
defici
genet
test
obtain
identifi
pathogen
heterozyg
variant
taci
mefv
taci
mutat
link
antibodi
defici
syndrom
genet
studi
famili
member
pend
mefv
gene
associ
autosom
recess
famili
mediterranean
fever
fmf
report
autosom
domin
fmf
well
fmf
character
recurr
episod
fever
associ
seros
arthralgia
arthriti
patient
fmf
elev
acut
phase
reactant
attack
return
normal
level
episodefre
period
multipl
studi
shown
patient
fmf
lower
bone
miner
densiti
zscore
gener
popul
inflamm
fmf
thought
mediat
sever
differ
cytokin
tnf
cytokin
play
role
osteoclast
activ
bone
resorpt
suggest
chronic
inflamm
acut
attack
subclin
inflamm
diseasefre
period
lead
bone
loss
osteoporosi
regular
use
colchicin
main
treatment
fmf
may
slow
osteoporosi
besid
care
monitor
clinic
laboratori
phenotyp
genet
evalu
import
step
distinguish
overlap
entiti
prevent
complic
promot
target
intervent
year
old
previous
healthi
boy
refer
period
fever
pfapa
mosquito
bite
hypersensit
eight
week
earlier
develop
fever
mouth
sore
exud
tonsil
rapid
strep
screen
neg
one
week
later
develop
moder
cervic
lymphadenopathi
posit
ebv
earli
antigen
antibodi
one
month
later
sever
sever
local
reaction
mosquito
bite
manifest
cm
erythema
indur
cm
bulla
left
ulcer
ruptur
heal
hypopig
scar
bite
accompani
fever
day
one
febril
episod
treat
low
dose
prednisolon
presum
pfapa
fever
resolv
within
hour
past
histori
posit
nasal
allergi
mild
asthma
parent
relat
mom
europeanindonesian
dad
europeanafrican
creol
ancestri
test
prior
visit
show
normal
igg
iga
igm
elev
ige
ul
normal
cbc
lymphocyt
subset
reveal
mcl
nk
cell
examin
appear
well
height
ile
weight
ile
lymphadenopathi
hepatosplenomegali
inflam
skin
lesion
round
scar
right
plantar
surfac
site
prior
mosquito
bite
laboratori
studi
confirm
nk
lymphocytosi
elev
ige
ul
lymphoprolifer
mitogen
cmvand
hsv
normal
absent
tetanu
candida
antigen
ebv
antibodi
reflect
past
infect
vcaigg
vcaigm
ebna
quantit
ebv
pcr
copiesml
whole
blood
nk
cytotox
express
decreas
bone
marrow
nk
analysi
suggest
conal
patient
diagnos
hypersensit
mosquito
bite
ebvassoci
nk
lymphoprolifer
disord
repres
subset
chronic
activ
ebv
caebv
rare
seen
outsid
east
asia
lack
organomegali
lymphadenopathi
hyperig
nk
lymphocytosi
decreas
nk
function
support
likelihood
nk
cell
target
ebv
infect
patient
diagnosi
may
precursor
hemophagocytosi
liver
necrosi
lymphomaleukemia
cur
treatment
bone
marrow
transplant
patient
sister
hla
match
seroposit
past
ebv
infect
histori
extrem
reaction
mosquito
bite
genet
mutat
caus
famili
hemophagocyt
lymphohistiocytosi
report
caebv
best
knowledg
famili
case
disord
identifi
respons
bmt
patient
pend
introductionbackground
number
case
report
describ
symptomat
hypogammaglobulinemia
follow
administr
antiepilept
drug
a
specif
lamotrigin
carbamazepin
levetiracetam
mechan
symptomat
hypogammaglobulinemia
develop
unclear
evalu
preval
clinic
signific
hypogammaglobulinemia
associ
use
a
object
aim
character
preval
aedinduc
hypogammaglobulinemia
identifi
specif
a
associ
hypogammaglobulinemia
character
timelin
develop
hypogammaglobulinemia
initi
therapi
method
retrospect
multicent
electron
medic
record
review
span
year
identifi
patient
hypogammaglobulinemia
a
therapi
lamotrigin
carbamazepin
levetiracetam
patient
exclud
preexist
primari
immunodefici
pid
malign
proteinlos
enteropathi
signific
proteinuria
patient
chronic
immunosuppress
therapi
without
laboratori
criteria
hypogammaglobulinemia
one
a
less
one
month
also
exclud
result
case
review
patient
met
inclus
criteria
median
age
adult
femal
white
lamotrigin
implic
case
carbamazepin
levetiracetam
tetanu
pneumococc
titer
avail
patient
patient
protect
titer
per
report
respons
serotyp
one
patient
report
sever
recurr
infect
remain
four
littl
symptom
interestingli
patient
sever
infect
protect
titer
five
laboratori
proven
hypogammaglobulinemia
patient
one
die
infect
two
continu
medic
due
refractori
seizur
respons
medic
two
current
taper
a
conclus
appear
aedinduc
hypogammaglobulinemia
quit
rare
consid
patient
without
secondari
caus
hypogammaglobulinemia
a
therapi
mani
antiepilept
downregul
nfkb
signal
suggest
patient
develop
symptomat
hypogammaglobulinemia
may
hypomorph
mutat
nfkb
signal
pathway
submiss
id
autoimmun
lymphoprolif
syndrom
alp
result
defect
apoptosi
lymphocyt
mediat
fasfa
ligand
fasl
pathway
hallmark
lab
find
expans
cell
express
alphabeta
cell
receptor
lack
doubl
neg
cell
set
normal
elev
lymphocyt
count
patient
present
chronic
nonmalign
noninfecti
lymphadenopathi
splenomegali
definit
diagnosi
patient
need
pathogen
mutat
fa
fa
ligand
caspas
defect
fasinduc
lymphocyt
apoptosi
describ
probabl
case
alp
heterozyg
mutat
fa
g
variant
previous
report
lymphocyt
apoptosi
assay
pend
uniqu
case
patient
castleman
diseaselik
featur
patholog
yearold
male
refer
hematolog
clinic
present
year
histori
chronic
lymphadenopathi
splenomegali
anemia
underli
diagnosi
malign
previous
exclud
bone
marrow
aspir
biopsi
year
prior
howev
right
side
lymph
node
increas
size
past
month
otherwis
asymptomat
lymph
node
biopsi
year
prior
reportedli
normal
exam
demonstr
signific
bilater
lymphadenopathi
greater
right
approxim
x
cm
mobil
right
neck
mass
splenomegali
palpat
cm
across
midlin
therefor
admit
excision
lymph
node
biopsi
evalu
possibl
malign
lab
sent
evalu
alp
lab
support
alp
elev
cell
receptor
alpha
beta
doubl
neg
cell
tcr
ab
dntc
blood
level
elev
pgml
plasma
solubl
fasl
level
elev
pgml
level
elev
pgml
respect
multilineag
cytopenia
anemia
hgb
gdl
neutropenia
absolut
neutrophil
count
kul
hypergammaglobulinemia
igg
level
mgdl
broad
infecti
workup
neg
includ
hiv
quantiferon
cocci
bartonella
toxoplasma
coxiella
burnetii
ebv
pcr
cmv
igm
lymph
node
biopsi
show
evid
malign
immunostain
flow
cytometri
show
presenc
expand
tcr
ab
dntc
lymph
node
consist
alp
interestingli
lymph
node
histolog
show
morpholog
featur
typic
plasma
cell
variant
castleman
diseas
numer
castlemanlik
follicl
show
typic
regress
chang
onionskin
morpholog
paracort
hyperplasia
sheet
plasma
cell
note
neg
stain
wellknown
caus
plasma
cell
variant
castleman
diseas
diagnosi
idiopath
multicentr
castleman
diseas
exclud
definit
set
alp
per
evidencebas
consensu
criteria
publish
addit
patient
show
symptom
typic
associ
fever
night
sweat
weight
loss
weak
fatigu
fasinduc
lymphocyt
apoptosi
defect
separ
assay
would
confirm
alpsfa
diagnosi
would
start
patient
sirolimu
head
immunolog
unit
children
hospit
ricardo
gutierrez
introduct
gene
encod
protocoupl
folat
transport
pcft
support
intestin
folat
uptak
particip
folat
transport
central
nervou
system
mutat
caus
pcft
defect
result
low
folat
level
serum
cerebrospin
fluid
hereditari
folat
malabsorpt
hfm
rare
autosom
recess
disord
pcft
defici
result
cerebr
folat
defici
patient
present
megaloblast
anaemia
moder
pancytopenia
first
month
life
failur
thrive
diarrhoea
andor
later
onset
neurolog
symptom
includ
seizur
development
delay
u
n
e
f
c
e
n
c
n
h
f
c
n
n
f
e
e
l
f
w
h
hypogammaglobulinemia
normal
tcell
function
bcell
precursor
compart
seem
particularli
vulner
folat
defici
hfm
patient
immunodefici
restor
specif
treatment
folic
acid
aim
describ
femal
patient
homozyg
patholog
variat
gene
result
month
old
girl
born
nonconsanguin
parent
start
month
old
diarrhoea
due
rotaviru
low
weight
bicytopenia
normal
bone
marrow
aspir
present
low
level
folic
acid
nv
ngml
first
thought
due
secondari
malnutrit
treatment
folic
acid
supplement
administr
improv
platelet
count
month
old
present
steatorrhea
sever
perian
pannicul
requir
surgic
treatment
germ
rescu
skin
biopsi
moreov
suffer
respiratori
infect
due
picornaviru
two
episod
pneumothorax
requir
intens
care
moment
ivig
treatment
administ
due
hypogammaglobulinemia
clinic
sever
chronic
diarrhoea
worsen
bloodi
deposit
three
rectal
ulcer
found
gut
biopsi
bowel
inflammatori
diseas
suspect
mesalazin
administr
start
weight
improv
furthermor
month
old
present
statu
epilepticu
patholog
eeg
normal
mri
one
relat
cmv
infect
success
treat
immunolog
evalu
igg
iga
low
normal
igm
igd
proteinantibodi
respons
evalu
present
normal
lymphocyt
cell
extend
popul
cell
prolifer
assay
dhr
treg
cell
complement
express
alphafetoprotein
without
autoantibodi
molecular
panel
test
done
ng
homozyg
variant
gene
found
caus
impair
intestin
folat
absorpt
conclus
hfm
consid
diagnosi
patient
cytopenia
hypogammaglobulinemia
order
provid
specif
treatment
hfm
wide
clinic
manifest
megaloblast
anaemia
neurolog
impair
also
gastrointestin
skin
manifest
folat
treatment
clinic
immunolog
defect
normal
introduct
multifoc
epitheli
hyperplasia
meh
heck
diseas
rare
benign
infect
mucosa
caus
human
papilloma
viru
hpv
clinic
meh
manifest
numer
painless
soft
sessil
papul
plaqu
typic
occur
labial
lingual
buccal
mucosa
meh
lesion
usual
associ
hpv
type
seen
commonli
patient
caribbean
centralsouth
american
descent
prior
studi
adult
shown
tumor
necrosi
factor
alpha
tnf
promot
hpv
may
influenc
durat
hpv
infect
case
present
fiveyearold
full
term
male
haitian
descent
refer
assess
multipl
flesh
color
papular
lesion
buccal
labial
mucosa
persist
quantit
increas
one
year
although
lesion
regress
pain
difficulti
eat
medic
histori
signific
one
seizur
neg
infect
famili
histori
infect
immunodefici
consanguin
miscarriag
head
neck
examin
fail
reveal
cervic
lymphadenopathi
mass
hypertrophi
salivari
gland
intraor
examin
reveal
multipl
papular
nodul
mostli
flat
although
corrug
greatest
concentr
note
lower
left
labial
surfac
extend
mucos
vermillion
interfac
involv
vermillion
commissur
region
lesion
extend
mandibular
vestibul
left
buccal
mucosa
lesion
note
extrem
genitalia
visual
mucos
surfac
base
histori
exam
diagnos
meh
white
blood
cell
count
neutrophil
lymphocyt
cell
b
cell
nk
cell
enumer
immunoglobulin
panel
normal
age
tetanu
streptococcu
pneumonia
titer
protect
cytomegaloviru
igg
igm
neg
epsteinbarr
viru
igg
posit
igm
earli
antigen
ab
neg
serolog
signific
elev
tnf
pgml
refer
rang
interferon
gamma
interleukin
normal
receptor
one
month
initi
visit
lesion
stabl
unchang
nineval
hpv
vaccin
consid
administ
conclus
meh
rare
benign
diseas
caus
hpv
awar
diseas
cours
import
prevent
unnecessari
expand
immunodefici
workup
possibl
procedur
elimin
lesion
although
mucos
immun
site
specif
especi
hpv
understand
tcell
cytokin
chemokin
respons
hpv
cervic
laryng
lesion
may
instruct
mechan
allow
hpv
persist
meh
character
like
due
increas
viral
persist
inabl
host
immun
respons
success
induc
viral
latenc
success
contain
elev
tnf
level
normal
level
may
correl
decreas
clearanc
hpv
prolong
durat
meh
remain
unclear
viral
persist
caus
sequela
increas
tnf
longitudin
monitor
cytokin
tnf
chemokin
serum
concentr
may
use
biomark
diseas
resolut
introduct
autosom
domin
hyper
ige
job
syndrom
rare
primari
immunodefici
character
eczema
sinopulmonari
infect
well
musculoskelet
vascular
complic
chronic
ill
patient
educ
ongo
need
rare
diseas
popul
patient
educ
especi
import
patient
must
abl
explain
uniqu
healthcar
concern
varieti
medic
set
focus
adhi
due
rel
larg
cohort
patient
frequent
lack
classic
sign
ill
often
impair
diagnosi
sever
infect
divers
nonimmunolog
clinic
featur
diseas
object
aim
increas
understand
clinic
manifest
adhi
promot
earlier
recognit
symptom
increas
selfefficaci
symptom
manag
adult
hie
popul
method
adult
patient
ask
particip
patient
educ
project
demograph
inform
collect
particip
also
complet
multipl
choic
test
symptom
recognit
adhi
promi
selfefficaci
manag
symptom
valid
survey
patient
educ
handout
focus
pulmonari
symptom
eczema
bone
health
cardiovascular
complic
review
particip
six
week
later
particip
ask
repeat
test
selfefficaci
survey
demograph
inform
test
selfefficaci
collect
anonym
result
particip
provid
demograph
inform
complet
test
selfefficaci
survey
particip
male
femal
particip
rang
age
year
report
look
inform
adhi
use
search
engin
patient
report
given
inform
adhi
doctor
particip
identifi
pulmonari
symptom
symptom
concern
particip
identifi
one
symptom
concern
particip
return
second
test
second
survey
mean
test
score
increas
particip
achiev
score
higher
selfefficaci
score
unchang
mean
score
review
patient
educ
handout
conclus
particip
feedback
project
gener
posit
adhi
patient
seek
inform
educ
intervent
improv
understand
diseas
selfefficaci
result
mix
unchang
overal
suggest
adhi
patient
manag
symptom
well
patient
chronic
ill
patient
educ
continu
encount
project
expand
includ
topic
pediatr
patient
rare
diseas
popul
fund
nci
contract
introduct
play
import
role
develop
mainten
immun
system
central
nervou
system
express
repress
nk
myeloid
factor
induc
cell
lineag
gene
thymocyt
stage
condit
loss
express
murin
thymocyt
lead
cell
defici
complet
knockout
fatal
within
day
birth
recent
specif
heterozyg
mutat
report
individu
global
develop
delay
howev
case
carri
heterozyg
missens
variant
low
trec
valu
case
frequent
infect
littl
known
regard
impact
human
nk
cell
function
method
identifi
novel
heterozyg
truncat
mutat
infant
first
detect
trec
newborn
screen
subsequ
develop
sever
autoimmun
hemolyt
anemia
age
month
use
standard
immunoblot
flow
cytometri
method
assess
protein
express
impact
mutant
cell
nk
cell
develop
function
result
patient
novel
singl
basepair
delet
gene
predict
produc
truncat
protein
loss
zinc
finger
domain
immunoblot
cell
blast
lysat
reveal
reduc
express
patient
consist
heterozyg
defect
also
gener
novel
band
smaller
molecular
weight
postul
repres
truncat
protein
product
mitogen
respons
cona
pha
normal
cell
count
decreas
especi
cell
suggest
reduc
thymic
output
function
cell
skew
reduc
product
increas
ifn
level
pma
ionomycin
stimul
moreov
regulatori
cell
count
normal
rang
nk
cell
count
normal
mostli
nk
cell
nk
cell
present
approxim
half
express
fc
receptor
adcc
perforin
present
express
nk
cell
stimul
understand
led
low
defect
nk
cell
degranul
function
stimul
cell
normal
control
nk
cell
count
conclus
report
novel
truncat
mutat
leaki
scid
phenotyp
manifest
tcell
lymphopenia
autoimmun
lower
thymicderiv
regulatori
cell
skew
cytokin
respons
incomplet
nk
cell
develop
suggest
import
develop
differenti
multipl
lymphocyt
lineag
introduct
chronic
diarrhea
one
common
gastrointestin
complaint
patient
common
variabl
immun
defici
cvid
lead
lifethreaten
complic
malabsorpt
malnutrit
chronic
diarrhea
cvid
could
caus
infect
inflammatori
bowel
diseaselik
pictur
well
malign
giardia
lamblia
one
common
parasit
caus
diarrhea
cvid
refractori
patient
lead
villou
atrophi
weight
loss
failur
thrive
case
report
femal
histori
cvid
present
chronic
diarrhea
signific
weight
loss
cvid
diagnos
hypogammaglobulinemia
low
level
igg
igm
iga
inadequ
respons
protein
polysaccharidebas
vaccin
decreas
memori
b
cell
recurr
sinopulmonari
infect
start
immun
globulin
replac
therapi
signific
improv
rate
infect
four
year
present
center
develop
chronic
sever
diarrhea
work
reveal
giardia
lamblia
infect
endoscopi
colonoscopi
biopsi
show
intraepitheli
lymphocyt
villou
blunt
atroph
gastriti
rare
plasma
cell
concern
noninfecti
enteropathi
relat
cvid
addit
high
burden
giardia
organ
initi
treat
metronidazol
sever
week
howev
diarrhea
improv
develop
signific
peripher
neuropathi
lead
lower
extrem
weak
limit
mobil
diarrhea
persist
associ
approxim
weight
loss
repeat
endoscopi
colonoscopi
two
year
later
show
persist
high
burden
giardiasi
small
intestin
well
reactiv
lymphocyt
infiltr
atroph
gastriti
treat
nitazoxanid
continu
diarrhea
stool
continu
show
trophozoit
given
signific
inflamm
lack
respons
multipl
antiparasit
agent
refer
center
evalu
start
oral
budesonid
mg
daili
oral
immun
globulin
gram
weekli
week
regimen
signific
improv
diarrhea
weight
gain
repeat
colonoscopi
show
consider
improv
inflamm
resolut
giardia
infect
though
stool
antigen
continu
posit
conclus
persist
diarrhea
patient
like
due
combin
cvid
enteropathi
giardiasi
prolong
cours
metronidazol
later
nitazoxanid
control
diarrhea
led
signific
side
effect
switch
immunomodulatori
approach
significantli
decreas
inflamm
bowel
may
even
help
reduc
burden
giardia
gut
target
underli
bowel
inflamm
well
activ
infect
cvid
patient
chronic
diarrhea
might
need
control
symptom
introduct
lipid
chemoattract
critic
lymphocyt
egress
lymphoid
organ
follow
concentr
gradient
maintain
lyas
ubiquit
express
tissu
lymphocyt
within
lymphoid
organ
drawn
effer
lymph
blood
unless
receptor
intern
downregul
owe
diminish
degrad
also
sphingoid
base
deleteri
mutat
encod
lyas
perturb
sphingolipid
catabol
numer
tissu
correspondingli
human
lyas
defici
result
multiorgan
dysfunct
includ
kidney
skin
endocrin
gland
neurolog
impair
alongsid
expect
lymphopenia
although
sever
cell
lymphopenia
cellsmicrolit
rival
sever
combin
immunodefici
scid
seen
patient
lyas
defici
patient
identifi
newborn
screen
cell
receptor
excis
circl
trec
count
surrog
measur
effect
cell
product
herein
describ
infant
boy
undetect
trec
count
birth
found
two
novel
biallel
mutat
result
lyas
defici
case
descript
boy
preced
histori
fetal
hydrop
born
gestat
age
week
present
renal
failur
anasarca
respiratori
failur
trec
analysi
dri
blood
spot
obtain
hour
life
reveal
zero
copiesmicrolit
subsequ
peripher
blood
studi
show
profound
lymphopenia
diminish
b
natur
killer
cell
count
recent
thymic
emigr
reduc
cell
ratio
cell
expedit
whole
genom
sequenc
identifi
two
novel
variant
patern
inherit
splice
site
variant
c
predict
impact
canon
splice
donor
site
matern
inherit
missens
chang
locat
wellestablish
function
domain
addit
nephrot
syndrom
lymphopenia
patient
display
evid
adren
insuffici
increas
plasma
level
sphingoid
base
ceramid
analys
could
pursu
infant
die
day
age
due
ongo
complic
renal
failur
eventu
cardiorespiratori
failur
summari
report
first
case
lyas
defici
identifi
newborn
trec
screen
scid
includ
commerciallyavail
scidtailor
gene
panel
lyas
defici
would
miss
convent
genet
test
therefor
analysi
variant
consid
neonat
lowtoundetect
trec
count
nephrot
syndrom
suggest
sequela
w
r
hypogammaglobulinemia
recurr
infect
myelokathexi
rare
autosom
domin
primari
immunodefici
caus
defect
gene
encod
chemokin
receptor
receptor
along
associ
ligand
regul
leukocyt
migrat
present
case
femal
present
selfidentifi
signatur
sign
whim
syndrom
multipl
famili
member
object
present
case
femal
present
histori
recurr
wart
leukopenia
unknown
caus
recurr
infect
child
child
experienc
multipl
ear
sinu
infect
along
recurr
wart
upper
lower
extrem
persist
day
furthermor
routin
examin
complet
blood
count
drawn
signific
leukopenia
workup
undertaken
time
continu
leukopenia
note
age
referr
hematologist
bone
marrow
biopsi
complet
bone
marrow
signific
myelokathexi
borderlin
hypercellular
marrow
patient
age
cellular
normal
cell
line
quantiti
trial
neupoegen
undertaken
without
signific
improv
famili
histori
signific
father
brother
leukopenia
recurr
wart
result
genet
analysi
show
heterozyg
pathogen
variant
gene
fs
recent
complet
blood
count
signific
total
wbc
count
kul
differenti
consist
neutrophil
lymphocyt
lymphocyt
subset
signific
quantit
low
subset
normal
number
nk
cell
immunoglobulin
level
reveal
igg
mgdl
iga
mg
dl
igm
mgdl
igg
antidiphtheria
tetanu
titer
protect
howev
none
pneumonia
serotyp
titer
ugml
mitogen
pha
cona
pwm
antigen
candida
tetanu
stimul
lymphocyt
normal
stimuli
conclus
present
case
femal
histori
recurr
infect
wart
myelokathexi
genet
analysi
note
pathogen
mutat
gene
substitut
phenylalanin
serin
decreas
one
seven
serin
phosphoryl
site
carboxi
tail
molecul
occur
upon
bind
ligand
addit
variat
gener
prematur
stop
condon
termin
remaind
carboxi
termin
amino
acid
includ
known
role
carboxi
termini
betaarrestin
bind
failur
gener
adequ
betaarrestin
bind
site
lead
prolong
interact
result
myelokathexi
background
lack
protect
antibodi
patient
primari
antibodi
defici
pad
suffer
frequent
respiratori
infect
lead
chronic
pulmonari
damag
macrolid
prophylaxi
proven
effect
success
manag
chronic
lung
diseas
cystic
fibrosi
bronchiectasi
copd
conduct
trial
evalu
efficaci
safeti
oral
lowdos
azithromycin
prophylaxi
ad
usual
care
pad
patient
method
phase
ii
prospect
multicent
random
doubleblind
placebocontrol
trial
pad
patient
age
year
chronic
infectionrel
pulmonari
diseas
patient
receiv
azithromycin
mg
placebo
daili
threetim
week
month
primari
outcom
decreas
annual
episod
respiratori
exacerb
secondari
endpoint
includ
time
first
exacerb
number
hospit
addit
dose
antibiot
health
relat
qualiti
life
measur
safeti
result
fortyfour
patient
receiv
azithromycin
patient
receiv
placebo
mean
number
exacerb
per
patientyear
ci
azithromycin
arm
ci
placebo
arm
azithromycin
group
hr
acut
exacerb
ci
hr
hospit
ci
rate
addit
antibiot
treatment
per
patientyear
ci
intervent
ci
placebo
group
improv
hrqofl
observ
intervent
group
azithromycin
safeti
prole
compar
placebo
conclus
pad
respiratori
exacerb
azithromycin
prophylaxi
led
reduct
exacerb
episod
addit
cours
antibiot
risk
hospit
given
deleteri
effect
respiratori
diseas
ad
azithromycin
pad
treatment
consid
valuabl
option
background
autosomaldomin
hyperig
syndrom
hie
primari
immunodefici
caus
mutat
signal
transduc
activ
transcript
lead
defect
immun
advers
reaction
follow
pneumococc
polysaccharid
vaccin
report
patient
includ
sever
local
reaction
appear
specif
vaccin
case
report
present
case
sixyearold
girl
second
child
nonconsanguin
healthi
parent
develop
extens
inflammatori
skin
reaction
vaccin
site
follow
singl
dose
vaccin
prescrib
due
histori
recurr
respiratori
tract
infect
incomplet
vaccin
calendar
previous
administ
pneumococc
vaccin
reaction
began
hour
local
erythema
edema
vaccin
site
expand
hour
phlyctenular
lesion
welldefin
border
within
first
week
progress
evolv
deep
necrot
lesion
requir
surgic
debrid
subsequ
skin
defect
requir
surgic
repair
splitthick
skin
graft
right
thigh
donor
site
complet
wound
heal
process
took
month
leav
larg
scar
figur
patient
longstand
histori
recurr
infect
multipl
hospit
includ
sever
neonat
pneumonia
requir
respiratori
support
colon
perfor
secondari
periton
septic
shock
requir
hemicolectomi
month
age
recurr
oral
candidiasi
recurr
pneumonia
differ
lobe
recurr
acut
otiti
media
cervic
phlegmon
three
episod
dental
abscess
multipl
kidney
abscess
due
gramneg
bacteria
treat
intraven
antibiot
surgic
drainag
famili
histori
notabl
older
sibl
die
due
sudden
infant
death
syndrom
patient
mother
larg
wide
nose
suggest
phenotyp
histori
infect
immunolog
work
show
mild
eosinophilia
cell
elev
ige
mgdl
normal
igg
iga
igm
lymphocyt
subset
peripher
cell
markedli
decreas
vs
normal
control
specif
pneumococc
antibodi
evalu
month
reveal
serotyp
protect
level
high
resolut
thorax
ct
show
multilobar
bronchiectasi
echocardiogram
total
spine
xray
normal
suspect
nation
institut
health
score
novel
heterozyg
missens
variant
affect
src
homolog
domain
found
nextgener
panel
sequenc
variant
posit
previous
report
hie
patient
clinvar
current
monthli
ivig
prophylact
antibiot
cotrimoxazol
azithromycin
fluconazol
conclus
case
present
rais
awar
risk
sever
local
advers
reaction
patient
etiolog
reaction
unclear
warrant
studi
benefit
risk
immun
patient
weigh
care
medic
provid
abstract
max
word
introduct
defici
rare
primari
immunodefici
character
suscept
viral
infect
atop
eczema
defect
tcell
activ
differenti
impair
eosinophil
homeostasi
dysregul
ige
date
report
case
malaysia
object
aim
describ
clinic
immunolog
profil
mutat
analysi
three
sibl
consanguin
parent
present
hyperig
lymphopenia
year
solv
mutat
analysi
second
third
sibl
method
clinic
data
investig
result
collat
medic
record
score
symptom
physic
examin
find
use
nih
score
perform
b
nk
lymphocyt
subset
serum
igg
iga
igm
total
ige
quantif
lymphocyt
prolifer
test
pneumococc
specif
antibodi
respons
perform
mutat
analys
perform
freiburg
germani
result
three
sibl
present
differ
time
point
span
rais
ige
level
recurr
infect
eczema
hypereosinophilia
bronchiectasi
nih
score
hyperig
syndrom
hie
rang
also
document
two
seriou
infect
sibl
dissemin
cryptococcu
neoforman
salmonella
sp
immunolog
result
show
tcell
lymphopenia
defect
tcell
prolifer
decreas
igm
rais
ige
hypereosinophilia
defect
pneumococc
antibodi
respons
present
sibl
identifi
larg
delet
start
exon
sibl
mutat
analysi
perform
proceed
next
gener
sequenc
protein
assay
malaysia
character
defect
conclus
ongo
studi
first
descript
famili
malaysia
diagnosi
suspect
case
rais
ige
level
recurr
infect
lymphopenia
despit
wart
infect
histori
studi
emphas
import
intern
research
collabor
network
solv
complic
case
index
patient
present
age
year
increas
suscept
lower
airway
gastrointestin
infect
hospit
admiss
puberti
suffer
mump
varicella
diseas
despit
immun
well
recurr
local
partial
destruct
hsv
infect
diagnos
common
variabl
immunodefici
cvid
age
start
immunoglobulin
replac
therapi
follow
hypoglycem
seizur
age
patient
diagnos
isol
acth
insuffici
secondari
adren
insuffici
requir
hormon
substitut
follow
first
pregnanc
age
suffer
recurr
bronchopneumonia
includ
pneumocysti
jirovecii
infect
result
bronchiectas
document
chest
ct
age
current
chronic
lung
diseas
sever
limit
qualiti
life
tabl
daughter
notic
hypogammaglobulinem
soon
birth
fail
develop
antibodi
respons
inactiv
vaccin
start
immunoglobulin
replac
therapi
suffer
sever
lower
airway
infect
develop
alopecia
totali
age
nail
dystrophi
w
h
l
e
e
x
e
e
q
u
e
n
c
n
g
r
e
v
e
l
e
h
e
e
r
z
g
u
mutat
exon
mother
daughter
monoallel
lossof
function
frameshift
mutat
found
gnomad
gv
washington
clinvar
databas
previous
publish
monoallel
mutat
ctermin
domain
lead
impair
phosphoryl
subsequ
reduc
nuclear
transloc
activ
form
pediatrician
intern
specialist
need
awar
combin
hypogammaglobulinemia
acth
defici
immun
dysregul
ectoderm
dysplasia
unusu
cvid
possibl
indic
defici
clinic
syndrom
may
overlap
symptom
sign
found
apec
air
ar
edaidnfkbia
ad
defici
besid
ig
hormon
replac
therapi
cur
treatment
hematopoiet
stem
cell
transplant
therapeut
option
patient
defici
although
experi
limit
tabl
introduct
mode
immunoglobulin
ig
administr
primari
immunodefici
diseas
pidd
differ
pharmacokinet
infus
paramet
toler
consecut
clinic
studi
cohort
patient
pidd
experienc
mode
administr
ig
product
sequenc
intraven
iv
subcutan
sc
hyaluronidasefacilit
sc
ighi
provid
uniqu
opportun
assess
administr
modal
within
patient
cohort
treat
observ
site
report
rate
infect
stratifi
igg
trough
level
rate
advers
event
ae
mode
ig
administr
ivig
scig
ighi
within
patient
cohort
design
method
analysi
includ
patient
pidd
age
year
particip
clinic
studi
studi
patient
receiv
ivig
everi
week
follow
weekli
scig
studi
patient
treat
ighi
everi
week
studi
extens
studi
patient
continu
ighi
dose
assess
potenti
associ
administr
rout
compar
igg
trough
level
infect
rate
igg
trough
level
categor
dl
mgdl
mgdl
mgdl
period
patient
trough
level
within
strata
assess
infect
frequenc
calcul
time
period
analysi
month
ivig
month
ighi
scig
year
treatment
order
account
differ
frequenc
administr
rate
system
local
ae
assess
aespatientyear
mode
therapi
result
igg
trough
level
mgdl
associ
annual
infect
rate
lower
similar
ighi
scig
treatment
involv
control
infect
immun
dysregul
chemotherapeut
regimen
follow
definit
treatment
hematopoiet
stem
cell
transplant
hsct
aim
describ
femal
patient
pathogen
variat
normal
express
result
year
old
femal
daughter
nonconsanguin
parent
without
relev
person
famili
record
admit
due
prolong
febril
syndrom
lymphoprolifer
pancytopenia
hepat
rescu
bone
marrow
blood
gancyclovir
treatment
start
good
respons
admit
one
month
later
similar
clinic
symptom
relaps
infect
furthermor
hemophagocytosi
found
bone
marrow
evalu
nk
cell
cytotox
demonstr
slightli
reduc
cytotox
activ
function
studi
primari
fhl
perform
perforin
express
surfac
express
normal
fulfil
criteria
fhl
treatment
gancyclovir
steroid
administ
despit
treatment
persist
activ
macrophag
paramet
start
treatment
protocol
improv
clinic
symptom
laboratori
paramet
persist
low
viremia
three
month
later
immunosupress
decreas
readmit
similar
clinic
manifest
ad
neurolog
symptom
facial
paralysi
abnorm
movement
sleep
tendenc
cerebr
spinal
fluid
patholog
posit
rescu
immunosupres
treatment
adjust
copi
blood
increas
markedli
foscarnet
treatment
administ
immunosupress
suspend
day
order
control
viral
infect
unfortun
patient
die
day
later
although
specif
function
test
normal
sequenc
gene
ng
reveal
homozyg
variat
previous
report
mutat
respons
fhl
conclus
despit
fact
normal
strong
clinic
laboratori
result
must
keep
fhl
diagnosi
mind
intens
treatment
earli
administ
order
give
patient
opportun
achiev
cur
treatment
object
report
character
clinic
cours
patient
apec
specif
antibodi
defici
method
retrospect
chart
review
perform
patient
enrol
niaid
irbapprov
protocol
result
patient
yearoldgirl
apec
caus
homozyg
air
manifest
cmc
hypoparathyroid
adren
insuffici
sjogrenslik
syndrom
autoimmun
hepat
intestin
dysfunct
autoimmun
pneumon
suffer
recurr
sinus
sever
pneumonia
requir
hospit
administr
intraven
antibiot
sever
time
per
year
age
present
institut
fever
cough
comput
tomographi
ct
chest
reveal
bilater
pulmonari
infiltr
bronchiectasi
bronchoscopi
show
mucopurul
secret
bilater
lower
lobe
cultur
bronchoalveolar
lavag
fluid
grow
streptococcu
pneumonia
evalu
underli
disord
primari
ciliari
dyskinesia
cystic
fibrosi
includ
exom
sequenc
sweat
chlorid
test
unrev
quantit
immunoglobulin
normal
despit
prior
vaccin
specif
antibodi
test
show
neg
rubeola
igg
protect
level
mcgml
pneumococc
serotyp
lymphocyt
enumer
show
normal
b
cell
subset
approxim
apec
patient
may
experi
asplenia
splenic
ultrasound
perform
confirm
presenc
cm
spleen
peripher
blood
smear
reveal
howelljolli
bodi
serotyp
pneumonia
isol
confirm
serotyp
part
vaccin
follow
vaccin
challeng
valent
pneumococc
polysaccharid
vaccin
show
inadequ
respons
henc
start
monthli
immunoglobulin
replac
follow
year
experienc
singl
methicillin
sensit
staphylococcu
aureu
pneumonia
miss
school
day
paramet
includ
linear
growth
improv
along
fifth
percentil
height
along
tenth
percentil
weight
although
continu
experi
intermitt
cough
remain
activ
particip
sport
without
limit
conclus
report
evalu
treatment
outcom
patient
apec
complic
autoimmun
pneumon
specif
antibodi
defici
infecti
suscept
apec
classic
pertain
signatur
infecti
diseas
cmc
patient
invas
recurr
infect
evalu
underli
immun
defici
investig
includ
assess
asplenia
quantit
immunoglobulin
specif
antibodi
respons
antigen
patient
predomin
respiratori
symptom
autoimmun
pneumon
evalu
given
near
preval
pneumon
observ
american
apec
patient
acknowledg
support
dirniaidnih
introduct
autoinflammatori
diseas
genet
heterogen
disord
innat
immun
character
recurr
fever
rash
seros
gener
consid
distinct
autoimmun
diseas
report
case
patient
lupuslik
diseas
mutat
nucleotidebind
oligomer
domaincontain
protein
yao
syndrom
suggest
overlap
autoinflammatori
autoimmun
process
case
present
man
evalu
recurr
pleural
effus
morn
stiff
erythemat
rash
fever
histori
notabl
hashimoto
thyroid
multipl
admiss
presum
pneumonia
recurr
bilater
lung
infiltr
pleural
effus
transbronchi
biopsi
show
nonspecif
pneumon
organ
pneumonia
antinuclear
antidsdna
antibodi
posit
receiv
prednison
presum
lupu
pneumon
lead
improv
prednison
taper
hydroxychloroquin
start
fever
pleurit
pain
pleural
effus
reoccur
genet
test
reveal
sequent
variant
associ
autoinflammatori
diseas
hydroxychloroquin
stop
colchicin
ad
regimen
allow
prednison
taper
without
recurr
symptom
immunolog
test
reveal
increas
signal
type
interferon
receptor
interferon
signatur
conclus
although
patient
sever
clinic
seros
arthralgia
immunolog
antinuclear
antidsdna
antibodi
interferon
signatur
manifest
lupu
clinic
present
also
consist
yao
syndrom
retrospect
recurr
inflammatori
symptom
mani
year
recent
studi
mice
human
suggest
inflammasom
activ
product
involv
pathogenesi
lupu
case
provid
support
idea
lupu
hashimoto
thyroid
prototyp
autoimmun
diseas
may
overlap
autoinflammatori
featur
background
implement
sever
combin
immunodefici
scid
newborn
screen
trec
assay
play
pivot
role
identifi
patient
earli
life
screen
also
led
identif
infant
immunolog
abnorm
clinic
implic
unclear
limit
data
outcom
object
review
immunolog
genet
outcom
infant
refer
immunolog
servic
tertiari
care
center
abnorm
newborn
scid
screen
method
retrospect
review
chart
infant
posit
scid
screen
juli
novemb
exclud
patient
posit
screen
week
correct
gestat
age
classifi
outcom
group
includ
scid
nonscid
tcell
lymphopenia
nscidtcl
normal
tcell
count
idiopath
tcell
lymphopenia
defin
nscidtcl
cellsmcl
neg
chromosom
microarray
neg
whole
exom
sequencingor
genet
panel
either
scid
panel
primari
immunodefici
panel
result
infant
male
caucasian
africanamerican
fiftyfour
infant
identifi
illinoi
missouri
screen
respect
mean
age
initi
evalu
day
day
infant
normal
tcell
count
normal
repeat
newborn
screen
nscidtcl
includ
mild
cellsmcl
moder
cellsmcl
tcl
scid
leaki
scid
complet
digeorg
genet
etiolog
nscidtcl
includ
delet
trisomi
mutat
three
infant
novel
variant
time
diagnosi
secondari
caus
tcl
identifi
infant
thorac
infantil
fibrosarcoma
one
infant
idiopath
tcl
eighteen
infant
nscidtcl
follow
clinic
without
complet
genet
test
perform
scid
mutat
found
ada
patient
leaki
scid
neg
whole
exom
sequenc
patient
scid
leaki
scid
underw
hematopoiet
stem
cell
transplant
median
age
week
week
month
success
engraft
patient
idiopath
nscidtcl
case
follow
clinic
least
one
followup
visit
median
age
month
month
year
major
improv
stabl
lymphocyt
count
without
seriou
infect
requir
intraven
antibiot
though
hospit
rsv
infect
patient
die
cord
blood
transplant
unclear
etiolog
studi
limit
half
infant
nscidtcl
complet
genet
workup
fifth
patient
nscidtcl
inpati
potenti
explain
rel
low
number
infant
secondari
lymphopenia
conclus
cohort
onefourth
infant
abnorm
scid
screen
nscidtcl
although
major
nscidtcl
well
approxim
onethird
underli
genet
abnorm
associ
tcell
lymphopenia
submiss
id
introduct
accumul
intracellular
adenosin
deoxyadenosin
nucleotid
daxp
due
adenosin
deaminas
defici
result
profound
lymphopenia
sever
combin
immunodefici
left
untreat
form
scid
uniformli
fatal
allogen
hematopoiet
cell
transplant
hct
autolog
gene
correct
stem
cell
therapi
gt
potenti
cure
adascid
initi
enzym
replac
therapi
ert
immedi
upon
diagnosi
regardless
definit
treatment
standard
care
hct
gt
therapeut
option
adascid
patient
ert
offer
immedi
therapeut
intervent
patient
lead
partial
immun
reconstitut
durabl
surviv
patient
treat
adagen
pegademas
approv
fda
usa
pegyl
bovin
ada
nada
enzym
harvest
bovin
intestin
unsustain
product
process
led
develop
recombin
enzym
sourc
base
bovin
protein
sequenc
improv
pegyl
linker
use
succinimidyl
carbam
revcovitm
elapegademaselvlr
method
phase
iiiii
clinic
trial
perform
us
site
institut
irb
approv
elig
adascid
subject
stabl
adagen
without
complic
underli
condit
demograph
medic
histori
lymphocyt
count
immunoglobulin
level
trough
plasma
ada
activ
rbc
daxp
measur
collect
patient
treat
adagen
singl
weekli
im
dose
adjust
achiev
trough
plasma
ada
activ
mmolhrl
rbc
daxp
mmoll
protocol
target
level
patient
achiev
level
week
sevenday
pk
adagen
done
patient
transit
revcovi
base
formula
enzym
equival
activ
revcovi
unit
adagen
week
revcovi
trough
ada
daxp
assess
sevenday
pharmacokinet
studi
conduct
week
patient
assess
period
clinic
laboratori
valu
evalu
studi
endpoint
done
week
subject
subsequ
continu
revcovi
assess
period
result
six
patient
age
enter
trial
initi
adagen
dose
see
tabl
adagen
dose
adjust
target
endpoint
ada
trough
activ
rbc
daxp
mmll
patient
transit
weekli
revcovi
use
aforement
convers
formula
dose
mgkgwk
spectrum
clinic
manifest
rang
infect
autoimmun
inflamm
among
patient
hypomorph
recombin
gene
pathogen
variant
autoantibodi
target
cytokin
ifnalpha
ifnomega
report
larg
proport
patient
occurr
often
coincid
viral
infect
report
time
emerg
rel
frequenc
anticytokin
antibodi
children
adult
persist
among
patient
hypomorph
rag
defici
antibodi
measur
plasma
sampl
patient
enzym
link
immunoassay
elisa
rag
cohort
includ
patient
defici
antibodi
target
ifnalpha
common
follow
ifnomega
two
asymptomat
patient
detect
newborn
screen
scid
receiv
hematopoiet
stem
cell
transplant
detect
anticytokin
antibodi
cohort
young
children
age
year
patient
detect
antibodi
ifnalpha
prior
histori
sever
viral
infect
subsequ
develop
autoimmun
cytopenia
anticytokin
antibodi
less
common
ifnomega
similarli
children
yo
age
also
high
fraction
antiifnalpha
antibodi
prior
histori
infect
continu
anticytokin
antibodi
less
commonli
ifnomega
adult
cohort
age
year
frequenc
antiifnalpha
anticytokin
antibodi
lower
ifnomega
continu
persist
three
adult
patient
anticytokin
ifnalpha
ifnomega
antibodi
test
multipl
timepoint
elev
titer
persist
year
data
demonstr
anticytokin
antibodi
especi
target
ifn
frequent
emerg
earli
life
associ
viral
infect
patient
rag
defici
lower
fraction
adult
patient
detect
anticytokin
antibodi
maintain
sever
year
antiifnalpha
may
serv
use
biomark
identifi
partial
rag
defici
among
young
adult
patient
histori
viral
infect
autoimmun
cytopenia
role
antibodi
cytokin
yet
determin
specif
signatur
antibodi
may
help
identifi
underli
immunodefici
initi
earli
definit
treatment
bone
marrow
transplant
anticytokin
antibodi
appear
novel
tool
evalu
autoimmun
diseas
includ
rag
defici
introduct
noroviru
one
common
pathogen
caus
gastroenter
immunocompromis
patient
often
lead
chronic
infect
caus
villou
atrophi
malabsorpt
weight
loss
organ
failur
need
parenter
nutrit
death
noroviru
treatment
immunocompromis
patient
challeng
oral
immunoglobulin
poig
use
treat
noroviru
gastroenter
variabl
success
aim
studi
determin
outcom
treat
noroviru
gastroenter
immunocompromis
patient
method
electron
medic
record
review
patient
noroviru
infect
confirm
rtpcr
sinc
januari
initi
cohort
focus
patient
primari
immunodefici
pid
lung
liver
transplant
data
demograph
immunolog
phenotyp
treatment
poig
number
bowel
movement
bm
viru
clearanc
collect
descript
statist
method
use
describ
treatment
outcom
analysi
patient
immunophenotyp
immunosuppress
medic
comorbid
ill
underway
result
twentysix
immunocompromis
patient
noroviru
infect
episod
one
patient
reinfect
analyz
twelv
femal
age
rang
year
twelv
patient
pid
diagnosi
common
variabl
immunodefici
sever
combin
immunodefici
xlink
agammaglobulinemia
wiskottaldrich
syndrom
digeorg
syndrom
hyperigm
gainoffunct
nemo
lymphopenia
patient
trisomi
patient
statuspost
liver
transplant
two
patient
statuspost
lung
transplant
patient
ig
replac
therapi
time
noroviru
infect
averag
number
bmday
patient
rang
eight
patient
receiv
poig
mgkg
weekli
durat
week
three
receiv
addit
nitazoxanid
receiv
ribavirin
patient
poig
group
receiv
total
parenter
nutrit
tpn
treatment
group
receiv
tpn
averag
number
bmday
poig
treatment
rang
rang
receiv
treatment
poig
vs
treatment
group
clear
viru
averag
number
week
return
baselin
bm
rang
poig
group
vs
rang
week
treatment
group
poig
continu
chronic
diarrhea
still
ongo
conclus
despit
anecdot
report
suggest
success
use
poig
immunocompromis
patient
data
show
signific
decreas
stool
output
patient
treat
poig
compar
treatment
howev
poig
led
higher
rate
viru
clearanc
studi
larger
sampl
size
might
warrant
identifi
patient
benefit
poig
context
noroviru
infect
ensur
appropri
use
ig
product
especi
given
concern
nation
shortag
ig
product
chief
medic
offic
novimmun
sa
primari
hemophagocyt
lymphohistiocytosi
phlh
lifethreaten
immun
regulatori
disord
character
immun
hyperactiv
driven
high
product
interferon
ifn
patient
hlh
typic
develop
fever
splenomegali
cytopenia
coagulopathi
recent
fda
approv
treatment
hlh
standard
dexamethasoneetoposidebas
treatment
evolv
significantli
year
emapalumablzsg
fulli
human
antiifnmonoclon
antibodi
neutral
ifnand
recent
approv
novemb
fda
treatment
adult
pediatr
newborn
older
patient
phlh
refractori
recurr
progress
diseas
intoler
convent
hlh
therapi
result
pivot
trial
support
approv
present
herein
method
openlabel
pivot
studi
includ
patient
year
diagnosi
phlh
activ
diseas
data
present
patient
fail
convent
hlh
therapi
prior
studi
entri
initi
emapalumablzsg
dose
mgkg
given
intraven
everi
day
subsequ
dose
could
increas
mgkg
base
evolut
respons
paramet
dexamethason
administ
concomitantli
mgm
day
could
taper
studi
treatment
durat
week
possibl
shorten
minimum
week
extens
time
allogen
hematopoiet
stem
cell
transplant
hsct
primari
efficaci
endpoint
overal
respons
rate
orr
end
treatment
assess
predefin
object
paramet
includ
normal
least
improv
baselin
fever
splenomegali
cytopenia
hyperferritinemia
fibrinogen
ddimer
central
nervou
system
cn
abnorm
sustain
worsen
serum
level
primari
analysi
use
exact
binomi
test
evalu
null
hypothesi
orr
onesid
signific
level
patient
elig
enter
extens
phase
followup
complet
main
studi
data
cutoff
appli
juli
result
patient
characterist
summar
tabl
efficaci
summar
tabl
diseas
studi
entri
consist
broad
spectrum
phlh
abnorm
patient
sign
andor
symptom
cn
diseas
orr
significantli
higher
prespecifi
null
hypothesi
meet
primari
endpoint
respons
rate
base
investig
clinic
judgement
emapalumablzsg
infus
gener
well
toler
mild
moder
infusionrel
reaction
report
patient
observ
safeti
event
prehsct
condit
mostli
includ
hlh
manifest
infect
toxic
due
administ
drug
infect
caus
pathogen
potenti
favor
ifnneutr
occur
patient
emapalumablzsg
treatment
dissemin
histoplasmosi
resolv
appropri
treatment
offtarget
effect
observ
conclus
treatment
emapalumablzsg
abl
control
hlh
activ
favor
safeti
toler
profil
fragil
popul
major
patient
proceed
hsct
favor
outcom
result
indic
emapalumablzsg
consid
new
therapeut
option
phlh
thank
target
mode
action
result
total
gene
differenti
express
cell
patient
healthi
control
log
fold
chang
rang
gene
test
pathway
enrich
top
pathway
lymphocyt
base
p
valu
includ
commun
innat
adapt
immun
cell
cross
talk
dendrit
cell
natur
killer
cell
allograft
reject
signal
dendrit
cell
matur
b
cell
receptor
signal
top
biolog
process
differenti
express
includ
immun
respons
inflammatori
respons
apoptot
process
interferon
gamma
mediat
signal
pathway
nucleosom
assembl
defens
respons
viru
lipopolysaccharid
mediat
signal
pathway
posit
regul
nfkappa
b
import
nucleu
type
interferon
signal
pathway
neutrophil
chemotaxi
gene
compar
gene
express
particip
low
cell
count
particip
normal
cell
count
found
gene
differenti
express
q
fold
chang
rang
patient
began
experienc
recurr
high
fever
develop
splenomegali
elev
transaminas
concern
lymphoprolif
diseas
prompt
splenectomi
liver
biopsi
spleen
liver
biopsi
posit
ebv
neg
malign
bone
marrow
biopsi
unrev
genet
test
identifi
pathogen
variant
xiap
patient
treat
high
dose
oral
steroid
result
improv
symptom
subsequ
therapi
anakinra
start
steroid
taper
steroid
taper
notic
chang
vision
left
eye
consist
naion
well
worsen
coliti
loss
inferior
visual
field
fundoscop
exam
signific
left
optic
disc
swell
oct
note
superior
retin
nerv
fiber
layer
thin
oral
steroid
restart
improv
optic
disc
swell
without
improv
chang
vision
recent
exam
patient
persist
bilater
inferior
visual
field
defect
segment
optic
nerv
atrophi
typic
naion
continu
therapi
anakinra
subsequ
taper
prednison
though
remain
physiolog
dose
hydrocortison
conclus
case
demonstr
unreport
ocular
manifest
patient
xiap
defici
clinic
appear
sensit
immunomodul
patient
unusu
candid
naion
due
young
age
averag
age
onset
mid
late
lack
vascular
risk
factor
hypothes
hyperinflammatori
condit
contribut
irrevers
vascular
damag
optic
nerv
head
result
naion
therefor
may
use
consid
involv
system
inflammatori
immun
dysregulatori
condit
treat
patient
atyp
naion
addit
naion
consid
patient
xiap
defici
sudden
unilater
vision
loss
import
de
novo
mutat
caus
sever
sporad
immun
diseas
well
describ
yet
signific
variat
less
sever
later
onset
immun
diseas
poorli
investig
whole
exom
sequenc
power
tool
resolv
explain
genet
basi
novel
syndrom
immun
relat
diseas
howev
prove
causat
complic
due
low
number
affect
individu
perform
whole
exom
sequenc
cohort
patient
noncongenit
immun
defect
along
detail
cellular
biochem
phenotyp
report
describ
novel
noncongenit
combin
immun
defici
aris
de
novo
gainoffunct
mutat
ikbkb
gene
encod
activ
canon
nfkb
signal
cellular
biochem
studi
proband
reveal
result
enhanc
nfkb
signal
well
b
cell
function
defect
highlyconserv
residu
prove
causat
gener
mous
model
carri
precis
ortholog
missens
mutat
show
mice
human
carri
missens
mutat
exhibit
remark
similar
cellular
biochem
phenotyp
dysregul
patient
total
rna
isol
cryopreserv
peripher
blood
mononuclear
cell
revers
transcrib
gener
cdna
select
four
known
transcript
target
encod
use
droplet
digit
pcr
quantifi
transcript
level
normal
lowexpress
gene
use
sampl
individu
wildtyp
wt
known
mutat
patient
mut
two
individu
suspect
defici
without
identifi
mutat
allel
imbal
transcript
analysi
reveal
significantli
decreas
transcript
level
mut
pbmc
compar
wt
wt
sampl
higher
transcript
mutat
patient
howev
reach
statist
signific
strikingli
abl
use
analysi
two
individu
suspect
defici
first
case
yr
old
femal
primari
lymphedema
hypogammaglobulinemia
recurr
infect
possibl
famili
histori
leukemia
refer
test
mutat
identifi
howev
note
homozyg
across
gene
prevent
allel
evalu
second
patient
yr
old
femal
erethemya
nodosa
leg
mycobacteria
kansasii
cytopenia
target
analyz
transcript
level
lower
wt
sampl
similar
rang
mutat
sampl
profil
consist
wt
sampl
propos
use
target
surrog
marker
case
mutat
identifi
allel
express
analysi
uninform
often
underreport
underrecogn
sought
understand
evalu
preval
type
associ
serum
immunoglobulin
e
ige
cvid
patient
atop
manifest
method
perform
retrospect
analysi
cvid
patient
atop
manifest
partner
healthcar
cvid
cohort
evalu
baselin
patient
characterist
atop
diagnos
serum
ige
level
result
partner
cvid
cohort
averag
age
year
old
femal
patient
diagnosi
asthma
major
diagnos
allergist
pulmonologist
eczemaatop
dermat
diagnos
patient
either
allergist
dermatologist
allerg
rhiniti
diagnos
posit
skin
prick
test
patient
food
allergi
diagnos
patient
median
cohort
serum
ige
iuml
median
serum
ige
higher
patient
atop
complic
compar
one
less
atop
condit
vs
iuml
statist
signific
conclus
report
higher
rate
atopi
previous
describ
cvid
cohort
consist
previou
report
find
low
median
cohort
serum
ige
level
cvid
patient
compar
gener
popul
howev
identifi
subset
patient
predisposit
toward
atopi
higher
ige
level
within
broader
character
cvid
patient
may
specif
molecular
diagnosi
lead
elev
ige
atop
condit
whole
exom
sequenc
underway
evalu
hypothesi
whim
wart
hypogammaglobulinemia
infect
myelokathexi
syndrom
primari
immunodefici
autosom
domin
inherit
patient
genet
caus
diseas
gainoffunct
variant
cxc
chemokin
receptor
type
result
arrest
neutrophil
migrat
bone
marrow
patient
develop
hypogammaglobulinemia
earli
wane
antibodi
respons
vaccin
howev
exact
origin
aberr
humor
immun
whim
syndrom
patient
yet
clarifi
describ
iraqi
femal
heterozyg
variant
present
haemophilu
influenza
mening
histori
tetralog
fallot
earli
onset
intermitt
neutropenia
lymphopenia
recurr
bacteri
viral
infect
immunolog
evalu
reveal
hypogammaglobulinemia
elev
igm
level
lack
protect
vaccin
titer
tetanu
prevnar
vaccin
bone
marrow
biopsi
consist
myelokathexi
immun
phenotyp
function
studi
apoptosi
assay
perform
peripher
blood
cell
flow
cytometri
whim
patient
control
although
found
lymphocyt
compart
reduc
helper
cell
switch
memori
b
cell
predominantli
affect
spontan
apoptosi
pronounc
b
rather
cell
compart
whim
patient
addit
b
cell
easili
activ
die
upon
activ
vitro
ligand
induc
elev
helper
cell
migrat
increas
actin
polymer
mutant
cell
conclud
intrins
b
cell
abnorm
increas
rate
apoptosi
alter
activ
might
respons
defect
antibodi
respons
whim
patient
although
individu
effect
control
herpesviru
infect
suffer
unusu
sever
andor
recurr
infect
requir
antivir
prophylaxi
subset
patient
possess
defect
nk
cell
innat
lymphocyt
recogn
lyse
herpesvirusinfect
cell
howev
exact
genet
etiolog
rare
diagnos
encod
signal
protein
nk
cell
b
cell
receptormedi
signal
dominantneg
gainoffunct
mutat
caus
cold
urticaria
antibodi
defici
autoinflamm
howev
lossoffunct
mutat
haploinsuffici
never
report
human
diseas
examin
famili
autosom
domin
nk
cell
immunodefici
mass
cytometri
wholeexom
sequenc
identifi
caus
diseas
identifi
two
novel
heterozyg
lossoffunct
mutat
impair
nk
cell
function
includ
calcium
flux
granul
movement
target
kill
although
express
mutant
protein
vitro
normal
phosphoryl
mutant
diminish
contrast
plaid
aplaid
b
cell
function
remain
intact
well
target
crispr
knockin
mice
also
display
impair
nk
cell
function
preserv
b
cell
function
phenocopi
human
haploinsuffici
report
first
known
case
haploinsuffici
clinic
mechanist
distinct
syndrom
previous
report
mutat
therefor
famili
repres
novel
diseas
highlight
role
haploinsuffici
herpesvirussuscept
patient
expand
spectrum
diseas
pursu
genet
diagnosi
identifi
biallel
frameshift
mutat
gene
previous
describ
taken
togeth
present
suggest
signific
immun
dysfunct
evolv
sinc
transplant
lead
extens
pulmonari
nontubercul
mycobacteri
infect
possibl
bronchiol
obliteran
therefor
undergo
subsequ
uncondit
stem
cell
boost
sister
origin
donor
complet
mycobacterium
abscessu
treatment
case
highlight
potenti
longterm
immun
dysfunct
may
evolv
uncondit
allogen
stem
cell
transplant
scid
full
engraft
myeloid
lymphoid
compart
expect
also
highlight
import
guidelinedriven
followup
patient
monitor
said
dysfunct
prevent
seriou
infect
longterm
sequela
somat
hypermut
shm
b
cell
receptor
bcr
heavi
igh
light
chain
gene
promot
affin
matur
also
mutat
away
selfreact
therefor
serv
import
peripher
toler
checkpoint
exampl
unmut
bcr
gene
give
rise
antibodi
bind
ii
antigen
red
blood
cell
rbc
may
elicit
cold
agglutinin
diseas
cad
variant
autoimmun
hemolyt
anemia
aiha
case
healthi
individu
frequent
shm
ii
bind
site
bcr
gene
decreas
rbc
reactiv
cad
patient
primari
immunodefici
pid
paradox
develop
autoimmun
diseas
includ
autoimmun
cytopenia
especi
aiha
unclear
impair
shm
bcr
particular
mutat
away
ii
bind
relev
develop
rbc
reactiv
consequ
aiha
pid
background
studi
focu
pid
patient
hypomorph
recombin
activ
gene
combin
immunodefici
phenotyp
histori
autoimmun
particular
aiha
rag
cidai
detect
increas
frequenc
unmut
bcr
memori
b
cell
repertoir
ragcidai
patient
well
elev
titer
unmut
antibodi
patient
plasma
lower
level
shm
like
reflect
abnorm
germin
center
gc
reaction
heterotetram
primarili
shape
preimmun
b
cell
repertoir
studi
interact
follicular
helper
cell
tfh
naiv
b
cell
via
vitro
cocultur
experi
interestingli
tfh
cell
rag
cidai
patient
exhibit
highli
activ
phenotyp
increas
express
compar
healthi
control
abl
initi
exagger
respons
class
switch
shm
healthi
donor
naiv
b
cell
contrari
vitro
activ
naiv
b
cell
rag
cidai
patient
show
impair
prolifer
class
switch
decreas
level
shm
diminish
induct
gene
involv
cell
costimul
shm
aicda
repair
enzym
compar
healthi
donor
naiv
b
cell
indic
intrins
defect
patient
b
cell
furthermor
b
cell
rag
cidai
patient
also
show
increas
apoptosi
accumul
foci
steadi
state
indic
reduc
cellular
fit
find
suggest
develop
aiha
multifactori
process
partial
rag
defici
studi
highlight
impair
germin
center
reaction
import
toler
checkpoint
inabl
patient
b
cell
respond
hyperact
tfh
cell
introduc
proper
level
shm
henc
propos
b
cell
fit
compromis
impair
proper
gc
interact
shm
includ
mutat
away
self
sustain
rbc
reactiv
hypomorph
rag
defici
introductionbackground
forkhead
box
transcript
factor
essenti
regul
cell
develop
affect
differenti
expans
thymic
epitheli
cell
tec
autosom
recess
mutat
caus
tbnk
lymphocyt
phenotyp
due
thymic
aplasia
conjunct
alopecia
universali
nail
plate
dystrophi
result
keratinocyt
dysregul
classic
nudescid
omim
phenotyp
report
identif
two
independ
patient
identifi
newborn
screen
absent
trec
tnkb
scid
phenotyp
present
cell
lymphopenia
compound
heterozyg
mutat
notabl
individu
normal
hair
nail
bed
object
determin
whether
distinct
compound
heterozyg
mutat
caus
novel
tnkb
phenotyp
absenc
classic
nude
present
neutral
autoantibodi
autoab
cytokin
increas
suscept
select
infect
eg
antiifnautoab
nontubercul
mycobacteria
nontyphoid
salmonella
mucocutan
candidiasi
antigmcsfauotab
infect
cryptococcu
nocardia
aspergillu
spp
howev
role
less
clear
key
mediat
acutephas
respons
releas
earli
bacteri
infect
patient
impair
signal
affect
product
increas
risk
sever
bacteri
infect
three
patient
hightit
neutral
suffer
sever
infect
caus
aureu
intermediu
e
coli
describ
far
investig
preval
patient
bacteri
infect
investig
cohort
patient
identifi
three
patient
previous
healthi
neutral
auotab
hardli
develop
acutephas
respons
first
patient
suffer
lifethreaten
pneumonia
caus
pneumonia
second
patient
develop
submandibular
abscess
septic
arthriti
caus
pyogen
third
patient
suffer
lifethreaten
pneumonia
caus
aureu
also
discov
neutral
two
adult
among
cohort
patient
autoimmun
diseas
n
one
adolesc
among
cohort
obes
individu
n
well
three
mother
neonat
impair
signal
far
none
later
individu
develop
sever
bacteri
infect
suggest
natur
occur
neutral
risk
factor
sever
bacteri
infect
yet
incomplet
penetr
submiss
id
persist
transamin
copa
syndrom
research
immunodefici
research
unit
nation
institut
pediatr
mexico
citi
social
servic
intern
immunodefici
research
unit
nation
institut
pediatr
pediatr
resid
pediatr
hospit
centuri
nation
medic
center
mexican
institut
social
secur
research
data
scienc
depart
mexican
autonom
institut
technolog
research
depart
research
methodolog
nation
institut
pediatr
background
inborn
error
immun
constitut
heterogen
group
individu
rare
congenit
diseas
involv
gene
code
protein
immun
system
result
increas
suscept
infect
inflamm
autoimmun
allergi
cancer
complex
diagnost
task
intrins
bias
limit
human
mind
aid
comput
tool
among
avail
machin
learn
approach
decis
tree
algorithm
select
best
node
split
base
entropi
inform
gain
random
forest
build
hundr
thousand
decis
tree
randomli
bootstrap
improv
accuraci
reduc
overfit
aim
implement
machin
learningassist
clinic
decis
support
system
diagnosi
inborn
error
immun
iei
method
local
databas
patient
suspect
iei
built
decis
tree
use
dtc
random
forest
python
jupyt
notebook
scikit
mathplotlib
panda
numpi
databas
obtain
conduct
electron
search
medsi
patient
term
immunodefici
electron
medic
record
handpick
case
iei
confirm
rule
consist
patient
diagnos
iei
first
split
dataset
randomli
train
test
set
decis
tree
task
classifi
correctli
pid
run
algorithm
train
set
evalu
test
set
random
forest
classifi
case
major
vote
nine
group
accord
iui
pid
group
next
repeat
process
larger
scale
dataset
patient
usidnet
accuraci
assess
outofbag
oob
error
estim
result
accuraci
greater
local
dataset
pid
group
usidnet
dataset
group
provid
list
decis
node
diagnost
rout
question
achiev
greater
inform
gain
less
entropi
might
help
clinician
direct
interrog
diagnost
approach
suspect
iei
patient
discuss
built
two
classif
model
decis
tree
lend
easili
learn
deriv
rule
thumb
sequenc
random
forest
robust
better
suit
categor
oppos
binari
classif
next
want
develop
chatbot
ask
relev
question
optim
sequenc
extract
undiagnos
patient
suspect
iei
base
statist
red
flag
research
immunodefici
research
unit
nation
institut
pediatr
mexico
citi
dna
repair
defect
inborn
error
immun
result
increas
apoptosi
oncogenesi
dna
ligas
patient
suffer
wide
rang
clinic
manifest
sinc
earli
life
includ
microcephali
dysmorph
facial
featur
growth
failur
development
delay
mental
retard
hip
dysplasia
skelet
malform
well
sever
combin
immunodefici
radiosensit
progress
bone
marrow
failur
may
present
later
life
hematolog
neoplasia
respond
catastroph
chemoand
radiotherapi
could
asymptomat
describ
clinic
laboratori
genet
featur
five
mexican
patient
defici
togeth
review
patient
avail
pubm
medlin
four
five
patient
dead
lymphoma
bone
marrow
failur
sever
infect
massiv
bleed
fifth
patient
asymptomat
despit
persist
lymphopenia
patient
report
literatur
microcephal
femal
growth
failur
sinopulmonari
infect
hypogammaglobulinemia
low
bcell
radiosensit
bone
marrow
failur
malign
may
develop
later
age
dysmorph
facial
featur
congenit
hip
dysplasia
chronic
liver
diseas
gradual
pancytopenia
lymphoma
leukemia
thrombocytopenia
gastrointestin
bleed
report
well
mutat
compound
heterozyg
hypomorph
two
common
truncat
mutat
account
major
patient
stemcel
transplant
reduc
intens
condit
regim
may
cur
depart
laboratori
medicin
clinic
centr
immunolog
allergi
rheumatolog
divis
depart
pediatr
baylor
colleg
medicin
texa
children
hospit
houston
texa
usa
laboratori
clinic
immunolog
microbiolog
fungal
pathogenesi
section
nation
institut
allergi
infecti
diseas
depart
intramur
research
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
bethesda
maryland
usa
defici
autosom
recess
primari
immunodefici
known
underlay
increas
fungal
infect
suscept
mostli
present
invas
cn
candida
infect
infanc
adulthood
dermatophyt
infect
recent
rare
variant
g
c
lead
exon
skip
show
signific
protect
associ
toward
inflammatori
bowel
diseas
ibd
present
heterozygos
nih
studi
male
patient
born
nonconsanguin
marriag
present
infant
recurrentsever
thrush
candida
esophag
episod
tinea
pedi
also
mild
hypogammaglobinemia
igg
age
gdna
test
whole
exom
sequenc
show
g
c
mutat
homozyg
state
segreg
analysi
sanger
confirm
determin
parent
elder
brother
carri
variant
heterozygos
asymptomat
younger
brother
also
homozyg
previous
describ
variant
caus
exon
delet
determin
pbmc
cdna
sequenc
lower
molecular
weight
protein
immunoblot
evalu
pbmc
well
heterozyg
parent
cell
show
defect
cytokin
gener
tnf
gmcsf
respons
heat
kill
candida
hkc
lp
patient
pbmc
fail
induc
phosphoerk
upon
hkcstimul
present
intact
respons
pmaionomycin
parent
cell
respond
normal
stimuli
moreov
tcell
activ
prolifer
affect
respons
hkc
pha
patient
wherea
parent
exhibit
normal
result
condit
cell
transient
transfect
wt
vector
togeth
plasmid
ligas
natur
associ
confirm
fail
bind
immunoprecipit
furthermor
coprecipit
wt
strongli
suggest
integr
part
cbmcomplex
summari
herein
demonstr
allel
fail
bind
turn
unabl
conform
completefunct
cbm
complex
data
also
show
act
domin
neg
fashion
term
cytokin
gener
previous
report
one
wt
allel
seem
suffici
gener
normal
level
hkcinduc
perk
well
tcell
prolifer
decreas
cytokin
gener
associ
heterozygos
describ
suffici
protect
toward
ibd
defect
pathway
affect
homozygos
like
necessari
confer
increas
suscept
fungal
infect
altogeth
result
suggest
act
gene
dosag
mechan
dissect
pathway
associ
ibd
protect
fungal
infect
suscept
work
warrant
explor
role
bcell
tcell
biolog
professor
endocrinolog
univers
michigan
medic
school
background
acquir
gener
lipodystrophi
agl
syndrom
heterogen
group
diseas
character
select
dysfunct
loss
adipos
tissu
birth
caus
ectop
lipid
deposit
defici
adipokin
leptin
promot
metabol
dysfunct
impair
glucos
handl
result
insulinresist
diabet
mellitu
dyslipidemia
steatohepat
metabol
effect
alter
adipokin
secret
known
molecular
mechan
less
clear
mani
agl
case
suspect
autoimmun
etiolog
effector
regulatori
cell
dendrit
cell
macrophag
resid
normal
adipos
tissu
cell
within
adipos
tissu
highli
express
regulatori
cell
express
limit
immun
activ
adipos
tissu
normal
circumst
thu
inhibit
immun
checkpoint
may
hypothet
caus
immun
activ
lead
adipocyt
dysfunct
autoimmun
destruct
encount
two
case
rais
clinic
concern
process
patient
case
patient
femal
present
failur
thrive
month
diagnos
insulinresist
type
diabet
hypertriglyceridemia
age
year
progress
subcutan
fat
loss
low
leptin
level
culmin
diagnosi
agl
childhood
clinic
cours
complic
hypertroph
cardiomyopathi
hepatomegali
autoimmun
hemolyt
anemia
massiv
splenomegali
sever
chronic
diarrhea
secondari
autoimmun
enteropathi
present
year
acut
liver
failur
thrombot
microangiopathi
nephrot
syndrom
progress
kidney
insuffici
evalu
multifacet
autoimmun
present
identifi
famili
heterozyg
pathogen
variant
gene
despit
aggress
immun
therapi
includ
abatacept
kidney
diseas
enteropathi
progress
patient
male
diagnos
local
malign
melanoma
right
neck
juli
underw
excision
biopsi
region
lymph
node
dissect
neg
margin
relaps
novemb
underw
modifi
radic
neck
dissect
lymph
node
posit
diseas
receiv
extern
beam
radiat
januaryfebruari
addit
start
therapi
human
antibodi
drug
pembrolizumab
april
discontinu
drug
februari
set
toxic
includ
hypothyroid
subsequ
develop
weight
loss
progress
loss
subcutan
fat
first
face
gener
rest
bodi
ensu
month
imag
petct
demonstr
loss
subcutan
fat
concurr
elev
alt
triglycerid
level
plu
low
leptin
level
consist
agl
conclus
case
rais
concern
inhibit
immun
checkpoint
may
facilit
develop
agl
hypothes
defect
significantli
increas
cell
autoimmun
activ
adipos
tissu
andor
alter
cell
metabol
result
agl
disord
immun
dysregul
consid
etiolog
agl
similarli
patient
either
genet
pharmacolog
inhibit
immun
checkpoint
monitor
develop
agl
care
physic
exam
period
monitor
glucos
triglycerid
level
background
rosaidorfman
diseas
rdd
also
known
sinu
histiocytosi
massiv
lymphadenopathi
rare
nonlangerhan
cell
histiocytosi
character
prolifer
accumul
activ
histiocyt
affect
tissu
classic
rdd
present
bilater
nontend
often
markedli
enlarg
cervic
lymphadenopathi
case
present
femal
present
histori
asymptomat
persist
bilater
enlarg
cervic
lymph
node
otherwis
healthi
signific
past
medic
histori
oper
excis
biopsi
largest
lymph
node
confirm
diagnosi
rdd
three
month
follow
diagnosi
routin
bloodwork
reveal
develop
lymphopenia
lymphocyt
count
x
postdiagnosi
patient
hospit
treat
intraven
antibiot
presum
episod
osteomyel
presum
episod
lymphaden
given
recurr
presum
infect
persist
lymphopenia
patient
refer
immunolog
evalu
receiv
full
immunolog
workup
lymphocyt
immunophenotyp
reveal
low
low
count
rest
immunolog
workup
within
normal
limit
approxim
postdiagnosi
decis
made
initi
treatment
rdd
start
taper
cours
prednison
therapi
within
start
corticosteroid
therapi
lymphadenopathi
diminish
lymphopenia
complet
resolv
recent
clinic
visit
free
seriou
infect
lymphocyt
count
remain
stabl
within
normal
limit
one
year
discuss
literatur
immun
system
dysfunct
report
rdd
autoantibodi
cellular
immunodefici
implic
patient
persist
lymphopenia
recurr
episod
presum
infect
appear
consist
immunodefici
given
known
associ
rdd
immunolog
dysfunct
certainli
reason
assumpt
howev
issu
resolv
follow
corticosteroid
therapi
question
whether
clinic
present
could
instead
repres
manifest
underli
rdd
case
highlight
diagnost
challeng
differenti
infect
rdd
exacerb
episod
presum
infect
consid
probabl
confirm
microbiolog
histopatholog
specimen
mechan
underli
lymphopenia
rdd
clear
may
involv
decreas
product
increas
destruct
sequestr
lymphocyt
knowledg
specif
studi
rdd
past
howev
lymphopenia
link
lymphocyt
maldistribut
diseas
exampl
studi
shown
experiment
alter
either
surfac
lymphocyt
environ
lymphocyt
travel
caus
sequestr
lymphocyt
variou
lymphoid
organ
includ
lymph
node
conclus
describ
case
patient
rdd
develop
persist
lymphopenia
multipl
episod
presum
infect
result
hospit
intraven
antibiot
therapi
lymphopenia
resolv
sustain
remiss
rdd
follow
treatment
corticosteroid
hypothes
lymphocyt
sequestr
enlarg
lymph
node
may
result
lymphopenia
combin
recurr
rdd
exacerb
clinic
resembl
infect
creat
present
mimick
immunodefici
background
expand
spectrum
immunodefici
phenotyp
link
dna
repair
defect
patient
may
diagnos
adulthood
well
recogn
genet
defect
link
dna
repair
gene
ataxia
telangiectasia
mutat
atm
caus
ataxia
telangiectasia
character
combin
immunodefici
neurodegener
radiat
sensit
ocular
telangiectasia
howev
sever
dna
repair
defect
associ
immunodefici
includ
syndrom
sever
combin
immunodefici
scid
disord
object
present
case
adult
patient
prolong
histori
recurr
infect
facial
abnorm
autoimmun
found
radiosensit
suggest
dna
repair
defect
method
retrospect
chart
review
immunodefici
evalu
flowbas
radiosensit
assay
gene
sequenc
result
femal
refer
clinic
due
complex
histori
recurr
infect
immun
dysregul
patient
lifelong
histori
sinopulmonari
infect
panhypogammaglobulinemia
low
vaccin
respons
lead
diagnosi
common
variabl
immunodefici
cvid
necessit
treatment
immunoglobulin
replac
clinic
featur
also
notabl
congenit
dysmorphia
strabismu
thin
angular
face
high
arch
palat
nasal
septal
defect
small
mouth
miss
dentit
clinodactyli
sever
equinovaru
scoliosi
subsequ
diagnos
autoimmun
featur
vasculitid
requir
trial
cyclophosphamid
azathioprin
rituximab
belimumab
later
discontinu
due
neutropenia
worsen
sinopulmonari
skin
infect
despit
immunoglobulin
replac
cours
evalu
reveal
sever
b
cell
lymphopenia
cell
lymphopenia
persist
iga
igm
defici
oneyear
post
rituximab
therapi
elev
alpha
fetoprotein
afp
radiosensit
assay
reveal
decreas
atm
phosphoryl
elev
level
lowdos
radiat
lymphocyt
subset
b
nk
cell
due
evid
radiosensit
elev
afp
level
concern
atm
genet
defect
dna
repair
pathway
therefor
target
primari
immunodefici
gene
panel
pursu
genet
test
gene
invita
san
francisco
evalu
identifi
variant
atm
gene
rather
variant
uncertain
signific
identifi
gene
exon
may
mosaic
variant
report
popul
databas
typic
associ
charg
syndrom
patient
dysmorph
featur
typic
charg
syndrom
current
studi
copi
number
variat
cnv
deep
intron
variant
atm
pend
conclus
dna
repair
defect
may
occur
adult
patient
primari
diagnosi
cvid
patient
exhibit
phenotyp
featur
variant
atm
lead
possibl
abnorm
dna
damag
respons
ddr
exact
caus
immun
defici
case
remain
present
unsolv
case
highlight
relev
function
studi
genet
evalu
complex
case
immun
dysregul
improv
understand
phenotyp
variabl
immunolog
disord
background
women
health
issu
patient
immunodefici
larg
underrepres
literatur
studi
assess
fertil
issu
patient
antibodi
defici
sizabl
studi
examin
pregnanc
outcom
progeni
cohort
two
largest
studi
pregnanc
antibodi
defici
idf
survey
studi
czech
popul
provid
conflict
data
safeti
pregnanc
patient
immunoglobulin
replac
shown
safe
benefici
pregnanc
patient
cvid
howev
dose
strategi
unguid
sought
understand
issu
associ
fertil
pregnanc
larg
cohort
patient
antibodi
defici
method
perform
retrospect
chart
review
patient
andor
code
cvid
anoth
antibodi
defici
januari
decemb
inclus
criteria
also
compris
reach
least
year
age
begin
child
bear
year
data
collect
includ
diseas
characterist
comorbid
laboratori
valu
outcom
follow
phone
survey
elucid
data
regard
fertil
pregnanc
deliveri
complic
outcom
children
studi
irb
approv
result
current
age
women
includ
rang
year
age
current
childbear
year
postmenopaus
forti
percent
women
pregnant
deliv
averag
babi
per
woman
pregnant
fertil
issu
promin
factor
women
never
becam
pregnant
major
women
babi
receiv
diagnosi
antibodi
defici
child
bear
year
recurr
upper
respiratori
tract
infect
bacteri
sinus
urinari
tract
infect
pregnanc
common
even
yet
diagnos
antibodi
defici
immunoglobulin
level
dose
intraven
andor
subcutan
replac
record
subset
patient
recent
pregnanc
data
reenforc
increas
dose
need
third
trimest
cord
blood
igg
level
also
record
babi
higher
mother
recent
igg
prior
deliveri
rare
children
patient
diagnos
antibodi
defici
relat
condit
although
cvid
hypogammaglobulinemia
combin
immunodefici
lymphoma
rheumatoid
arthriti
diagnos
found
conclus
largest
report
outcom
pregnanc
patient
antibodi
defici
unit
state
report
highlight
import
close
monitor
women
pregnanc
recurr
infect
regardless
whether
diagnosi
antibodi
defici
present
also
highlight
close
monitor
igg
level
pregnanc
necessari
women
antibodi
defici
background
autoinflammatori
diseas
aid
group
disord
inborn
error
innat
immun
character
recurr
episod
fever
inflammatori
attack
spectrum
aid
expand
data
clinic
present
symptom
variabl
exist
iranian
popul
time
precis
diagnosi
studi
aim
establish
first
autoinflammatori
registri
iranian
popul
focus
clinic
laboratori
featur
may
help
clinician
toward
better
understand
diagnosi
disord
method
clinic
laboratori
characterist
patient
clinic
genet
diagnos
aid
collect
use
updat
version
classif
criteria
eurofev
registri
clinic
diagnosi
result
retrospect
studi
clinic
laboratori
characterist
particip
collect
mean
age
diseas
onset
diseas
cours
manifest
mean
durat
episod
atyp
symptom
laboratori
imag
studi
well
complic
respons
treatment
also
review
data
result
patient
male
age
rang
year
genet
diagnos
famili
mediterranean
fever
fmf
common
clinic
genet
approv
diagnosi
also
patient
suspect
mutat
age
diseas
onset
differ
variabl
rang
neonat
period
adulthood
fever
present
particip
durat
episod
day
frequenc
attack
per
year
common
clinic
manifest
follow
myalgia
fatigu
arthralgia
arthriti
abdomin
pain
aphthou
stomat
chest
pain
chronic
gastrointestin
symptom
skin
lesion
rang
urticari
rash
sever
nodular
acn
pyoderma
gangrenosum
exud
erythemat
pharyng
consanguin
parent
symptom
type
allergi
lymphadenopathi
splenomegali
increas
acut
phase
reactant
elev
liver
function
test
individu
report
posit
famili
histori
one
case
patient
carri
homozyg
mutat
mefv
gene
shown
clinic
manifest
conclus
studi
highlight
common
manifest
aid
popul
iranian
origin
use
evidencebas
clinic
criteria
diagnosi
background
term
benign
ethnic
neutropenia
ben
use
describ
patient
africanarab
descent
absolut
neutrophil
count
anc
less
cellsul
absenc
caus
histor
race
use
support
diagnosi
ben
selfreport
race
notori
imprecis
duffi
null
phenotyp
fya
fyb
known
molecular
caus
ben
may
reliabl
marker
ben
selfreport
race
addit
although
anc
known
lower
patient
ben
lower
limit
anc
poorli
describ
import
differenti
patient
ben
primari
immunodefici
diseas
pidd
recogn
expect
anc
valu
method
elig
subject
includ
patient
less
year
seen
univers
michigan
januari
duffi
null
fya
fyb
patient
identifi
use
electron
medic
record
search
engin
emers
softwar
search
term
duffi
fyab
potenti
subject
identifi
patient
met
inclus
criteria
includ
duffi
null
statu
absenc
condit
medic
potenti
impact
anc
uniqu
healthi
anc
valu
record
duffi
null
patient
age
sex
match
control
identifi
use
emers
softwar
search
term
tonsillectomi
depart
anesthesiolog
absolut
neutrophil
count
subject
condit
medic
might
impact
anc
africanarab
descent
exclud
control
group
asian
caucasian
patient
includ
control
presum
duffi
null
given
popul
expect
duffi
null
control
subject
identifi
met
inclus
exclus
criteria
statist
analysi
perform
use
twosid
twosampl
ttest
anova
onesampl
ttest
result
median
age
duffi
null
case
year
iqr
male
african
arab
descent
mean
anc
duffi
null
patient
cellsul
sd
mean
anc
control
cellsul
mean
differ
control
duffi
null
case
cellsul
ci
anc
level
duffi
null
individu
control
evalu
five
age
categori
age
categori
howev
differ
anc
level
duffi
null
case
differ
age
categori
anova
duffi
null
cbc
anc
level
nonneutropen
rang
cellsul
cbc
mild
neutropenia
cellsul
cbc
moder
neutropenia
cellsul
cbc
sever
neutropenia
cellsul
conclus
although
neutropenia
associ
pidd
often
sign
compromis
immun
system
duffi
null
patient
wide
rang
valu
often
much
lower
previous
appreci
degre
neutropenia
relat
duffi
null
phenotyp
appear
persist
throughout
childhood
young
adulthood
context
patient
africanarab
descent
present
asymptomat
neutropenia
duffi
null
statu
assess
ben
consid
differenti
complic
hypogammaglobulinemia
uniqu
characterist
decreas
suscept
envelop
viral
infect
object
investig
role
impair
host
nlink
glycosyl
viral
suscept
ebola
viru
method
mimic
condit
observ
cdgiib
patient
test
vitro
three
proprietari
iminosugar
act
competit
inhibitor
glucosidas
ii
abil
inhibit
trim
nglycan
compar
known
nglycan
modifi
castanospermin
tunicamycin
well
bacteri
enzym
peptidenglycosidas
f
pngasef
ebola
viru
envelop
protein
chosen
prototyp
glycoprotein
heavili
glycosyl
nglycosyl
site
hek
cell
seed
cellswel
well
plate
cell
transfect
pflagebolaviru
coupl
cell
treat
inhibitor
harvest
treatment
trim
nglycan
evalu
via
molecular
weight
assess
westernblot
result
three
inhibitor
compar
effect
inhibit
trim
nglycan
ebola
glycoprotein
compar
castanospermin
greater
molecular
weight
shift
seen
tunicamycin
pngase
f
expect
conclus
chemic
inhibit
nlink
glycosyl
pathway
success
achiev
use
three
new
mog
inhibitor
approach
merit
investig
potenti
applic
antivir
therapi
investig
laboratori
human
genet
infecti
diseas
necker
branch
inserm
necker
enfant
malad
hospit
pari
franc
head
immunodefici
research
unit
nation
institut
pediatr
gof
mutat
associ
infect
autoimmun
inflammatori
manifest
rosacea
one
manifest
describ
diseas
howev
etiolog
rosacea
clearli
establish
characterist
rosacea
describ
stat
gof
differ
clinic
seri
describ
differ
characterist
rosacea
famili
affect
member
gof
famili
eight
member
gof
mutat
diagnos
first
affect
member
affect
tuberculosi
onychomycosi
seven
member
clinic
histori
mycobacteri
viral
fungu
infect
autoimmun
diseas
seven
document
mutat
six
adult
patient
document
rosacea
start
adolesc
local
face
andor
eye
progress
amelior
medic
treatment
caus
nose
deform
rosacea
describ
previous
uniqu
manifest
etiolog
clear
autoimmun
hypothesi
propos
fact
present
patient
gof
could
suggest
effect
autoimmun
compon
physician
face
patient
rosacea
must
look
manifest
present
gof
mutat
genet
studi
rosacea
patient
could
evid
new
gene
defect
introduct
homozyg
mutat
caus
loss
function
transcript
factor
forkheadbox
underli
autosom
recess
sever
combin
immunodefici
congenit
alopecia
nail
dystrophi
nude
scid
affect
human
like
scid
mous
small
absent
thymu
absent
sever
diminish
cell
alopecia
nail
dystrophi
infant
nude
scid
neonat
lymphopenia
sever
lifethreaten
infect
studi
heterozyg
carrier
mutat
limit
report
phenotyp
mild
diseas
manifest
nail
dystrophi
without
lymphopenia
recurr
infect
object
describ
six
infant
includ
two
brother
tcell
lymphopenia
tcl
follow
abnorm
california
newborn
screen
nb
scid
singl
heterozyg
variant
case
report
six
infant
femal
male
refer
evalu
abnorm
california
nb
scid
tabl
tcell
receptor
excis
circl
trec
count
undetect
normal
infant
well
time
initi
evalu
five
infant
absolut
cell
count
cellsul
cell
count
cellsul
began
evalu
outpati
home
isol
patient
undetect
trec
cell
count
cell
count
urgent
admit
inpati
evalu
manag
immedi
start
antimicrobi
prophylaxi
patient
evalu
signific
lymphocyt
prolifer
mitogen
initi
normal
wane
time
prompt
treatment
patern
haploident
hematopoiet
cell
transplant
month
age
patient
develop
neutropenia
within
week
birth
treat
granulocyt
coloni
stimul
factor
gcsf
patient
remain
well
gcsf
persist
growth
failur
continu
evalu
patient
remain
stabl
antimicrobi
prophylaxi
persist
moder
tcl
part
immun
evalu
patient
gene
panel
test
reveal
heterozyg
variant
variant
patient
presum
share
patient
brother
predict
pathogen
patient
dystroph
nail
spars
hair
evid
year
age
featur
share
mother
brother
patient
patient
lack
clinic
featur
previous
describ
phenotyp
nude
scid
heterozyg
variant
unknown
signific
function
role
variant
patient
clinic
phenotyp
unknown
conclus
six
infant
abnorm
nb
scid
lymphopenia
heterozyg
variant
infant
variat
exist
level
tcl
presenc
hair
nail
find
heterozyg
variant
unknown
signific
uncov
other
includ
infant
abnorm
nb
scid
highlight
need
function
studi
address
possibl
role
heterozyg
variant
congenit
lymphopenia
neutropenia
work
need
attribut
tcl
novel
variant
unknown
signific
absenc
famili
histori
abnorm
hair
nail
function
evid
remain
poorli
understood
character
intestin
microbiom
metabolom
patient
cgd
determin
intestin
microbiom
metabolom
signatur
could
distinguish
subpopul
patient
cgd
use
metabolom
add
function
dimens
observ
microbiom
signatur
method
clinic
metadata
fecal
sampl
collect
crosssect
healthi
volunt
hv
patient
cgd
metabolom
profil
rrna
sequenc
perform
fecal
sampl
total
sampl
readssampl
median
result
sampl
patient
cgd
distinct
intestin
microbiom
signatur
metabolom
profil
depend
genotyp
presenc
cgdibd
specif
intervent
eg
treatment
element
diet
notabl
sampl
patient
activ
cgdibd
compar
sampl
patient
without
histori
cgdibd
significantli
differ
alphaand
betadivers
enrich
enterococcu
spp
signal
transduc
activ
transcript
gain
function
primari
immunodeysregulatori
diseas
subset
patient
featur
autoimmun
autoinflamm
enteropathi
growth
failur
nutrient
wast
common
featur
immunodysregul
ruxolitinib
janu
kinasestat
inhibitor
shown
effect
treatment
immunodysregulatori
featur
patient
year
old
male
g
sever
total
parenter
depend
enteropathi
led
growth
failur
weight
treatment
ruxolitinib
led
resolut
diarrhea
return
normal
diet
catch
growth
dose
twice
daili
initi
start
decreas
everi
morn
mg
everi
even
due
elev
transaminas
thrombocytopenia
follow
year
patient
thrive
gain
normal
everi
day
stool
despit
weight
gain
remain
stabl
dose
ruxolitinib
outgrew
dose
develop
increas
frequenc
upper
respiratori
infect
parainfluenza
coronaviru
rhinoviru
one
year
initi
ruxolitinib
develop
profus
wateri
diarrhea
noroviru
posit
weight
bsa
place
bowel
rest
ruxolitinib
dose
escal
goal
reach
twice
daili
enteropathi
complet
resolv
liver
function
test
began
rise
gain
weight
began
thrive
week
therapi
six
month
later
enteropathi
control
transaminas
remain
elev
alt
iul
ast
iuml
stabl
appropri
dose
pharmacokinet
ruxolitinib
treatment
immunodysregulatori
symptom
pediatr
patient
thoroughli
studi
dose
use
extrapol
data
use
ruxolitinib
pediatr
myelofibrosi
dose
appear
provid
benefit
toler
advers
effect
dose
maintain
order
prevent
recurr
diseas
relat
manifest
abstract
clathrinmedi
endocytosi
cme
major
endocyt
pathway
eukaryot
cell
intern
cellsurfac
cargo
protein
extracellular
molecul
therebi
allow
broad
rang
biolog
process
includ
cell
signal
nutrient
growth
factor
uptak
cell
fate
fbar
domain
protein
involv
initi
clathrin
coat
pit
format
whether
function
redund
distinct
function
unclear
report
first
case
sever
immunodefici
due
genet
defect
affect
cme
use
whole
exom
sequenc
genom
analysi
target
pid
gene
panel
identifi
biallel
lossoffunct
mutat
five
patient
unrel
famili
italian
turkish
algerian
origin
sever
cell
lymphopenia
manifest
recurr
sever
infect
bacteri
mycobacteri
viral
fungal
origin
develop
ebvassoci
diffus
larg
b
cell
lymphoma
three
patient
die
childhood
wherea
aliv
full
donor
chimer
year
allogen
hematopoiet
stem
cell
transplant
respect
clear
pretranspl
infect
patient
carri
homozyg
frameshift
mutat
predict
caus
prematur
termin
westernblot
analysi
haor
flagtag
construct
show
express
truncat
product
wherea
protein
detect
presum
due
mrna
decay
carri
homozyg
splicesit
mutat
invari
posit
respect
lead
skip
exon
cdna
qpcr
analysi
demonstr
differenti
express
gene
former
predominantli
express
lymphoid
cell
wherea
abundantli
express
fibroblast
cell
analysi
cell
activ
patient
pretranspl
pbmc
avail
reveal
reduc
cell
prolifer
tcr
intern
respons
crosslink
normal
consist
recent
evid
tcr
intern
occur
clathrinindepend
pathway
chase
experi
demonstr
transferrin
intern
abolish
activ
cell
previous
report
missens
mutat
tfrc
encod
transferrin
receptor
impair
transferrin
intern
intracellular
iron
deliveri
caus
combin
immunodefici
defect
cell
prolifer
data
identifi
first
form
sever
immunodefici
due
defect
clathrinmedi
endocytosi
provid
addit
evid
support
critic
role
play
iron
cellular
metabol
cell
function
homeostasi
